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Major Depressive Disorder (MDD) is the leading source of disability globally. 
Treatment-resistance among patients is common and even effective pharmacological 
therapies have a delayed effect on symptom relief. Better understanding of the 
mechanisms underlying depression and the search for potential effective and novel 
therapeutic targets are high research and healthcare priorities. Animal models are 
commonly used to mimic aspects of the phenotype of the human disorder to 
characterise candidate antidepressant agents. Despite these tools, no new 
pharmacological interventions have been discovered in the last decade and no 
reliable biomarkers have been identified for clinical use.  
 
Systematically reviewing the literature on animal models of depression may provide 
an overview of our current understanding of the underlying biological mechanisms 
and why no new therapies have been effectively translated to clinic. This field of 
research is large, and over 70,000 potentially relevant articles were identified in 2016. 
Therefore systematically reviewing this literature presents challenges for human 
resources. To combat these challenges, the following contributions to the field have 
been made: (1) the novel application of machine learning techniques to identify errors 
in human systematic review citation screening; and (2), the novel application of 
regular expression dictionaries to large corpuses of preclinical animal literature to help 
cluster publications into the disease model investigated and drug intervention tested. 
These tools have been applied for systematic review and meta-analysis methodology 
to the field of animal models of depression.  
 
All literature on animal models of depression has been systematically identified using 
searches carried out in PubMed and EMBASE in May 2016. This literature has been 
screened with the help of machine learning classification algorithms, based on a 
random set of dual human screened records (5749 records).  This achieved a 
sensitivity of 98.7% and a specificity of 86% as assessed on in an independent 




Machine learning has been used to identify human screening errors in the set of 
documents used to train the algorithm. Correction of these errors with further human 
intervention, sees an improvement in specificity to 88.3%. These algorithms allow 
irrelevant documents to be automatically removed, reducing the corpus to 18,407 
articles that highly likely to be relevant to the research area of animal models of 
depression. Custom-made regular expression dictionaries of (1) techniques to induce 
depressive-like phenotypes in animals, and (2) known antidepressants have been 
curated.  The text-mining dictionaries for anti-depressant drugs and commonly used 
methods of model induction have been applied to categorise and visualise this large 
corpus of records to allow prioritisation of sub-topics of depression for further in depth 
systematic review and meta-analyses. These machine-assisted tools for systematic 
review methodology are available free to use, online.  
 
Systematic review and meta-analysis has been conducted on two sub-topics of the 
literature on animal models of depression. Firstly, the literature on the effects of 
ketamine as an anti-depressant in animal models of depression has been 
summarised with systematic review techniques and the effects of ketamine on 
depressive-like behaviour in the forced swim test, has been pooled using meta-
analysis. The timing of administration of ketamine relative to the outcome assessment 
was significantly associated with decreases in effect size. This meta-analysis 
revealed no statistically significant heterogeneity between the studies. Secondly, the 
literature on use of gut microbial altering interventions to induce and treat depressive-
like phenotypes in animal models of depression has been summarised and their 
effects have been pooled across studies using meta-analysis. The systematic review 
and meta-analysis of microbiota interventions identified a broad range of outcomes 
investigated in the primary literature and several probiotic treatments to reduce 
depressive-like behaviour were investigate gaps in the literature. Finally, a primary 
hypothesis-confirming animal experiment, where measures to reduce the risk of bias 
have been implemented was carried out to investigate the effects of prebiotics on 
depressive- and anxiety-like behaviour in a genetic animal model of depression, the 
Flinders Sensitive Line (FSL) rats.  
 
Online tools have been developed to provide an overview of animal models of 
depression and anti-depressant drugs investigated in the literature, using systematic 
 
 
review methodology and automation tools. This thesis reports meta-analyses on two 
sub-topics within animal models of depression; the effect of microbiota interventions, 
and the effects of ketamine; along with a primary animal experiment to test the effects 










Major Depressive Disorder (MDD) is a psychiatric condition characterised by low 
mood and lack of interest in hobbies and activities once enjoyed. Depression is the 
leading source of disability globally. Not all patients respond to current drug 
treatments and these drugs have a delayed effect on symptom relief. It is therefore a 
healthcare priority to find effective treatments and to better understand the underlying 
biology behind the symptoms and the development of depression. A considerable 
number of studies performed in animals are used to investigate potential novel drugs 
before the treatments are licensed for use in humans. Many different interventions are 
used to ‘mimic’ symptoms of human conditions in animals, commonly referred to as 
animal models.  
 
Systematic review is a methodology to systematically identify and summarise all 
literature in a particular topic. Meta-analysis of the data can be subsequently 
performed across many studies to see under which circumstances a drug is effective. 
This study aims to provide an overview of the literature on animal models of 
depression.  
 
Searching online medical databases picked up many studies that likely contain 
information about using animals to model depression. To see whether all studies 
identified (70,365 studies) are relevant requires a great deal of human resources. 
Here, tools to help automate this process have been tested and implemented 
successfully.  An online tool has been developed to provide an overview of all 
literature reporting animal models of depression, categorised by different types of 
antidepressant drugs investigated and by different techniques used to induce the 
model of depression.  
 
Using these tools, two systematic reviews of sub-topics within this field have been 
carried out. Firstly, a systematic review and meta-analysis of all literature on the use 
of ketamine, was conducted, providing a quantitative summary of the effect of this 
drug across all the studies. Further, a systematic review of interventions targeting the 
gut bacteria was carried out to provide an overview. The results of the primary studies 
in this review were also summarised quantitatively with meta-analysis. Results from 
 
 
this review revealed that there were still many questions left to be answered by this 
literature about different types of interventions on the gut bacteria.  
 
A primary animal study was conducted to expand our understanding of the effect of 
different microbiome-targeting interventions on depression. A genetic animal model 
of depression was used. Animals received non-digestible fibres that promote the 
growth various gut bacteria. The effect of this was measured in behavioural tests of 
depression and anxiety.   
  
Online tools have been developed to provide an overview of animal models of 
depression and different anti-depressant drugs investigated, using systematic review 
methods and tools to automate this process. This thesis reports quantitative 
summaries of two sub-topics within animal models of depression; the effect of gut 
microbiota-targeting interventions, and the effects of the anti-depressant ketamine.  
This thesis reports a primary animal experiment to test the effects of prebiotics on 
depressive-like behaviour in a genetic rodent model of depression.  
 
The tools of systematic review and meta-analysis provide an overview of the evidence 
available on potential treatments that have been tested in animals; how different 
exposures such as stress and genetic alterations affect the development of 
depression; the underlying biological mechanisms behind these treatments and 
exposures; and the quality of this research can help us make decisions about future 
research. We can use this research to better design future animal experiments, and 
together with other research, make decisions about drugs to investigate with clinical 
trials in humans. In future, further tools can be developed to help automatically 







Depression er en af de mest alvorlig psykiske sygdomme i verden og er forbundet 
med massive samfundsøkonomiske omkostninger. Antidepressiv medicin kan være 
længe om at virke og omkring 50% af patienterne er behandlingsresistente. Der er 
derfor behov for øget viden omkring biologiske markører, som muligvis har indflydelse 
på sygdommens udvikling. Dyremodeller af depression kan bruges til at identificere 
biologiske reaktionsveje, hvilket kunne bidrage til en mere målrettet diagnosticering. 
Anvendelse af dyremodeller har også til formål at kunne give indikationer om 
præparater, som kan udvikles til forbedret og individualiseret anvendelse af 
antidepressiv medicin. 
Formålet med mit ph.d. projekt var at belyse publicerede forskningsresultater for at 
skabe et bedre overblik og større indsigt i forskningen i dyremodeller af depression. 
En systematisk review er en metode, som systematisk indsamler og analyserer 
videnskabelig litteratur vedrørende et specifikt emne. Dermed forbedres 
mulighederne for at identificere de nøgleområder, herunder biomarkører og mulige 
antidepressiv stoffer, som kan danne fundamentet for bedre diagnosticering og 
behandling af depression. 
Vores systematiske analyse har identificeret 70.365 unikke videnskabelige studier 
relateret til dyremodeller af depression. Det har sine udfordringer med så stort et 
datamateriale.  Idet en manuel gennemgang af datamateriale af denne kaliber vil 
være både tids- og ressourcekrævende.Machine learning teknikker samt regular 
expression “udtryksordbøger” er blevet anvendt til at hjælpe forskere med at udføre 
systematiske reviews, identificere fejl i citat gennemgang og tillade automatisk 
kategorisering af videnskabelige studier.  Disse værktøjer er frit tilgængelige online, 
med henblik på at fremtidige forskere kan anvende- og videreudvikle dem, til gavn for 
fremtidig forskning i dette felt. Disse værktøjer hjælper med at evaluere hvilke 
medicinske præparater, der har vist sig effektive og under hvilke omstændigheder, 
samt kvalitet af dette data. Der er blevet foretaget to særskilte analyser for at belyse:  
1) anvendelsen af ketamin som effektiv antidepressiv stof og 2) anvendelsen af 
dyremodeller af depression med ændret sammensætning af tarmbakterier. 3) På 
grundlag af den systematisk review af ændret sammensætning af tarmbakterier 
blevet der udført et eksperimentel dyreforsøg for at øge forståelsen af effekten af 
præbiotika i en genetisk dyremodel (Flinders Sensitive Line rotter).  
 
 
Disse undersøgelser viste: 1) Samlet kvantitative data viste at ketamin er en effektiv 
antidepressiv præparat. 2) Samlet kvantative data viste at mange forskellige slags 
indgreb er blevet fortaget for at ændre sammensætning af tarmbakterier hvor, nogle 
virker som antidepressiv midler og andre som depressiv midler.  Der var ingen forsøg 
som undersøgt præbiotika. 3) Dette forsøgte jeg at undersøge ved at tilføre ikke-
fordøjelige kostfibre til rotters almindelig kost og undersøg effekten på depressiv- og 
angst-opførsel i en genetisk dyremodel på Flinders Sensitive Line rotter.   
 
De nyudviklede værktøjer har forbedret vores overblik over anvendte dyremodeller i 
depression samt virkningen af antidepressiv medicin.  Resultere af systematisk 
review er med til at skabe et overblik over tilgængelig forskning om depression: a) 
hvilken effekt forskellige præparater har i forsøg med dyremodeller, b) hvordan 
forskellige faktorer, såsom stress og genetiske ændringer, påvirker udviklingen af 
depression. Dette kan give indblik i c) de underliggende biologiske mekanismer bag 
behandling og eksponering. Disse analyser forbedrer beslutningsgrundlaget for 
udvælgelse af mere målrettet og resultatskabende forskning.  Dyreforsøgene kan 
blive tilrettelagt mere specifikt og viden om virkning af testede præparater er øget. I 
fremtiden kan disse værktøjer bruges på mange andre forskningsområder, således at 
forskningsmidler kan anvendes mere målrettet og ny viden kan sammenlignes med 
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1.1 Problem Statement  
Depression is the leading cause of disability worldwide impacting an estimated 322 
million people worldwide with a global prevalence of 4.4% (World Health Organisation, 
2017). Current treatments are adequate at best. Many patients are non-responsive to 
the current treatments and many patients do not receive the treatment they require. 
A number of challenges exist which decrease the speed of discovering new viable 
treatments. Most importantly, the pathophysiological mechanisms underlying this 
complex disorder are not yet understood, there is large heterogeneity in the symptoms 
present across patients. Drug discovery in psychiatry is slow. Given the high 
experimental control of animal models, they have been used to elucidate the 
underlying mechanisms of antidepressant treatments and pathophysiology. 
Systematic review is a method of openly and systematically collecting and 
synthesising the available evidence of a given topic. Systematic review is a 
hypothesis-generating tool and meta-analysis can be carried out subsequently, by 
statistically pooling the data to produce an estimate of overall effect. 
 
The aim of this thesis is to apply systematic review and meta-analysis techniques to 
synthesise the evidence available on animal models of depression and 
antidepressants investigated. Further, to achieve an overview of what species are 
used, and what techniques have been used to induce depressive-like phenotypes. 
We can get an understanding of which treatments have been investigated in animal 
models of depression, how confident can we be in these findings, and what 
information is required to translate these findings accurately to useful treatments for 
the clinical population? Findings from systematic review and meta-analysis can inform 
and refine the design of primary animal experiments, however, they are resource-
consuming tools. Therefore, to facilitate the research process of evidence synthesis, 
automation tools have been developed, tested, and implemented to provide an 
overview of the literature more quickly.  
 
In this thesis I provide an overview of the literature on animal models of depression to 
inform primary in vivo research. I apply automation tools to this systematic review of 
animal models of depression. Two systematic reviews of the available literature on 
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ketamine and microbiota-targeting interventions in animal models of depression were 
conducted. Findings from the systematic review of microbiota-targeting interventions 
were used to inform a primary animal experiment on prebiotics in Flinders Sensitive 
Line animals. We can use findings from a systematic review to better understand 
factors that impact the efficacy of treatments in animal models and improve the quality 
of research conducted, to better understand depression and improve the treatments 
available to patients. 
 
1.2 Depression 
1.2.1 Prevalence and burden of depression 
Depression is the leading cause of disability in the world (Marcus et al., 2012) and is 
currently the brain disorder with the highest financial cost in Europe (Gustavsson et 
al., 2011). The number of people diagnosed with depression worldwide is estimated 
at 322 million with a global prevalence of 4.4% (WHO, 2017). Major Depressive 
Disorder (MDD) is a mental illness characterised by “low mood, loss of interest and 
pleasure or loss of energy” (DSM-5 & ICD-10). The Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) and the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10) guidelines differ slightly as to the 
core symptoms required for a diagnosis of depression. The DSM-5 requires that 
patients present with 5 out of the 9 symptoms for at least 2 weeks, where at least one 
symptom being depressed mood or loss of interest. The ICD-10 requires patients to 
present with two out of the first three symptoms; depressed mood, loss of interest, 
and reduction in energy, for at least two weeks, with two subsequent symptoms from 








Table 1.1 An overview of symptoms required for a diagnosis of depression in the ICD-
10 and DSM-5 diagnostic manuals. The asterisk denotes the core symptoms required 
for diagnosis.  
ICD-10 DSM-5 Major/Minor Depression 
Depressed Mood* Depressed mood by self-report or 
observation made by others* 
Loss of interest* Markedly diminished interest or 
pleasure* 
Reduction in energy* Fatigue/loss of energy 
Loss of confidence or self-esteem Feelings of worthlessness/excessive or 
inappropriate guilt 
Unreasonable feelings of self-reproach 
or inappropriate guilt 
Recurrent thoughts of death, suicidal 
thoughts or actual suicide attempts 
Recurrent thoughts of death or suicide Diminished ability to think/concentrate or 
indecisiveness 
Diminished ability to think/concentrate 
or indecisiveness 
Psychomotor agitation or retardation 
Change in psychomotor activity with 
agitation or retardation 
Insomnia/hypersomnia 
Sleep disturbance Significant weight loss/gain or 
increased/decreased appetite 
Change in appetite with weight change  
 
 
Depression places a huge burden on patients and is a great cost to healthcare 
systems and governments. It is estimated to contribute over 50 million Years Lived 
with Disability globally (WHO, 2017). Mood disorders are the largest contributors to 
the European cost of brain disorders, costing €113.4 million out of the total €476.9 
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million direct healthcare costs (Gustavsson et al., 2011). Depression reduces life 
expectancy by an average of 7-11 years (Chesney, Goodwin & Fazal, 2014).  
 
The severity of a major depressive episode and associated functional impairment is 
part of the diagnosis and is classified into three broad classes by the ICD-10 and the 
DSM-5; mild, moderate and severe. These classifications are made based on the 
number of symptoms patients present with, with less (4) symptoms required for a 
diagnosis of depression in the ICD-10 (see table 1.2). This approach, the counting of 
symptoms, is in line with the idea that depression is a consistent syndrome (Fried & 
Nesse, 2015a). However, the utility of this approach has been called into question as 
it does not take into account individual symptom severity or the level at which the 
individual is functionally impaired by the disorder (NICE Guidelines, 2010). Clinicians 
are advised to assess individual patients on their degree of functional impairment 
before making a diagnosis (NICE Clinical Guidance, 2010). Further, symptoms of 
depression can be classified into indistinct subtypes; melancholia, catatonia, seasonal 
affective disorder, post-partum depression, and depression with psychotic features 
(psychotic depression). Classification of symptoms into subtypes may have an impact 
on the treatment intervention plan in certain cases, such as light therapy to seasonal 
affective disorder (NICE Guidelines, 2010). However these subtypes are critiqued for 
their validity and poor utility when implemented (Lichtenberg & Belmaker, 2010; 
Baumeister & Parker, 2012; Rush, 2007).  
 
Table 1.2  Classification of major depression. Numbers refer to the number of 
symptoms required for each classification 
 DSM-5 major depression ICD-10 depressive episode 
Mild Minimal above the minimum (5) 4 
Moderate Between mild and severe 5-6 
Severe Several symptoms in excess of 5 7+ 
 
Depression is a disorder that persists across the lifetime, often with relapsing and 
remitting periods. Furthermore, symptoms can persist between episodes (NICE 
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Clinical Guidance, 2009). The primary aim of interventions is complete relief of 
symptoms (NICE, 2009). Depressive episodes can last weeks to years, and the 
probability of recovery from a depressive episode decreases the longer an episode 
lasts (Pattern, 2006). The probability of experiencing another depressive episode is 
greatly increased after experiencing an initial episode. Throughout this thesis when I 
refer to “depression”, I mean the range of symptoms which are characteristic of the 
clinical disorder, major depression disorder.  
 
There are currently several interventions implemented as part of the National Health 
Service (NHS) in the United Kingdom to reduce the symptoms of depression. These 
interventions include exercise, psychological therapies, and pharmacological 
interventions, or a combination of these, depending on the severity of the depression 
experienced (NHS, 2014).  
 
The rate of remission with antidepressant medication is at best 70%, and may only 
be achieved after several different interventions have been tried (Rush et al., 2006; 
Geddes et al, 2003). Psychotherapy has comparable efficacy as pharmacological 
interventions in patients with mild to moderate MDD (Spielmans et al., 2011). 
Currently, treatment-resistance is highly prevalent among patients. This is estimated 
to be approximately 50% of patients that have moderate to severe depressive 
symptoms and do not respond to more than 4 “lines” of pharmacological treatments 
(Rush et al., 2011). 
 
1.2.2 Risk factors  
Depression commonly manifests in adolescence or early adulthood, between the 
ages of 14 and 24, although can occur earlier or later in life (Kessler et al., 2005). 
There are several risk factors that are known to be associated with the increased risk 
of developing depression as well as the progression and recurrence of the disease 
across the lifetime. These interact to influence the risk of depression. These include 
a range of environmental, sociodemographic, and genetic factors (Colman et al., 2014; 
Kessler et al., 2005), such as being female, acute and chronic stressful life events in 
childhood such as separation from primary caregiver or parental divorce, and 
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adulthood such as living in poverty, death of a loved one or an employment crisis, low 
birth weight and delayed age of reaching childhood developmental milestones 
(Colman et al., 2014; Kessler et al., 2003). A recent genome-wide association study 
identified 44 single nucleotide polymorphisms associated with an increased risk of 
experiencing MDD (Wray et al., 2018).  
 
1.2.3 Heterogeneity 
Depression presents heterogeneously, with many adjunctive symptoms and sub-
types or categories. The possible combination of symptoms that are needed to 
classify for a clinical diagnosis contributes to this heterogeneity. At least five out of 
nine symptoms under DSM-5 are required for a clinical diagnosis, where several key 
symptoms can present with dimensionality e.g. insomnia/hypersomnia, weight loss or 
gain. Under this classification system, two patients can be diagnosed with MDD but 
not share symptoms in common, as shown in the table highlighted by Dzirasa and 
Convington (2012) (see table 1.3 below).  
 
Fried and colleagues note that the DSM criteria of depression can “lead to 1497 
potential unique symptom profiles that all qualify for the same diagnosis (Ostergaard 
et al., 2011), including profiles that do not have a single symptom in common” (Fried 
et al., 2014). Taking into account the sub-types and dimensionality of some of the 
symptoms, e.g. sleep disturbance which may feature hyper- or hyposomnia, 
increases the number of possible unique profiles to 16,400 (Fried & Nesse, 2015b), 
remembering that each symptom contributes equally to the diagnosis (Fried et al., 
2014). Fried and Nesse analysed the presence of symptom profiles in a well-known 
dataset, the STAR*D cohort, and identified 1,030 unique profiles across the cohort of 
3,703 patients. 24% of patients described the most common 30 symptom profiles, and 
13.5% of patients had completely unique symptom profiles. The most common 
symptom profile was only prevalent in about 2% of patients. This highlights the huge 
variability in the presentation of depression. This finding may also have implications 
for the current approach in psychiatry for diagnosis, mainly the approach of using 
symptom counting to assess depression severity, which is critiqued for being 
inadequate for gaining full insights and understanding into the condition from clinical 




This heterogeneity in the human condition can impact the apparent efficacy of 
treatments tested in a clinical trial, in that two patients with a diagnosis of a depression 
could present with two completely different symptom profiles without overlap of a 
single symptom. When trying to study depression and the efficacy of treatments in 
clinical trials, the symptom profile of a patient is largely ignored during recruitment and 
the current approach of symptom counting is favoured.  
 
Table 1.3. Symptom presentation for two hypothetical patients (Dzirasa & Convington, 
2012). 
Patient 1 Patient 2 
Poor Mood Anhedonia 
Hypersomnia Insomnia 
Feelings of worthlessness Decreased concentration 
Psychomotor retardation Significant weight loss 
Fatigue Suicidal thoughts 
 
To further muddy the waters, inter-rater reliability between psychiatrists’ diagnosis of 
MDD can be poor. In the DSM-5 field tests, Reiger and colleagues captured the lower 
end of this spectrum, reporting kappa values of 0.25 between psychiatrists’ diagnosis 
of major depressive disorder (Reiger et al., 2013). This can present difficulties in 
‘characterising’ groups of patients with depression for the testing of treatments in 
clinical trials, unpicking why some patients respond and others do not. The poor 
agreement between clinicians in the diagnosis of symptoms can add further 
complexity when preclinical evidence for treatments fail to translate to clinical trials, 
as is seen in many other preclinical models (O’Collins et al., 2006). 
 
To try and understand why there is such a wide variety in symptom profiles and if 
symptom profiles can help target treatment strategies, researchers have attempted to 
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cluster symptoms using a data-driven approach from studies of clinical populations. 
This aims to empirically create sub-types of depression that are more informative than 
the current subtype classification. A central theoretical rationale behind this approach 
to understanding the heterogeneity in depression is that patients, in fact, suffer from 
different syndromes with different aetiology, predisposing factors, and symptom 
presentation (Fried & Nesse, 2015a).  
 
Various techniques, such as factor analysis, principal components analysis and latent 
cluster analysis, are used to identify patterns of symptoms across large groups of 
patients with depression, and to identify latent variables based on similarity in the data 
from patients. These techniques have been applied to a number of datasets with 
different cohorts of patients who have been diagnosed with the help of different tools. 
A systematic review of these approaches was conducted by van Loo and colleagues 
(2012). Although there are a number of findings that support a finding of cognitive or 
somatic symptom dimensions, there is inconclusive evidence to suggest that the 
finding of symptomatic subtypes hold true across methods and across datasets. The 
results vary based on the clustering technique used, which screening tool was used, 
and across patient samples. These differing results from symptom-cluster studies 
have lead other researchers in the direction of using network models to understand 
heterogeneity in symptoms. This enables an understanding of the direct and indirect 
influences on dynamic causal networks connecting symptoms and investigating which 
symptoms “cluster” (Fried, 2015). Findings from these new network models may 
provide important information for understanding the link between symptoms and may 
provide insight into underlying mechanisms (Fried, 2017).  
  
Despite decades of investigation into depression, little is known about the biological 
mechanisms underpinning the disease (Nestler, Gould & Manji, 2002; Slattery & 
Cryan, 2014). With a better understanding of the mechanisms causing the 
development and progression of depression, the development of novel and more 
reliable treatments might be possible. There is solid rationale that further investigation 
into the mechanisms and factors that contribute to the development of depression is 
needed. This is a highly important area to tackle, both from a clinical, and a preclinical 
perspective. The National Institute of Mental Health in the USA has recognised that 
the current diagnostic approach lacks validity (Insel, 2013), which explains their recent 
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decision to only fund projects that aim to elucidate underlying neurobiological 
mechanisms. Others also call for a novel approach to diagnosis under a slightly 
different methodology. One such approach is the concept of ‘Symptomics’, the 
investigation of psychopathology at the level of individual symptoms, aiming to 
understand associations between symptoms to try and untangle cause and effect 
relationships (Fried, 2017; Fried, 2015) 
 
This section has introduced the prevalence and burden of depression, the symptoms 
of depression, the subtypes of depression, risk factors, and the current method used 
for diagnosis in clinical practice. The heterogeneity of the disorder has been discussed 
and the next section will build on this to highlight the limitations of the current paradigm.  
 
1.3 Treatments for MDD 
1.3.1 Current Pharmacological Interventions 
Historically the discovery of modern pharmacological drugs occurred by serendipity 
in the early 1950s in the search for pharmacological treatments for tuberculosis 
(Hillhouse & Porter, 2015). Trials of iproniazid for the treatment of tuberculosis 
produced “side-effects” such as psychostimulation, increased appetite, and improved 
sleep, which were then tested formally in patients with depression (Loomer, Saunders 
& Kline, 1958) which showed a 70% improvement in symptoms. Isoniazid was the first 
monoamine oxidase inhibitor (MAOI). MAOIs act by inhibiting monoamine oxidase A 
and monoamine oxidase B, enzymes throughout the body that catalyse the oxidation 
monoamine neurotransmitters, thus reducing the breakdown of key neurotransmitters 
such as serotonin, norepinephrine, and dopamine, increasing the availability of these 
neurotransmitters around the synapse (Youdim, Edmondson, & Tipton, 2006). 
Iproniazid was marketed as an antitubercular compound but used off-label for MDD 
(Hillhouse & Porter, 2005).  
 
The initial non-selective MAOIs, were discontinued shortly after introduction due to 
adverse side-effects and serious concerns regarding interactions with foods 
containing large amounts tyramine such as cheese, causing increased heart rate and 
sweating (Hillhouse & Porter, 2015).  Attempts were swiftly made to alter the 
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pharmacodynamics of early MAOIs to make them more selective and reversible. 
Currently marketed MAOIs include; selegiline and moclobemide. Rates of efficacy for 
modern MAOIs are comparable to other traditional antidepressants, with reports 
between 50-70% of response rate in patients (Krishnan, 2007; Henkel et al., 2006). 
Common side effects reported include insomnia, gastrointestinal disturbances, and 
some sexual dysfunction (Shulman, Herrmann & Walker, 2013).  
 
Concurrently, compounds that had antipsychotic properties for schizophrenia were 
being tested, one of which, imipramine, failed to have an antipsychotic impact but did 
reduce symptoms in depressive patients. Imipramine, modified from the antihistamine 
structure, was given FDA approval for major depressive disorder and thus the advent 
of tricyclic antidepressants (TCAs) began. TCAs have been shown to act via a broad 
range of mechanisms but mainly via the serotonin transporter and the norepinephrine 
transporter. Further, many TCAs act as histamine H1 receptor antagonists. Other 
mechanisms include selectively blocking serotonergic, adrenergic and muscarinic 
receptors (Tatsumi et al., 1997; Hillhouse & Porter, 2015).  
 
Currently marketed TCA drugs include; imipramine, desipramine, amitriptyline, and 
clomipramine (Gillman, 2007). TCAs perform well in comparison to other 
antidepressants. In a recent meta-review, TCAs had a medium effect size (relative 
risk of response to treatment) with moderate strength of evidence (Gartlehner et al., 
2016), similar to previous reports and to the efficacy of MAOIs (Krishnan, 2007). A 
more recent network meta-analysis found amitriptyline to be the most effective 
antidepressant among 21 licensed drugs (Cipriani et al., 2018). Despite their efficacy, 
TCAs have a number of serious side-effects including cardiotoxicity, cognitive and 
psychomotor dysfunction (Montgomery & Kasper, 1995). Research around the 
mechanisms of TCAs and pharmacological work to reduce adverse side-effects lead 
to further discovery of groups of drugs known as selective serotonin reuptake 
inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs) and 
norepinephrine reuptake inhibitors (NRIs). Research into TCAs, together with the 
discovery of the monoamine oxidase inhibition by iproniazid and the noradrenaline 
reuptake inhibition of imipramine, fuelled the postulation of the Catecholaminergic 
Hypothesis by Schildkraut in 1965 who stipulated that depression was the result of a 
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reduction of noradrenaline in and around the synaptic cleft (López-Muñoz & Alamo, 
2009).  
 
Serotonin reuptake inhibitors (SSRIs) were the first drug to be discovered through 
rational drug design. Rational drug design involves identifying a target receptor or 
enzyme associated with the disease, the target receptor is characterised, and a 
molecule that targets that receptor, whilst ideally not binding to or targeting similar 
receptors or enzymes, to reduce side-effects (Todd, Anderson & Groundwater, 2009). 
The exact mechanisms of SSRIs have not yet been fully elucidated, but the primary 
mechanism is thought to be through blocking the uptake of serotonin at the 
presynaptic neuron. SSRIs have also been shown to possess a low binding affinity 
for some postsynaptic receptors, for example, dopamine D2 and adrenergic alpha-1, 
alpha-2 and beta (Owens et al., 1997). Fluoxetine was the first marketed SSRI in 1987 
(López-Muñoz & Alamo, 2009). This discovery sparked the study of theories 
surrounding the role of neurotransmission in depression. Following on from the 
Monoamine Hypothesis, the Serotonin Hypothesis was proposed, which postulated 
that a deficit of serotonin in the brain was the cause of depression (Albert, Benkelfat 
& Descarries, 2012). The early evidence for this theory came from studies of post-
mortem brain samples from suicide patients which showed decreased serotonin 
(Shaw, Camps & Eccleston, 1967). Currently marketed SSRI drugs include; 
citalopram, fluoxetine, escitalopram, fluvoxamine. These SSRIs perform better than 
placebo, overall have medium acceptability and have fewer dropouts due to adverse 
side-effects (Cipriani et al., 2009; Cipriani et al., 2018).  
 
The discovery of fluoxetine and the rise of the Serotonin Hypothesis of Depression 
sparked the further investigation into serotonin modulation in the central nervous 
system (López-Muñoz & Alamo, 2009). With this came a wave of new classes of drugs 
named after their selective or combined modulation, stimulation, antagonism or 
reuptake inhibition of serotonin and norepinephrine; Norepinephrine Reuptake 
Inhibitors (NRIs), Serotonin & Norepinephrine Reuptake inhibitors (SNRIs), Serotonin 
Modulators & Stimulators (SMS), Serotonin Antagonists & Reuptake Inhibitors 
(SARIs), and Norepinephrine–Dopamine Reuptake Inhibitors (NDRIs). The new wave 
of drugs was classified by their main mechanism of action. For example, dual 
serotonin and norepinephrine reuptake inhibitors (SNRIs) inhibit the reuptake of 
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serotonin and norepinephrine at the synapse to increase the concentration of these 
neurotransmitters at the synaptic cleft.  Commonly prescribed drugs include; 
Bupropion (NDRI), Reboxetine (NRI), Trazodone (SARI), Vilazodone and Vortioxetine 
(SMS), Venlafaxine, Duloxetine, Levomilnacipran, and Milnacipran (SNRIs). These 
drugs perform similarly to SSRIs, they generally perform moderately better than 
placebo and have good acceptability profiles (acceptable drop-out rates or 
discontinuation due to adverse side-effects).  
 
To summarise this section, a range of antidepressants are currently available, 
sparked out of serendipity in the early 1950s. Current antidepressants are more 
efficacious than placebo with modest effect sizes (Cipriani et al., 2018; Cipriani et al., 
2009). Drop-outs due to side-effects, remission, and mood symptoms were 
investigated for 21 different pharmacological treatments. Agomelatine, amitriptyline, 
escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were found to be 
most effective. Critique of the current approach of classifying antidepressants will be 
discussed below.  
 
1.3.2. Classification of Antidepressants   
The current classification of antidepressant drugs has been critiqued for a number of 
reasons. Firstly, many antidepressants act through several mechanisms, potentially 
targeting several neurotransmitter receptors both pre- and post-synaptically. 
Secondly, although meta-analyses show antidepressants to be moderately more 
effective than placebo, there is still a high incidence of treatment-resistant depression 
with reports up to 50% of patients not responding after 2 lines of pharmacological 
intervention (STAR*D trial, Huynh & McIntyre, 2008). Thirdly, it is common that 
pharmaceuticals originally marketed for depression, for example, are prescribed for 
patients with other psychiatric disorders such as schizophrenia and Attention-Deficit-
Hyperactivity Disorder (ADHD). Therefore, a task force from the European College of 
Neuropsychopharmacology (ECNP) is attempting to reclassify the current 




The task force from ECNP is developing a new nomenclature for classifying the 
currently available neuropsychiatric drugs. This classification is based on the 
pharmacology and known modes of action on the neurotransmitter or system (NbM2, 
Zohar et al., 2014). Although not all of the modes of action, antagonism and agonism, 
are known for each drug, the rationale is that it will help patients, by presenting the 
most cutting-edge knowledge from neuroscience and psychiatry. The task force has 
additionally added information on four dimensions concerning; approval from 
regulatory bodies, efficacy and known prevalent or life-threatening side-effects based 
on “solid” clinical evidence, a brief summary of the clinical knowledge for treating 
patients, and lastly a summary of the knowledge of neurobiology from clinical and 
preclinical studies (Zohar et al., 2014). Drugs are classified based on major and minor 
receptor agonism and antagonism.  
 
For example, the drug desipramine, TCA, acts on norepinephrine as a reuptake 
inhibitor (Figure 1.1). The application shows that desipramine is approved for Major 
Depressive Disorder, and based on major clinical evidence, has been shown to be 
effective. The application goes on to describe the side-effects, the practical notes for 
prescription, and the underlying neurobiology with evidence from clinical and 





Figure 1.1. An example of an entry in the NbM2 nomenclature for psychiatric drugs, 
Despiramine.  
 
One limitation of this approach is that it is based on the expertise of the members of 
the task force. Although the task force is comprised of world-leading expert 
psychiatrists and neuroscientists, the literature can be susceptible to publication bias, 
and it is not clear through what tools the literature has been searched for and collated, 
or whether this evidence will be quantified with meta-analysis of findings. With the 
application of automation tools for systematic evidence synthesis, many of these 
limitations can be eliminated. Even despite the current limitations, this approach 
shows great promise and could greatly impact the field of neuropsychiatry, closing the 
gap between clinical administration and current biological knowledge. The constant 
integration of new solid knowledge will ensure that patients receive advice on 







1.3.3 Other Treatments for Depression 
1.3.3.1 Other treatments for MDD 
The above paragraphs outline the main pharmacological therapies for depression. 
Prior to the serendipitous discovery of pharmacological treatments, the main method 
of treatment was psychotherapy and psychoanalysis. Psychological therapies for 
depression have continued to develop alongside the development of antidepressants. 
The current primary therapies for depression include cognitive behavioural therapy 
(CBT), behavioural therapies, psychodynamic therapies, systematic therapies, and 
humanistic therapies. A comprehensive analysis of these therapies is beyond the 
scope of this work. Please refer to recent reviews and systematic reviews on the topic 
(for recent review of systematic reviews on psychological and pharmacological 
treatments see Gartlehner et al., 2016, for recent review on psychological therapies 
in depression see Shinohara et al., 2013; Linde et al., 2015a, Linde et al., 2015b).  
Other interventions for mild or sub-threshold depressive symptoms include exercise 
(NHS, 2016; Krogh et al., 2017) which generally decreases the risk of relapse, but the 
evidence synthesised is of poor quality, and prebiotics and probiotics (NHS, 2016). 
Other alternative therapies include light therapy in particular for seasonal affective 
disorder and dietary and herbal supplements such as omega-3 fatty acids and St. 
John’s wort. Supplements show varying efficacy with insufficient strength of evidence 
(Gartlehner et al., 2016).    
 
Comparatively, based on a review of systematic reviews, CBT has a medium effect 
size for reducing depressive-like symptoms. Dietary and herbal supplements, light 
therapy, and exercise, however, show varying efficacy with low or insufficient strength 
of evidence (Gartlehner et al., 2016).  
 
1.3.3.2 Other treatments for treatment-resistant MDD 
For more severe cases of depression and depression that does not respond to several 
lines of pharmaceutical interventions, electroconvulsive therapy (ECT) may be 
administered. ECT has been a treatment for major psychiatric conditions since 1938 
(Cerletti & Bini, 1938 & Kalinowsky, 1939 in Abrams, 2002). The antidepressant 
effects of ECT have been shown to act through a number of mechanisms; inhibitory 
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neurotransmission and monoamine neurotransmitters, endocrinological pathways, 
and neurogenesis (Merkl, Heuser & Bajbouj, 2009). A systematic review and meta-
analysis of clinical trials of ECT has shown its superior effect to placebo stimulation 
and slight superior efficacy in relation to pharmacotherapy for major depressive 
disorder (UK ECT Review Group, 2003). There are, however, a number of serious 
side effects including significant cognitive impact such as amnesia (Merkl, Heuser & 
Bajbouj, 2009). Despite its concerns, ECT is still used routinely, in particular for 
patients resistant to pharmacological interventions. Patients with severe depression 
and at risk of suicide report that the procedures have been life saving (Hersch, 2013). 
 
More recently, ketamine, commonly used in anaesthesia, has been investigated as a 
rapid-acting, acute antidepressant and has been shown to be effective in patients with 
otherwise treatment-resistant depression (Williams & Schatzberg, 2016). It is thought 
to work through blocking Glutamatergic NMDA receptors. Animal studies have shown 
that ketamine upregulates BNDF and mTOR signalling, leading to synaptogenesis in 
prefrontal cortical neurons (Williams & Schatzberg, 2016). To date, Phase III clinical 
trials for ketamine in depression are still underway to assess the optimal route and 
number of administrations and to reduce possible psychotic side-effects (Trial: 
NCT02401139, Black Dog Institute Australia).  Results from the completed clinical 
trials on ketamine show promising effects. Ketamine is markedly more effective than 
placebo at 24 hours, 3 days and 7 days post administration (McGirr et al., 2015). 
Ketamine shows promise to achieve FDA approval for clinical use and has the 
potential to reduce symptoms for many patients who do not achieve remission with 
standard pharmacological therapy.  
 
1.4 Current Limitations in Clinical Research 
Despite years of investigation into the underlying biological mechanisms and 
antidepressants, there are still a number of key issues that prevent us from fully 
understanding and ‘curing’ depression. Firstly, the efficacy of antidepressants and 
treatment resistance. Currently, treatment-resistance is highly prevalent among 
patients. Approximately 50% of patients with moderate to severe depressive 
symptoms do not respond to more than 4 different pharmacological interventions 
(Rush et al., 2011). The current treatments have reports of slow-acting symptom relief, 
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with up to 12 weeks before there is an onset of therapeutic action, which adds 
significantly to the disease burden (Murrough, 2012). There is an apparent 
discrepancy between the rising prevalence of depression and the reported efficacy of 
anti-depressant treatments which has been coined ‘The Depression Conundrum’ 
(Celie et al., 2017). Many large systematic reviews and meta-analyses including the 
recent network meta-analysis by Cipriani and colleagues (2018) have found that 
antidepressant pharmacological and psychological treatments are effective in 
comparison to placebo. With reports that prevalence rates of depression are on the 
rise, there is a discrepancy between these two pieces of information. This might be 
because there are problems delivering mental health and psychiatric services to 
patients, or patients having difficulties seeking and accessing help, or that the efficacy 
of treatments is overstated. Our understanding about treatment efficacy from large 
systematic reviews and meta-analyses, such as the recent network meta-analysis by 
Cipriani and colleagues (2018), has been critiqued in that publication bias is common 
and can affect the findings of efficacy from meta-analyses (Ioannidis, 2009). 
Therefore, it’s key to understand what can differentiate patients that are likely to 
respond and those that are likely not to respond to certain treatments.   
 
Secondly, the heterogeneity of the symptoms present in disorder has added to the 
complexity of understanding the underlying biological mechanisms and the search for 
novel treatments. The mainstay approach in psychiatry has been to understand 
depression as having a single cause and to search for the underlying mechanisms of 
symptoms of a latent disorder (Fried & Nesse 2015). As the above section has 
outlined, there is wide variation in the symptoms patients with depression present with, 
and there are multiple brain circuits and biological mechanisms involved in single 
symptoms (outlined below in section 1.5). What can be done to elucidate these 
patterns of symptoms and can they be useful for predicting treatment response or 
understanding the underlying pathological mechanisms?  
 
A better understanding of the underlying biological mechanisms could assist in the 
search for reliable biomarkers for depression. Biomarkers that can reliably measure 
a disease state, a symptom, or a likely response to treatment and that is an 




Some attempts to differentiate between patients that respond and do not respond to 
drug treatments include the use of structural equation modelling of positron emission 
tomography scans (PET), using activation patterns of limbic-cortical connections 
(Seminowicz et al., 2004). However, it is clear that our understanding of the molecular 
mechanisms underlying depression and treatment response will need to be improved. 
This includes the development of novel pathophysiological models, and 
understanding of the complex heterogeneity (Murrough, 2012), enabling discovery of 
accurate biomarkers to improve the treatment available to patients suffering from 
depression.  
 
1.5 Current Understanding of Underlying Pathology & Mechanisms  
This section will outline the key psychopathological and neurobiological mechanisms 
that are proposed or known to be underlying depression and depressive-like 
phenotypes. This section will discuss data and evidence from both animal literature 
and human literature. The structure of this section is highlighted in figure 1.2, starting 
with the hippocampus, its projections to the prefrontal cortex (PFC), the amygdala, 
and the ventral tegmental area (VTA) and nucleus accumbens (NAc). Finally, the 






Figure 1.2. Main mechanisms involved in depression by brain area.  
 
1.5.1 Hippocampus  
The hippocampus is thought to be one of the most vital brain areas involved in 
depression due to its key role in several stress-related processes. The hippocampus 
is a key part of the limbic pathway and is connected to key brain areas involved in 
emotional processing, including the PFC and the amygdala.  
 
The hippocampus is sensitive to stress which impacts plasticity, due to it being the 
primary site for adult neurogenesis (Lui et al., 2017). The key processes of synaptic 
transmission and connectivity are synaptic long-term potentiation and synaptic long-
term depression. These are involved in memory formation and are affected after 
stress (Marsden, 2013). Regions of the hippocampus are affected differentially by 
stress and with different types of stress (Marsden, 2013). Stress decreases dendritic 
branching, the formation of new connections between neurons, decreases the 
generation of hippocampal neurons and increases cell death (Petrick et al., 2012).  
Depressed patients exhibit overgeneral processing of sensory information, with a 
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decrease in pattern separation, defined as being able to distinguish similar stimuli with 
non-overlapping neuronal representations (Belzung, Willner, Philippot, 2015). 
Depressed patients show an increase in pattern completion, which refers to being 
able to generalise stimuli in the case of partial sensory input (Belzung, Willner, 
Philippot, 2015). The granule cells in the dentate gyrus of the hippocampus are 
heavily involved in pattern separation (Yassa & Stark, 2011). With adult neurogenesis 
occurring mainly in the hippocampus, a decrease in adult neurogenesis with 
depression decreases pattern separation, with this association being bi-directional 
(Belzung, Willner, Philippot, 2015). Further converging evidence comes from the 
decreased volume of the hippocampus seen in patients with MDD, which is due to 
neuronal loss (Hanson et al., 2011). The primary hypothesis through which 
antidepressants are thought to be effective is through adult hippocampal 
neurogenesis. Many different antidepressants have been shown to induce 
hippocampal neurogenesis in humans and animals (Paizanis et al., 2007; Hamon & 
Blier, 2013), the processes is dependent on glucocorticoid receptor function (Anacker 
at al., 2011). The hippocampus has a high level of glucocorticoid receptors and 
glutamate which make it vulnerable to impact from HPA activation, which will be 
discussed further below.  
 
1.5.2 Prefrontal Cortex 
One of the main connections thought to be involved in depression is the connection 
between the hippocampus and the prefrontal cortex (PFC). Two main pathways are 
hippocampus-thalamus-PFC pathway, involved in attentional processing and memory, 
and the ventral hippocampus-basolateral amygdala-PFC involved in fear memory and 
social behaviour (Samptah, Sathyanesan & Newton, 2017). The PFC is a key centre 
for cognitive functioning, affection, attention, and goal-directed behaviour, which are 
implicated in depression and depressive-behaviour. The episodic buffer, a component 
of working memory integrating multimodal information, relies on the hippocampus and 
the PFC. The episodic buffer is involved in the development and maintenance of 
depressive schemata through the activation of depressive thought processes 
(Belzung, Willner, Philippot, 2015). Depressive thought processes are maintained by 
a feedback loop, increasing the bias toward the negative thoughts (Belzung, Willner, 
Philippot, 2015). Further, negative cognitive bias, the increased memory sensitivity 
for negative stimuli, is associated with increased activity in PFC, amygdala and 
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hippocampus (Belzung, Willner, Philippot, 2015). Rumination, is an important 
psychological process in depression. It describes the tendency to over analyse one’s 
problems, feelings, and depressed mood states (Belzung, Willner, Philippot, 2015), 
and is found to correlate with decreased activity in the ventromedial PFC (Zhu et al., 
2012). In depressed patients, different patterns of activity are involved, e.g. 
hyperactivity is seen in the ventromedial PFC and hypoactivity is seen in the 
dorsolateral PFC (Koenigs & Grafman, 2009).  
 
Further, glutamate in the PFC plays a key role in depression. Ketamine, the NMDA-
receptor antagonist, has been shown to increase the number of synapses and the 
synaptic function in the PFC through mammalian target of rapamycin (mTOR) and 
extracellular signal-regulated kinase (ERK) signalling pathways (Liu et al., 2017). 
Drugs that increase glutamate clearance prevent or reverse effects of chronic stress 
and chronic glucocorticoid exposure and exert antidepressant effects (Lang & 
Borgwardt, 2013) through synaptic plasticity. There is an association between 
immune activation and mechanisms involved in depressive symptoms, 
communication between the neuro-immune system and neural stem cells, which are 
able to regulate neuroplasticity (Krishnan & Nestler 2012; Eyre & Baune, 2012).  
 
1.5.3 Amygdala 
The hippocampus is further implicated in depression via its connection to the 
amygdala, which in turn is also closely linked to the PFC. The amygdala is an area of 
the brain strongly associated with emotional modulation, emotional memory encoding 
and fear conditioning in animal studies. However, dissimilar to the hippocampus and 
PFC, stress is found to induce dendritic branching, the formation of new connections 
between neurons (Marsden, 2013). Furthermore, brain-derived neurotrophic factor 
(BDNF) expression, a protein that encourages growth of new neurons and regulates 
of synaptic plasticity, is increased in areas of the amygdala under stress (Lang & 
Borgwardt, 2013). Several studies find a decrease in BDNF levels in the hippocampus 
after stress (Lee & Kim, 2010). BDNF levels are however decreased in plasma of 
patients with depression. The decrease in neurogenesis and BDNF may be mediated 
through the neuroimmune system, with evidence of a decrease of CD4+ cells leading 




1.5.4 Ventral Tegmental Area & Projections 
The hippocampus is further linked to the ventral tegmental area (VTA). The VTA is 
responsible for dopamine synthesis in neurons (Hamon & Blier, 2013). These 
dopamine neurons further project to nucleus accumbens and PFC (Oades & Halliday, 
1987), part of the mesocorticolimbic pathway, and are involved in reward processing 
and aversion, as well as mediating short term to long term memory consolidation (Lui 
et al., 2017; Samptah, Sathyanesan & Newton, 2017). Increased firing rate of neurons 
in the VTA has been linked to susceptible and resilient animals after a repeated social 
defeat stress. This increase in firing rate is dependent on the projections of the 
neurons, with decrease firing rate seen in neurons projecting to the PFC (Chaudhury 
et al., 2013). However, stimulating VTA neurons using optogenetic techniques has 
also been shown to reverse the stress-induced deficits on the forced swim test and 
the sucrose preference test (Tye et al., 2013). The dopaminergic neurons from the 
VTA, PFC, and amygdala in the mesocorticolimbic pathway project to the nucleus 
accumbens (NAc), which is involved in the reward circuitry and motivation. Patients 
with depression show reduced activation in the NAc linked to the reward circuitry 
(Satterthwaite et al., 2015). The role of the VTA in depression and the complex 
interplay between stress and neurocircuitry will hopefully be further elucidated with 
more research (Polter & Kauer, 2015). 
 
The lateral habenula, which receives input from the hippocampus and sends 
projections to the VTA has been implicated in depression and treatment. Deep brain 
stimulation (DBS) of this brain area has an antidepressant effect in patients with 
treatment-resistant depression (Sartorius et al., 2010). Studies in animal models of 
depression show that NMDA burst firing in the lateral habenula induced depressive-
like behaviour (Yang et al., 2018). Infusions of ketamine into the lateral habenula 
cause rapid anti-depressant activity (Yang et al., 2018). This evidence suggests that 







The hippocampus is further involved in depression through its sensitivity to stress 
toxicity through the overactivation of the HPA axis (Hamon & Blier, 2013). One of the 
major theories of depression is the cortisol hypothesis which suggests that an 
overactive HPA axis may mediate symptoms of depression via 1) the increased 
production of corticotrophin-releasing factor (CRF) from the hypothalamus, and 2) the 
reduced negative feedback at the central glucocorticoid receptors (Krishnan & Nestler, 
2011). Glucocorticoid receptor functioning in the HPA axis is inhibited by 
proinflammatory cytokines such as interleukin-6 and tumour necrosis factor-alpha 
(Eyre & Baune, 2012). Increased HPA axis activity is seen in patients with depression. 
Higher levels of cortisol in the plasma and increased CRF in the cerebrospinal fluid 
are seen in MDD patients (Hamon & Blier, 2013; Mongeau et al., 2011). 
Antidepressants can restore cortisol levels by increasing the expression of 
glucocorticoid receptors which returns the feedback function to normal levels (Hamon 
& Blier, 2013). Glucocorticoid receptors can impact adult neurogenesis in the 
hippocampus. Overexpression of CRF during development in animal models leads to 
increased depressive-like behaviour in the forced swim test (Krishnan & Nestler, 
2011). The HPA axis plays a pivotal role in depression through a number of 
mechanisms. 
 
1.5.6 Other Mechanisms 
In addition to neurobiological evidence, several other factors have been correlated 
with depression including metabolic disorders, such as obesity and diabetes. Leptin, 
a hormone that regulates energy balance in inhibiting hunger, acts at receptors in the 
hypothalamus. Leptin has been associated with mood symptoms as well as being 
involved in neurogenesis (Lawson et al., 2012). There appears to be a bi-directional 
risk between diabetes and depression, both diseases increase the risk of developing 
the other (Lang & Borgwardt, 2013). In addition, ghrelin, an amino-acid peptide 
involved in increasing hunger, is correlated with mood. Increased ghrelin is observed 
after acute and chronic stress (Chuang & Zigman, 2010) which may cause anti-
depressant behaviour. Lastly, insulin growth factor increases hippocampal 
neurogenesis and can display anti-depressant behavioural responses (Lang & 




Non-neuronal correlates for depression have recently been investigated. Most 
prominently, the gut microbiota has been shown to play a role in depression, through 
the brain-gut-microbiota axis. This communication occurs via direct signalling through 
the vagus nerve and independently of the vagus nerve through complex metabolic, 
endocrine, immune and neural pathways (Dinan & Cryan, 2017). The evidence for the 
role of the brain-gut-microbiota axis will be further discussed in chapters 5 and 6.  
 
To summarise, several brain areas and complex mechanisms are involved in 
depression including influences from peripheral mechanisms. Several streams of 
evidence converge to give us the current understanding of pathophysiological 
mechanisms behind the disorder but there are many questions still to be answered to 
provide the full picture. One way to help us elucidate the unknown mechanisms is by 
utilising animal models. The animal models currently used will be discussed in the 
section below.  
 
1.6 Animal Models of Depression  
Preclinical investigations contribute significantly to understanding the mechanisms 
underlying depression, which can, in turn, inform treatment development and have 
shown successful translation into clinical research. One example of this contribution 
is the investigations into the CLOCK gene’s involvement in circadian rhythms and 
depression (Vitaterna et al., 1994; Bunney & Bunney, 2000). This research 
contributed to advances in successful treatments such as light therapy for depression 
and seasonal affective disorder (Eastman et al. 1998; Tuunainen et al., 2004). 
Preclinical experiments have the ability to model and dissect important mechanisms 
of action in the development and treatment of depression and can, therefore, provide 
insights into the neurobiology behind the disorder (Krishnan & Nestler, 2008). 
Additionally, preclinical experiments enable investigation into the safety and efficacy 
of proposed treatments prior to exposure in human cohorts (Kieburtz & Olanow, 2007), 
as well as the effect of treatments on a broad range of outcome measures, potentially 
characterising potential side effects. This knowledge can subsequently aid 
investigations into the optimal way to prevent the occurrence of depression, and the 
best and earliest interventions, which are top research priorities recently identified by 
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an MQ: Transforming Mental Health report (MQ: Transforming Health, 2016). Animal 
models contribute significantly to our understanding of depression.  
 
1.6.1 Ethics of Animal Experiments 
Animal experiments are a cornerstone of medical scientific discovery. Animal 
experiments have contributed significant understanding of underlying biological 
mechanisms and benefits to human health (Ioannidis, 2012; Comroe & Dripps, 1976). 
  
However, frequently animal studies do not translate to benefits for human health due 
to poor quality and poor reporting of animal studies (Pound et al., 2004). Less than 
10% of promising findings enter routine clinical use (Contopoulos-Ioannidis et al., 
2003) and data from animal experiments was rarely considered during clinical trial 
design (Pound et al., 2004). The public acceptance of animal research and indeed 
the ethical implications of conducting animal research hinges on producing benefits 
for human (Pound et al., 2004). Organisations such as the National Centre for the 
Replacement Refinement and Reduction of Animals in Research in the UK, endorse 
and assist researchers and legislators to adhere to the principles of 3Rs 
(Replacement, Refinement & Reduction). The principles of 3Rs were introduced in 
1959 (Russel & Burch, 1959) to reduce the inhumanity in animal experimentation. 
Replacement refers to methods used to avoid or replace the use of animals to answer 
scientific questions (Russel & Burch, 1959). Reduction refers to utilising appropriately 
designed methods to ensure that experiments are robust and reproducible, adding to 
the knowledge while using the minimum number of animals necessary and 
maximising the information gathered from each animal used (Russel & Burch, 1959). 
Refinement refers to methods to minimise the suffering and improve animal welfare 
(Russel & Burch, 1959). The NC3Rs in the United Kingdom work continuously to 
improve the techniques and methodologies used in animal experiments to ensure 
animal welfare (Prescott & Lidster, 2017). 
 
Animal experiments are only informative for clinical trials if the results are valid and 
precise (Pound et al., 2004). The internal and external validity of animal experiments 
and the potential reasons for translational failure are discussed further in section 1.6.4.  
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There is sufficient evidence to suggest that animal experiments are not adequately 
reported. These findings come from systematic reviews of animal experiments 
summarising and pooling data. The utility of systematic reviews of animal experiments 
is outlined in Chapter 2.    
 
Therefore, for animal ethics to be justified, we must ensure experiments are 
conducted accurately, that the maximal output is retrieved, that the minimum amount 
of suffering is gained whilst still getting the scientific benefit, and that we do get the 
benefit to human health (Pound & Bracken, 2014). If research is not conducted to a 
high quality, if the internal validity and external validity of the experiment are not 
considered and controlled, then the animal research may be considered unethical and 
not justified.  
 
The following sections will discuss the ways in which animal models of depression are 
characterised. Additionally, it will discuss ways in which animal models are assessed, 
generally on two broad concepts; internal and external validity. Internal validity is 
defined as “differences observed between groups of animals allocated to different 
interventions may, apart from random error, be attributed to the treatment under 
investigation” (van der Worp et al., 2010, pg. 2). External validity refers to the 
generalizability of a study to a broader population beyond the animals investigated in 
the study, both to the same and to other species. The commonly used animal models 
in the literature will be discussed.  
 
1.6.2 Characteristics of Animal Models of Depression 
Broadly speaking, there are two types of interventions that are employed in the 
research on animal models. We distinguish between (1) interventions used to induce 
a model of depression or to mimic a depressive-like phenotype, and (2) interventions 
used to “rescue” depressive-like phenotypes through the testing of potential 
antidepressants. Further, we distinguish these from the measurement or assessment 
of depressive-like outcomes or variables of interest that could elucidate the underlying 




In animal models of depression, the intervention being investigated is not always easy 
to distinguish. A model can be defined as including both a dependant variable (an 
outcome assessment/measurement) as well as an independent variable (model 
induction or manipulation) (Geyer & Markou, 1995). In the study of animal models of 
depression, the independent variable, “model induction”, and the dependant variable, 
outcome measurement, can occur simultaneously or the assessment of the outcome 
is carried out soon after the model induction, (e.g. often the case in forced swim test 
experiments). The extent to which these experiments have external validity or the 
extent to which these findings can be generalised to other species, particularly the 
human condition, can be brought into question (Walker et al., 2014). A clinical 
diagnosis of depression requires that symptoms be present for at least two weeks 
(see section 1.2). When an animal model of depression is induced simultaneously 
with the outcome measure assessment, this brings into question how predictive this 
model is of an antidepressant effect in the human condition. This concept is discussed 
further in section 1.6.3 Translational Failure.   
 
One proposal to improve translational failure is by incorporating the entire illness 
trajectory into the preclinical modelling of depression (McGorry et al., 2006). Currently, 
few animal models attempt to mimic different stages of the progression of depression, 
acknowledging that different symptoms may emerge at separate stages of the 
disease (Walker et al., 2014). This may be one of the reasons why recent compounds 
have been found to display great promise at the preclinical phase, but have failed to 
translate successfully to clinical trial (e.g. NK-1 receptor antagonist, Belzung, 2014; 
Cryan & Slattery, 2007). ‘Back-translation’, or the use of information from clinical 
studies to improve the preclinical modelling of diseases, was improve translational 
failure in depression. The use of clinical or epidemiological data on the progression of 
depression through the course of the human lifetime could improve the translation of 
preclinical data. One way to get a step closer to stage-specific animal models could 
be to develop metrics or measures, based on existing outcome measures, such that 
performance on an outcome measure is indicative of which stage of the disease an 
animal is displaying (Walker et al., 2014). For example, grading a recognised outcome 
measure, such as intracranial self-stimulation for anhedonic behaviour, and assigning 
‘intensity-dependant’ levels or cut-offs in the outcome measure to particular stages of 
the disease may be worthwhile research (Walker et al., 2014). The aim of this 
28 
 
approach is to guide phase-specific interventions clinically, which could slow or halt 
disease progression. Further, developing or targeting specific drugs for acute 
depression or suicidal patients, interventions to ensure patients experience a longer 
remission period, or drugs for maintaining remission in between depressive episodes, 
could result in benefits to the treatment and wellbeing of patients suffering from 
depression. By modelling depression at a stage-specific level, this could improve the 
translation of drug treatment findings into clinical trials (Walker et al., 2014). One 
potential limitation of this approach is the quality of the clinical data available. If these 
data do not fully characterise the progression of depression or there isn’t sufficient 
data, then this could impact the success of the modelling preclinically (see section 1.3 
and 1.6.2).   
 
Another potential method for improving the external validity of depression models by 
more closely mimicking the human disease is to characterise sub-types of depression 
within the preclinical data. An example of this would be performing clinical meta-
analyses that characterise symptom-clusters to guide preclinical research. Symptom-
clusters are defined as “two or more symptoms that are related to each other and that 
occur together” (Kim et al., 2005, pg. 278). Characterising and successfully modelling 
several different symptom-clusters preclinically that commonly occur in the human 
disease could prove a fruitful avenue to test novel compounds to create more targeted 
or tailored drug treatments. This method could produce higher remission rates in 
patients when potential treatments are translated through to clinical trials. Further 
investigation into ‘symptom-clusters’ clinically could generate knowledge about the 
different underlying mechanisms leading to symptoms or why some symptoms 
frequently co-occur (Fried, 2017). See above section 1.3 for further discussion.  
 
As presented above, animal models aim to help us understand the underlying 
mechanisms behind a disorder, with increased experimental control, and to 
investigate potential treatments. By assessing the validity of animal models and 
experiments, we can evaluate whether we are getting as much information as possible 
from animal models and assess the potential for improvement to model the disorder 




1.6.2.1 Internal Validity 
Internal validity refers to the fact that “differences observed between groups of 
animals allocated to different interventions may, apart from random error, be 
attributed to the treatment under investigation” (van der Worp et al., 2010, pg. 2). 
Several biases can threaten the internal validity of an experiment namely; selection 
bias, performance bias, detection bias, and attrition bias. Selection bias occurs when 
the allocation of animals to treatment groups is biased. The main method to combat 
this is to use an unbiased method to randomly allocate animals to groups, preventing 
any conscious or unconscious bias arising from experimenters manually selecting the 
animals (van der Worp et al., 2010). One tool to help researchers randomise is the 
National Centre for the Replacement, Refinement & Reduction of Animals in 
Research (NC3Rs) Experimental Design Assistant (https://eda.nc3rs.org.uk/) to 
generate a spreadsheet with the randomised allocation report for experiments. 
Performance bias occurs when bias is introduced when an experimenter handles the 
animals differentially during care or under experimental conditions. The main method 
to combat this is to blind the experimenters to the group the animals belong to, where 
possible, so that experimenters do not consciously or unconsciously handle animals 
from separate groups differently (van der Worp et al., 2010). Detection bias or 
observer bias occurs when bias is introduced into the results when an experimenter 
is assessing the outcome. This bias may be introduced if the experimenter has 
knowledge of the group or treatment allocation. One of the main methods to combat 
this issue is to ensure the experimenter is blinded to the group or treatment allocation 
during outcome assessment (van der Worp et al., 2010). Attrition bias occurs when 
drop-outs from experiments or exclusions from the experiments are handled in a 
biased manner or introduce bias into the results (de Vries et al., 2014; Hoojmans et 
al., 2014). One of the main methods to combat this is by pre-specifying how and on 
what basis animals will be excluded from analyses and if possible, or to state a priori 
an intention-to-treat analysis plan where all subjects are included in the final analysis 
even if there are drop-outs (de Vries et al., 2014; Landis et al., 2012). 
 
It is important to assess the extent to which these measures to reduce the risk of bias 
are reported in preclinical models of depression to assess the reported quality of these 
experiments. For example, if reporting of measures to reduce the risk of bias in the 
literature pertaining to a particular drug is poor, then that provides a rationale for 
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further studies with higher quality to be conducted prior to translating the findings 
through to a clinical trial.   
 
1.6.1.2 External Validity 
External validity refers to the generalisability of a study to a broader population beyond 
the animals investigated in the study. There are several areas to note when assessing 
the external validity of a preclinical study and its generalizability to the human disease 
namely;  
1) differences between animals and humans, differences in comorbidities 
assessed in the animal literature and the comorbidities likely experienced by 
patients,  
2) differences in the timing of treatment administration and the dosing of 
treatment between preclinical and clinical situations,  
3) differences between the selected outcome measures at the preclinical level 
and the comparability of these with the outcome measures used in clinical 
trials. 
Traditionally, face validity, predictive validity, and construct validity have been 
important factors in the development of animal models of depression (Willner, 1984). 
According to the original criteria of evaluation proposed by Willner (1984), face validity 
refers to whether the model resembles depression clinically, and whether the 
antidepressant effects are seen after similar chronic administration, similar to 
antidepressant efficacy in humans. The concept of face validity can be linked to the 
diagnostic criteria (ICD-10 & DSM criteria), which rely on cognitive and behavioural 
dimensions (Belzung & Lemoine, 2011). This brings into consideration a debate of 
whether face validity should assess how well models mimic a single symptom or 
whether face validity should refer to how well the model mimics the whole disorder 
(Belzung & Lemoine, 2011; Willner & Mitchell, 2002).  If a model mimics a single 
symptom, this bears the assumption that the symptoms of a disorder are independent. 
Currently, research is being carried out to understand the clustering of symptoms in 
humans and to what extent symptoms are dependent or causally linked (see above 




Predictive validity refers to the pharmacological effects of drugs, whether a model of 
depression is sensitive and specific to drugs that have an antidepressant effect in 
humans, and whether the dosage required for efficacy reflects the doses given 
clinically (Willner, 1984). Geyer and Markou (1995) added an important dimension to 
predictive validity, namely that it should allow one to make “predictions about the 
human phenomenon based on the performance of the model” (Geyer & Markou, 1995, 
pg 790), which does not limit the definition to the predictability of a drug but expands 
it also to include underlying psychopathology. As Belzung and Lemoine (2011) note, 
a definition based only on pharmacological potency relies on “knowing” what effect a 
drug has in humans.  
 
Broadly speaking, construct validity can be defined as “the accuracy with which the 
model measures what it is intended to measure” (Koob, Heinrichs & Britton, 1998). 
Further it can be defined as the theoretical relationship to depression (Willner, 1984). 
As Willner (1994) expanded on in a subsequent publication, this includes the similarity 
with the human etiology, biological dysfunctions, the cyclical nature of the disorder, 
and information pertaining to events that trigger depression, as well as the link 
between the etiology and the dysfunctions (Belzung & Lemoine, 2011).  
 
In addition to assessing these main types of validity, Belzung and colleagues have 
worked extensively to further characterise aspects of the animal models of 
neuropsychiatry that can assist to improve animal models of neuropsychiatry 
(Belzung & Lemoine, 2011; Willner, 1994). Their proposed new framework broadly 
encompasses the same three main criteria; construct validity, predictive validity and 
face validity, in much more detail with sub-categories of validity within these broad 
groups, as well as incorporating new concepts such as mechanistic validity, biomarker 
validity, and induction validity. These newly defined concepts will be discussed in 





Figure 1.3. “Criteria of validity for animal models” (Belzung & Lemoine, 2011, pg. 8) 
 
Firstly, homological validity assesses which strain and species have been chosen for 
the model. This concept takes into consideration the biological and anatomical 
similarity between the species used as a model and human biological mechanisms 
(Belzung & Lemoine, 2011). Pathological validity assesses “the similarity of processes 
that lead to disease” (Belzung & Lemoine, 2011, pg. 7). This concept encompasses 
two sub-categories of validity, ontopathogenic validity, which refers to whether similar 
environmental factors in early life produce a vulnerable state in the organism (Belzung 
& Lemoine, 2011).  The second; triggering validity, refers to whether similar factors 
during adulthood trigger the organism to enter a vulnerable or disease state (Belzung 
& Lemoine, 2011). Mechanistic validity assesses the “similarity of the mechanisms we 
suppose or know in the animal disease, compared to the mechanism that is proposed 
or known in humans” (Belzung & Lemoine, 2011, pg. 8). This concept encompasses 
both the mechanisms that we postulate cause a symptom, as well as the mechanisms 
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through which therapeutic interventions are thought to work. Belzung and Lemoine 
differentiate between the mechanisms and the effects of the mechanisms. Symptoms 
may be the result of interactions of several mechanisms, rather than the direct effect 
of a mechanism (Belzung & Lemoine, 2011).   
 
Secondly, face validity corresponds similarly with Willner’s original concept, the 
referring to the similarity between what is observed in animals and humans, with the 
addition of explicit sub-concepts; ethological validity and biomarker validity. 
Ethological validity refers to whether pathological behaviours are similar in the animal 
model compared to the human disease. Belzung and Lemoine highlight that this 
needn’t be a direct comparison, rather behaviours characteristic of that species 
(Belzung & Lemoine, 2011). Biomarker validity refers to whether the function of 
biomarkers is similar across species.  
 
Thirdly, predictive validity refers to “the similarity of the relationship between the 
triggering factors and the occurrence of the disease as well as the relationship 
between the therapeutic agent and the disease state” (Belzung & Lemoine, 2011, pg. 
9). This concept assessed symptoms with broad brush strokes and refers to whether 
there is a similarity between the impact of etiological factors as well as the observable 
effects of the treatment investigated without looking at the mechanism that is at work 
(Belzung & Lemoine, 2011), and encompasses the sub-concepts induction validity 
and remission validity.  
 
“ An animal model of disease is not just a model of the action of a therapeutic agent 
at time point T. It has to draw from the comparison between two pathological 
organisms, but possibly also mimic the temporal and etiological process of 
transformation from a healthy organism to a pathological one via the state of 
vulnerability.” 




Induction validity refers to whether the etiological factors have similar actions of the 
observable factors in the outcome measures as in the human condition. Remission 
validity refers to the same concept, but whether the observable effects of a treatment 
in an animal model are similar to that seen in the human condition.  
 
There is merit to the added understanding of the strengths and limitations of animal 
models, as assessed by these criteria. There is a potential lack of understanding of 
the interface between the psychopathology, the underlying psychological processes 
behind depression, and the pathophysiological, the biological implications. (Belzung, 
Willner, Philippot, 2015). How much do we know about the human biology, psychology, 
and the interaction of these mechanisms, and how far can we map these mechanisms 
in animal models? How can we best use the data and knowledge from animal models 
to inform our treatments in the human condition? And how can we use knowledge 
about the clinical condition to help improve the animal models we currently have?  
 
1.6.3 Broad Categories of Model Induction in Animal Models of Depression 
Building on the framework laid out by Belzung and Lemoine (2011), an organism may 
have a predisposing genetic vulnerability, early environmental factors or triggering 
factors. These may take the organism from a vulnerable state into a pathological 
organism, where the cognitive and biological mechanisms are different from the initial 
organism state.  
 
Animal models of depression can be categorised into models that aim to mimic 
genetic factors, early environmental factors, and triggering factors. Therefore, these 
models can be categorised into Genetic Models, Developmental (in early life or 
adolescence) Models, and Acute Models, respectively. A number of techniques are 
used to induce depression across these stages. Stress, pharmacological 
interventions, and genetic manipulations can be implemented across all life stages.  
Stress models grew out of the Diathesis-Stress hypothesis, which hypothesises that 
disorders develop out of an interaction between a predisposition to a vulnerable state 
and a stressful event caused by life experiences (Monroe & Simmons, 1991; 
Abramson, Metalsky, & Alloy, 1989). Predisposition has expanded from its original 
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definition of biological or genetic factors, to include psychological and situational 
factors.  
 
These models exhibit a number of cognitive, behavioural, and biological phenotypes. 
Genetic Models include transgenic models, and selectively bred models such as 
Flinders Sensitive Line (FSL) or congenital learned helplessness. Transgenic models 
are where a specific gene has been manipulated to increase or decrease expression 
and induce behavioural phenotypes such as learned helplessness behaviour (Wang 
et al., 2017; Ridder et al., 2005). Most transgenic models alter genes involved in the 
serotonin and glucocorticoid pathways and help elucidate the mechanisms behind the 
involvement of these genes and proteins in depression. Selectively bred models take 
animals that display a certain behavioural phenotype and breed them to maintain the 
behaviour across generations. Selectively bred animals such as the FSL animals 
exhibit behavioural despair phenotypes as well as biological phenotypes similar to 
depressed patients such as cholinergic sensitivity (e.g. Overstreet et al., 1996).  
Developmental Models include early life stress models such as maternal separation, 
and the use of pharmacological interventions such as cytokine and corticosterone 
injections to target the HPA-axis or inflammatory pathways and induce a biological 
state similar to depression. Gluco-corticosterone injections induce a physiological 
state of stress with behavioural despair and anhedonia (Zhao et al., 2008). Stress or 
pharmacological interventions can be administered acutely or chronically to induce a 
depressive-like phenotype, and they can be administered both in early life, 
adolescence and adulthood.  
 
Acute models in adulthood aim to mimic the triggering factors that mean an organism 
transfers into a disease state, either from an initial “healthy” state, or from a vulnerable 
state. Several different interventions have been developed and implemented in 
relation to depression. Firstly, models that utilise stress have been implemented 
including; unpredictable chronic mild stress (Katz et al., 1981) where animals are 
subjected to a series of different unpredictable stressors over a period of weeks. 
Further models include chronic restraint stress (Holsboer et al., 1987), where animals 
are restrained from moving for a number of days or weeks, and social defeat stress 
where animals are subjected to an emotional stressor of an older, more aggressive 
animal in the home cage (Blanchard & Blanchard, 1977). Animals exposed to stressful 
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events display key behavioural phenotypes such as anhedonia and learned 
helplessness as well as key biological readouts such as changes in body weight, 
sexual behaviour, and changes in biological readouts from the HPA axis network and 
neurotransmitter levels (Wang et al., 2017). Additional models include olfactory 
bulbectomy, a surgical model where removal of the olfactory bulb in rodents elicits 
biological and behavioural mechanisms that mimic depression (van Reisen, 
Schnieden & Wren, 1976). Other acute pharmacological models include administering 
corticosterone, cytokine, or glucocorticoid insults (Wang et al., 2017) either a single 
administration or chronically over a number of days to stimulate the HPA axis or 
inflammatory pathways, see above section 1.3 Pathology.  
 
Another commonly administered acute stressor is the forced swim test (FST) in rats 
or the tail suspension test (TST) in mice. The FST was originally developed by Porsolt 
and colleagues in 1977 for mice and the TST in 1978 for rats were introduced as 
models of depression. The FST involves subjecting animals to an acute stressor of 
being in a water tank from which they are unable to escape. The TST involves hanging 
mice by the tail above the ground, similar to the FST, a stressful event from which 
animals are unable to escape (Steru et al., 1985). At first, animals try to escape from 
the situation, but after some time give up and display behavioural despair. In some 
experiments, a pre-swim is administered approximately 24 hours prior to the testing, 
where animals are exposed to the stressful situation for a longer period.  
 
Although sensitive to pharmacological agents, recent critique has characterised this 
test as an antidepressant screening tool rather than a model of depression in line with 
the validity criteria set out by Janssen in the 1960s; that the aim of behavioural tests 
such as these was to find a “reproducible, reliable and rapid method to test 
compounds” (Janssen, 1964). Further critique towards the FST and TST has called 
into question the cognitive mechanisms behind the behavioural despair, with some 
authors claiming that despair behaviour reflects coping mechanisms and adaptive 
behaviour (Commons et al., 2017; Molendijk & de Kloet, 2015).  Despite these 
criticisms, the FST and TST are still widely used to assess behavioural despair in 




1.6.4 Translational Failure 
The aim of using animal models is to help understand the human disorder and to 
extensively test therapeutic agents prior to application in humans. To maximise 
information gained from animal models in depression, it is paramount to have a clear 
framework with which to understand our work.  The field of neuropsychiatry has many 
methods of inducing depressive-like phenotypes, all of which contribute unique 
knowledge, however, attempts to systematically synthesise this evidence in light of a 
clear framework has been lacking, as well as concerns regarding the quality of 
preclinical animal studies.  
 
Even with seemingly good face validity and predictive validity, preclinical findings, do 
not always translate successfully into clinical trials. This has been seen especially in 
the field of drug interventions for depression (Cryan & Slattery, 2007). One example 
of poor translation is the case of NK-1 antagonists for depression. NK-1 antagonists 
displayed very promising results in reducing depressive-like behaviour in preclinical 
trials and were tested thoroughly, with various models and in a range of outcome 
measures (Belzung, 2014). This potential treatment was taken through clinical trial 
with mixed results in Phase 2 and ultimately discontinued. The following section will 
go into more detail about the potential reasons for translational failure. 
 
There are some potential pitfalls when translating promising findings from preclinical 
studies into clinical trials. These fall generally into three categories;  
1) limited internal validity of the preclinical studies,  
2) limited external validity of the preclinical studies, and  
3) poor design of clinical trials (van der Worp et al., 2011). 
 
Firstly, internal validity, as highlighted above, has important ramifications for the 
confidence in the findings from a study. The investigation into the reporting of 
measures to reduce the risk of bias in other neurological fields has revealed that 
studies that do not report measures to reduce the risk of bias tend to overstate the 
efficacy of a drug (Van der Worp et al., 2007; Van der Worp et al., 2010). This might 
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translate to animal models of depression both for the overstatement of efficacy of 
treatments as well as an overstatement of the evidence for biological mechanisms 
altered with knock-out animals for example.  
 
Secondly, external validity, the confidence with which we can generalise the findings 
of a study to a broader population beyond the subjects investigated in the study. Some 
original criteria by which to evaluate the external validity of animal models of 
depression can be critiqued. The idea of predictive validity that is based on 
pharmacological efficacy similar to human efficacy, can be seen as a problematic 
argument, in that the efficacy must be known in a human population. For the 
development of new drugs and alteration of mechanisms thought to be involved in 
depressive-phenotypes, the mechanisms must be known in the human population. 
Further, the use of screening assays such as the FST and the TST can be critiqued. 
When interventions used to induce depressive-like phenotypes are simultaneously 
used as outcome measure assessment, this brings into question how predictive this 
model is of an antidepressant effect in the human condition. Further, the acute 
administration of antidepressant agents reverses the behavioural despair in FST and 
TST, whereas these drugs take weeks to be effective in humans (Krishnan & Nestler, 
2011).  These are just examples of potential issues that could impact the translation 
of findings from animals to inform human treatments and research.  
 
Thirdly, the final issue when translating preclinical findings to clinical trial is the 
potential for key limitations of preclinical literature to be overlooked when designing 
the clinical trial (van der Worp et al., 2010). Potential ways to tackle this would be to 
have inter-disciplinary groups involved when translating preclinical research, or for 
thorough systematic reviews of the preclinical literature to be conducted prior to the 
clinical trial design.   
 
Therefore, it is of interest to systematically gather information about animal models of 
depression, both to provide an overview of the field as well as assess the reported 
quality of these studies. With regard to external validity, which animal models do we 
have most confidence in? What is the quality of evidence available from different 
animal models? What types of models that are used in further understanding the 
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mechanisms behind depression by modelling phenotypes in animals and experiments 
used to understand antidepressant drug development? Is there evidence that these 
differences could this affect the success of subsequent translation?  
 
The aims and objectives of this thesis are outlined below.  
 
1.7 Aims & Objectives 
Overall Aim: To provide an overview of the in vivo animal models of depression used 
in the literature. 
 
Objectives: 
1. Model induction: Investigate how animal models of depression are induced. 
Which models provide the most reliable outcome yet cause least suffering to 
animals? 
2. Outcome measures: 
a. Commonly used outcome measures: Investigate the outcome 
measures assessed in animal models of depression. What are the 
relationships between outcome measures? Are there tests which are 
more reliable to measure an outcome? Investigate the cost-
effectiveness of outcome measures, are there any commonly used 
tests which can be streamlined (e.g. in severity or number of animals 
used) and still produce a reliable/significant effect? 
b. Outcome measures of clinical relevance: Are the outcomes measured 
in animal models significantly relevant to the endpoints investigated in 
human trials? Can translatability be increased? Do behaviours induced 
in animals reflect the data-driven clusters of symptoms in patients? 
3. Quality of studies: Investigate reporting bias and quality in the in vivo 
modelling of depression literature. What is the standard of reporting and what 
measures are commonly implemented in the preclinical depression literature 
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to reduce bias? How can bias in the preclinical depression literature be 
reduced? 
4. Drug efficacy: Provide an overview of the efficacy of different drug 







2 SYSTEMATIC REVIEW & META-ANALYSIS  
2.1 Systematic Review 
 
“Large-scale review and integration of existing theory and research may be 
considered a type of research in its own right - one using a characteristic set of 
research techniques.”  - Feldman, 1971, pg. 86 
 
Systematic review is a technique used to systematically search for and gather 
published literature to answer a specific research question. This technique was coined 
by Feldman in 1971 when he wrote that this technique should be a research field of 
its own. The use of this technique has increased since the term was coined, as is 
reflected in the amount of papers published with this key term. A PubMed search 
yielded 5719 results for ‘systematic review’ in 1971 and over 120,000 hits in 2017. 
The Cochrane Collaboration has been fundamental in the setting up of gold standards; 
a framework for systematic review methodology and advocating for the use of these 
techniques to inform healthcare policy (Vesterinen et al., 2014). Whilst Cochrane have 
helped to revolutionise the use of systematic review and its wide-spread use, their 
techniques are primarily for the analysis of interventions in humans and there are 
considerations that need to be taken into account when transferring the use of these 
tools for systematically reviewing and analysing data from animal studies.  
 
Systematic review (SR) is different to other literature synthesis techniques in that the 
formal steps of the process are explicitly defined so they can be reproduced by other 
teams (Biondi-Zoccai et al., 2011). The formal steps involve; extensive searching for 
primary studies on a topic, using explicit criteria for selecting studies, and criteria for 
appraising the internal validity of studies, indentifying what data or information will be 
extracted from the studies, and where appropriate the pooling of statistical data, and 
finally, publishing the findings. The steps taken for a project are all outlined in a 
prespecified protocol to ensure the process is transparent and clearly defined. These 





Figure 2.1. Steps of a Systematic Review 
 
2.1.1 Research Question 
Forming the research question is the first step of SR and outlines the rest of the 
process. Research questions can ask a specific, usually healthcare related, question 
or simply provide an overview of a field. In SRs of animal studies, research questions 
may relate to a) understanding which variables impact the effectiveness of an 
intervention to inform the design of future animal studies; as well as b) getting an 
overview of the type, breadth and quality of evidence about an intervention to assess 
whether there is enough evidence to translate the findings to clinical trials.  
 
2.1.2 Search Strategy 
The aim is to identify all available literature pertaining to your research question. 
Systematically searching for literature relevant to the research question often involves 
creating search strings to interrogate online bibliographic repositories or databases of 
published studies. Repositories such as PubMed, EMBASE, Web of Science, and 
PSYCHinfo are commonly searched. Systematic searching may also involve 
searching through grey literature and unpublished literature such as in-house animal 
trials done in pharmaceutical companies, or hand searching the reference lists of 
studies included in the review. The methods for identifying literature should be 
explicitly described. Systematic Review Centre for Laboratory Animal 
Experimentation (SYRCLE) has developed extensive search strings for PubMed and 
EMBASE that encompass animals and animal experimentation (Leenaars et al., 
2012). These search strings can be added to the disease/drug search string to try and 











Study Quality Meta-Analysis Publication
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2.1.3 Study Selection 
Criteria for selecting studies to be included in the systematic review are very specific 
to the field and to the research question. Inclusion criteria often include key terms 
included in the research question, such as whether the paper mentions the use of the 
drug of interest, the disease model of interest, and the experiment performed on the 
species of interest. Inclusion or exclusion criteria may also relate to the experimental 
design used in the study, the dates the study was published, the language in which 
the study was published, and whether the paper mentions key pieces of information 
such as sample sizes or measures to reduce the risk of bias. These criteria must be 
clearly defined and pre-specified to reduce bias in the review where studies are 
included based on significant findings and reduce the subjectivity of the independent 
reviewers (de Vries et al., 2015). It may be necesary to apply different inclusion criteria 
at title and abstract screening stage and at the full-text screening stage because there 
may not be sufficient information in the abstract to make a decision as to whether an 
article is relevant or not.   
 
2.1.4 Criteria for appraising internal validity of studies 
It is relevant to assess the quality of the primary studies that are included in the 
systematic review, to know the strength of evidence. The criteria with which internal 
validity is assessed, discussed more in depth in the previous chapter, involves the 
reporting of measures to reduce the risk of bias such as whether subjects were 
randomly allocated to groups, whether the experimenter was blinded to the group 
allocation for the duration of the experiment and during outcome assessment. Criteria 
upon which to assess measures to reduce the risk of bias may include, the 
CAMARADES checklist (Macleod et al., 2004), the Landis 4 criteria (Landis et al., 
2012), SYRCLE risk of bias tool (Hooijmans et al., 2014), and aspects of the ARRIVE 
guidelines (Kilkenny et al., 2010). 
 
2.1.5 Data Extraction 
In the protocol of the SR, the information and data that will be extracted from all 
primary articles, where reported, are specified. Information extracted may relate to 
factors of experimental design thought to be relevant to the impact of the intervention 
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or drug. If a quantitative summary of the data is planned, key values such as group 
sample size, the key statistic of interest, and a measure of variance for each group 
may be extracted to compute a summary effect size. All data extraction is done in 
duplicate; therefore it is key to pre-define what aspects will be extracted.  
 
2.1.6 Meta-Analysis 
Where appropriate, it may be possible to pool the statistical data from the primary 
articles to get an overall estimate of whether an intervention is effective and explore 
the variables that impact the effectiveness of the intervention. It might further be of 
interest to assess the degree of publication bias within a field. These analyses are 
conducted using meta-analysis (MA) and will be discussed in more depth below.  
 
2.1.7 Publish 
The final stage of the SR process is to publish the findings and disseminate the 
knowledge to ensure that the key stakeholders and consumers of the research, 
whether policymakers, primary animal researchers, or clinical trialists, have access.  
The report of the SR and MA should include all the necessary information for readers 
to assess how the systematic review has been carried out and assess the measures 
to reduce the risk of bias in the SR in compliance with the PRISMA guidelines (Liberati 
et al., 2009). Just as it is important to assess the quality of primary studies included 
in a systematic review, it is just as important to ensure that systematic reviews are 
reported adequately and that methods are transparent and reproducible. Several tools 
for assessing the reporting of systematic reviews, such as the Oxman and Guyate 
Index for appraising systematic reviews (Oxman & Guyatt, 1991) which spurred the 
development of the AMSTAR tool (Shea et al., 2009) to assess the quality of 
systematic reviews, and guidelines for authors of SRs to ensure transparent reporting, 
the PRISMA guidelines (Liberati et al., 2009). A similar guide has been developed for 






2.2 Meta-Analysis  
“I like to think of the meta-analytic process as similar to being in a helicopter. On the 
ground individual trees are visible with high resolution. This resolution diminishes as 
the helicopter rises, and in its place we begin to see patterns not visible from the 
ground” 
- Ingram Olkin, quoted in Biondi-Zoccai et al., 2011 
 
Meta-analysis is a statistical technique used to quantitatively summarise the primary 
data, often by summarising the effects for each study or experiment. The estimation 
of effect sizes from several studies is a method that has been used since Pearson in 
1904. Pearson estimated the average correlation between inoculation for enteric fever 
and mortality. This was applied to other fields in 1931 when Tippet compared different 
farming techniques on agricultural yield. The term ‘meta-analysis’ was first coined by 
Glass and Smith in 1976 when they introduced statistical techniques for pooling data 
from several studies that had been collected systematically. The statistical tools of 
meta-analysis are dependent on the type of primary data that you are trying to pool. 
As the data from and characteristics of animal studies differ from clinical studies, 
different effect size calculations are used, and different considerations need to be 
taken.  
 
The first step of meta-analysis involves extracting the statistics from the primary 
articles of interest to calculate an effect size for each study, the mean or correlation, 
the number of subjects per group and an estimate of variance from each group. 
Several types of effect sizes can be calculated based on the data in the primary 
studies, including the effect sizes of means, correlational data, and effect sizes based 
on binary data such as risk ratio and odds ratio. The effect sizes from each study are 
pooled together under one of two assumptions, based on whether the true effect size 
is assumed to be the same in all studies or whether the true effect sizes differ between 
studies (Borenstein et al., 2009). The pooled effect size allows us to understand the 
direction of the effect and the magnitude of the effect (de Vries et al., 2015). Further, 
we can investigate the heterogeneity, the variation in true effects between studies, to 
“make sense of the pattern of effects” (Borenstein et al., 2009, pg. 107). Firstly, 
heterogeneity can be quantified using various statistics (see Borenstein et al., 2009 
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and Vesterinen et al., 2014). Then differences between studies are explored with, for 
example, sub-group analyses or meta-regression to assess the relationship between 
study-level variables and the effect size (Borenstein et al., 2009).  
 
Borenstein and colleagues provide an extensive guide to meta-analysis in their book 
published in 2009. Further they provide workshop and training materials to 
researchers embarking on this research endeavour (https://www.meta-analysis.com/). 
For a more specific guide on meta-analysis of data from animal studies, see the article 
by Vesterinen and colleagues (2014), which clearly outlines the considerations 
necessary for applying this technique to data from animal studies. Specific equations 
used in the below met-analyses will be explicitly stated in the relevant results chapters 
(Chapter 5 microbiota systematic, Chapter 6 Ketamine systematic review).  
 
2.3 Systematic Review and Meta-Analysis of Animal Studies 
The field of applying systematic review and meta-analysis to animal modelling 
literature first started pooling data from experimental stroke studies in the early 2000s. 
In 2001 Horn and colleagues investigated nimodipine in experimental stroke, and later 
in 2004 Macleod and colleagues investigated the effects of nicotinamide on 
experimental stroke (Macleod et al., 2004) and O’Collins and colleagues investigated 
evidence across interventions that target stroke in animal models (2006). The 
Collaborative Approach to Meta-Analysis and Review of Animal Data from 
Experimental Studies (CAMARADES) was founded that year in 2004. A research 
group with similar efforts is the Systematic Review Centre for Laboratory Animal 
Experimentation (SYRCLE), which was established in 2008. Since the initial 
application of these tools to the field of stroke in 2001 and 2004, they have been 
applied to many other neurological fields including Alzheimer’s disease (Egan et al., 
2016), breast cancer (Chen et al., 2016), glioma (Jue et al., 2018), spinal cord injury 
(Watzlawick et al., 2016), Parkinson’s disease (Rooke et al., 2011), multiple sclerosis 
(Vesterinen et al., 2010), pain (Currie et al., 2013; Seretny et al., 2014), and 
schizophrenia (Bahor et al., 2016). It has not yet been applied to the field of animal 




SRs of animal studies are exploratory and hypothesis-generating (Vesterinen et al., 
2014). All available relevant studies are included in a review and the impact of 
experimental design variables and sources of bias are explored to inform the design 
of future animal studies and of clinical trials (Vesterinen et al., 2014). Due to the sheer 
volume of preclinical investigations of depression continually being published, it is 
difficult to achieve an overview of what is already known, and to assess the marginal 
contribution of new research (de Vries et al., 2011). In this context, a systematic 
review of the existing preclinical literature can provide an unbiased, collective 
overview of existing knowledge which can help avoid unnecessary replication of good 
quality evidence as well as highlight gaps in knowledge and areas for additional, 
higher quality evidence to inform future experiments (Vesterinen et al., 2014). It can 
also provide a broader overview and understanding of the laboratory methods used 
to induce depression, the range of outcome measures used to assess depressive-like 
phenotypes, and the variables that might impact on the efficacy of different treatments 
(de Vries et al., 2011). Providing a broad overview of the literature can help avoid 
unnecessary replication of good quality animal studies (Vesterinen et al., 2014). This 
information is valuable to translation of findings through to clinical trials and can inform 
trial design (Vesterinen et al., 2014). The findings from preclinical systematic review 
and meta-analysis may also contribute to the refinement of methods used in animal 
investigations of depression, reducing the distress caused to animals by substitution 
with equally informative methods of lower severity; contribute to the optimisation of 
the numbers of animals used in depression research by informing well founded power 
calculations. 
 
The nature and design of primary animal studies means that the conduct and 
interpretation of meta-analysis is different to the established meta-analysis of clinical 
trial data. Animal studies tend to have small sample sizes, with studies being 
conducted across many laboratories introducing variance (Vesterinen et al., 2014). 
Even with the use of transgenic animals, the impact of sex of animals, animal 
husbandry and other experimental design variables mean there are more differences 
between studies in SRs of animal data vs SRs of clinical trials. Therefore, investigating 
heterogeneity, the differences between studies, is a primary aim of meta-analysis of 
animal data.  Further, there is more lack of independence both within studies and 
between studies. In a single study there may be several outcomes from the same 
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groups of animals, as well as a single control group serving multiple treatment groups, 
which contribute to the lack of independence within studies. Several studies may have 
been conducted at the same laboratory or by the same experimenter, which 
contributes to the lack of independence between studies. Nesting of outcomes from 
the same animals is the primary technique used to combat the lack of within study 
independence (Vesterinen et al., 2014). Hedges and colleagues have proposed a 
number of further statistical tools to deal with the lack of independence between 
studies (Hedges et al., 2010).  
 
2.3.1 Limitations of Systematic Review and Meta-Analysis Methods 
Despite its merits, there are a number of limitations of this methodology. Firstly, 
statistical limitations of meta-analysis, including the quality of the studies included. 
Secondly, bias in the sampling and issues of publication bias. Thirdly, the timeliness 
of the findings from the review. These issues, discussed below, can influence the 
overall results and reliability of a systematic review and meta-analysis.  
 
The findings from MA can be critiqued in that no meaningful information can be gained 
from averaging data from studies that have different definitions of the dependent or 
independent variable, or similar research questions (Hunt, 1997 in Rosenthal & 
Dimatteo, 2001). However, Rosenthal and DiMatteo argue that a quantitative 
summary can be useful when generalising findings to a field. In disease modelling in 
animals, it can be useful to understand the effects of an intervention in different 
circumstances, for example in different species, to evaluate the generalisability of 
findings.   
 
Meta-analysis is dependent on the quality of studies. In SRs of randomised controlled 
trials, poor primary study quality may be an exclusion criterion. In SRs of animal 
studies, often we don’t have this option as the reporting of measures to reduce the 
risk of bias varies greatly, and many primary studies are of poor quality (Sena et al., 
2007; Rosenthal & DiMatteo, 2001). There are differences in the reported 
effectiveness of treatments, were studies that do report measures such as, whether 
animals have been randomly assigned to treatment or control group and whether the 
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experimenter was blinded to the group assignment during outcome assessment, tend 
to report a more conservative effect size measure compared to those that do not 
report these measures (Macleod et al., 2015). It is important to assess the reporting 
of measures to reduce the risk of bias, as SR is also a form of observational research, 
we cannot exclude these factors from having an impact on the reported effectiveness 
of an intervention and we therefore we can only assess what has been reported 
(Vesterinen et al., 2014).  
 
Issues of non-independence of effects between and within studies, as discussed 
above, are dealt with using nesting techniques and other statistical tools (Vesterinen 
et al., 2014; Hedges et al., 2010). We must be sure to assess systematic reviews and 
meta-analyses with stringent criteria to ensure the quality of the findings, including 
ensuring that meta-analyses are adequately powered to detect pooled effects (Wang 
et al., 2018). Adequate power ensures that the findings from a study are not likely to 
be falsely positive, and therefore we conclude wrongly from the analysis. In meta-
analysis, statistical tests are used to determine whether there is significant 
heterogeneity between studies. If a meta-analysis is underpowered, there is a higher 
chance that a significant result in heterogeneity tests is falsely positive (Wang et al., 
2018). Simulation studies by Wang and colleagues found that meta-analyses using 
normalised mean difference to calculate effect size were higher powered than when 
calculating effect size using standardised mean difference (Wang et al., 2018). 
Further, they assessed the power of methods to explore heterogeneity. They found 
that when exploring heterogeneity, meta-regression was preferred with lower false 
positive rates compared to stratified meta-analysis (Wang et al., 2018). Quantitative 
methods for assessing publication bias can also be assessed for appropriateness. 
Funnel plots are the technique used for plotting of effect sizes against precision, 
where identification of asymmetry can indicate small study effects and publication bias. 
Zwetsloot and colleagues found that using standardised mean difference as your 
measure of effect size in funnel plots can distort the funnel plot and cause over-
estimation of the presence of publication bias (Zwetsloot et al., 2017). Authors 
recommend for meta-analyses where the use of standardised mean difference for 
calculating effect size is required, to use sample size based precision estimates. 
Using the most appropriate statistical methodology for meta-analysis, and 
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acknowledging known pitfalls, ensures that findings from SR and MA are as robust as 
possible.  
 
Systematic reviews can only present findings that are accessible. There will inevitably 
be studies that are missed during the search, however publication bias is rife across 
the field of biomedical sciences (Sena et al., 2010; Rosenthal & DiMatteo, 2001). 
Publication bias occurs when published studies are more likely to find their way into 
a meta-analysis, combined with the fact that significant studies are more likely to be 
published (Borenstein et al., 2009). If the studies that are not published have different 
findings or conclusions to those that are published, this introduces bias both in 
systematic reviews of the literature and in general searches of the online databases, 
and therefore the current understanding of a field can be biased (Sena et al., 2010).  
 
One approach that can potentially improve publication bias as well as addressing the 
internal validity of studies is the Open Science movement. The Open Science 
movement has been trying to address some of these issues we see in animal studies, 
by advocating to make scientific research and data accessible to all. They campaign 
actively for open access publications to make research more easily identifiable, 
available and make the reporting of research more transparent. They facilitate the use 
of open tools to make this process easier, including open notebook science and open 
software (UNESCO, 2017).  
 
“Sharing data and materials signals that researchers value transparency and have 
confidence in their own research.” - (McKiernan et al., 2016) 
  
Open access research has huge benefits to the community in that patients can access 
research to understand benefits and limitations of available treatments, tax-payers 
can access research that has been paid for with their contributions. Further benefits 
for researchers are that open access research is used more and has higher impact 
including, increased citation (Harnad, 2007; McKiernan et al., 2016; Wagner, 2010). 
Open access research is twice as likely to be published (Harnad, 2007). Not least, a 
major benefit of open access is the increased access for other researchers, including 
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meta-researchers, allowing more research to be available and included in evidence 
synthesis to provide the fullest picture of the evidence (Harmad, 2007). 
 
The practise of uploading partial or completed studies to preprint servers and 
experimental data from these studies to repositories has also increased (Lin, 2018). 
This practise has a number of benefits; encouraging the linking of data and pre-
specified analyses can improve the internal validity of studies, the content is 
accessible in future both for researchers and for data requests (McKiernan et al., 
2016). This overall increased transparency and increase in access of data can ensure 
that all available data is included in systematic summaries of a research topic 
providing a more accurate estimate in meta-analysis.  
 
Olkin noted over 25 years ago that a repository where data from published papers 
would be ideal to solve many of these issues, but that in 1995 was unattainable at the 
current date (1995). The field has made progress since Olkin’s remarks. A recent 
culture shift from the International Committee of Medical Journal Editors (ICMJE) 
comes in the form of a proposal to require data generated by interventional clinical 
trials that are published in its member journals to be responsibly shared with external 
investigators. Many large funders are supportive, with support from industry and 
academic trialists as well (Ross, 2016).  
 
Further, the registration of preclinical trials has been proposed as another method that 
would increase the internal validity of animal studies and ensure that published 
findings are in keeping with initial primary hypotheses, that exploratory research is not 
published as hypothesis-testing confirmatory experiments. A set-up similar to the 
proposal by the ICMJE, requiring hypothesis-testing animal experiments that 
investigate an intervention to responsibly share the data, at least for the primary 
hypothesis, would also aid in increasing transparency and aim to increase the quality 
of published experiments (Naci et al., 2015).  
 
Not all stakeholders share this viewpoint and enthusiasm for the topic. Researchers 
are apprehensive that competitive data that may form the basis for patents or 
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intellectual property rights may cause research groups to miss out or being “scooped” 
(Flather, 2015). Further concerns include data being analysed by teams or individuals 
without statistical expertise, and that post-hoc analyses are performed without 
sufficient statistical power. Further, although open access is growing in popularity, the 
widespread adoption of these practices has not yet caught on (McKiernan et al., 2016).  
 
The final limitation of systematic review and meta-analysis is that they are resource 
consuming research activities. The larger the review, the more studies are involved 
in the process, the longer the process takes. An average Cochrane review has been 
estimated to take approximately 67 weeks (Borah et al., 2017). This means that 
findings from large systematic reviews are likely to be out of date when published. 
The increasing amounts of literature published in biomedical sciences make the 
process of systematic review and meta-analysis time consuming. Olkin remarked in 
1995, that meta-analysis is the key to dealing with the increasing amounts of 
information. However, this era of information explosion has further erupted, and novel 
tools and approaches are required to help sort and categorise all of the information.  
One technique to assist with this limitation is the application of automation tools. 
Machine-learning and text-mining tools can be applied to steps of the systematic 
review to help reduce the amount of human resources required. These will be 
discussed further in Chapter 3 and Chapter 4.  
 
The methodology for this broad systematic review and meta-analysis is outlined below 
with a pre-specified protocol published in 2016.  
 

































2.4.1 Corrigendum to the Protocol  
In section 8.3 “Statistical methods to assess heterogeneity” of the published protocol 
there is an error in the section sentence on the p-value of Q. It should read, “A P-
value can be calculated for Q, giving an indication of whether all studies share a 
common effect size (P > 0.05) or not (P < 0.05)”.  
 
2.4.2 Implementation of the protocol 
The protocol for this study aimed to explicitly state the research questions and aims 
of this SR and MA, the search strategy used to identify records, the inclusion and 
exclusion criteria, the key pieces of information to be extracted from the primary 
articles, and the proposed methods for pooling the information together. A systematic 
search of PubMed and EMBASE was conducted in May 2016. The search retrieved 
70,365 unique research articles that were potentially relevant to the research topic, 
animal models of depression. With this amount of studies, it was not feasible to screen 
using two independent reviewers in a reasonable time-frame (estimated 64 person 
months). Therefore, machine learning algorithms were employed to learn the 
classification of papers into “Relevant” and “Not Relevant”.  
 
A sub-set of the studies was screened using an online systematic review facility to 
assist the conduct of systematic reviews, SyRF.org.uk (SyRF). 7000 studies were 
screened on SyRF by two independent reviewers against the inclusion criteria (see 
above pre-specified protocol), with a third independent reviewer reconciling any 
differences. These 7,000 studies were used to train machine learning algorithms to 
learn the decision-making capacity. The performance was assessed on sensitivity and 
specificity, and the aim was to achieve performance to pre-specified criteria. The 
algorithm achieved the desired level of performance and was applied to the remaining 
unseen documents (63,365). See Chapter 3: Methods Development for the methods 
and implementation of the machine learning techniques.  
 
The algorithm identified 18,409 documents to be included in the systematic review. 
The use of text-mining techniques to assist in annotating the included documents 
reduced the human resources required to categorise documents by topic of interest. 
66 
 
This enabled the next step of systematic review, extracting and analysing data from 
primary articles. The application of text-mining tools and custom dictionaries is 
outlined in Chapter 4. The methodology for subsequent systematic reviews and meta-
analyses of sub-topics within this broad review has been outlined with a separate 
protocol for each review.  
 
The following two chapters outline and detail the automation tools developed, tested, 




3 Methods Development – Machine Learning for Citation Screening 
The work in this chapter has been completed with help from internal and external 
collaborators. James Thomas from EPPI-Centre, University College London and Piotr 
Przybyła from National Centre for Text-Mining, University of Manchester contributed 
significantly with testing their machine learning approaches (Methods > Feature 
Generation & Classifiers). Kaitlyn Hair and Paula Grill from the CAMARADES team 
assisted with second screening the training set (Methods > Training Set). Special 
thanks to Jing Liao from CAMARADES for assistance throughout the project. This 
chapter has been submitted for publication and an earlier version of the manuscript 




The rate of publication of primary research is increasing exponentially within 
biomedicine (Bornmann & Mutz, 2015). Researchers find it increasingly difficult to 
keep up with new findings and discoveries even within a single biomedical domain, 
an issue that has been emerging for a number of years (Cohen et al., 2010). 
Synthesising research – either informally or through systematic reviews - becomes 
increasingly resource intensive as searches retrieve larger and larger corpuses of 
potentially relevant papers for reviewers to screen for relevance to the research 
question at hand.  
 
This increase in rate of publication is seen in the animal literature. In an update to a 
systematic review of animal models of neuropathic pain, 11,880 further unique 
records were retrieved in 2015, to add to 33,184 unique records identified in a search 
conducted in 2012. In the field of animal models of depression, the number of unique 
records retrieved from a systematic search increased from 70,365 in May 2016 to 
76,679 in August 2017.  
 
The use of text-mining tools and machine learning (ML) algorithms to aid systematic 
review is becoming an increasingly popular approach to reduce human burden and 
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monetary resources required and to reduce the time taken to complete such reviews 
(Howard et al., 2015; Tsafnat et al., 2014; O’Mara-Eves et al., 2015). ML algorithms 
are primarily employed at the screening stage in the systematic review process. This 
screening stage involves categorising records identified from the search into 
‘Relevant’ or ‘Not-Relevant’ to the research question, typically performed by two 
independent human reviewers with discrepancies reconciled by a third. This decision 
is typically made on the basis of the title and abstract of an article in the first instance. 
In previous experience at CAMARADES (Collaborative Approach to Meta-Analysis 
and Review of Animal Data from Experimental Studies), screening a preclinical 
systematic review with 33,184 unique search results took 9 months, representing 
(because of dual screening) around 18 person months in total. Based partly on this, 
we estimate that a systematic review with roughly 10,000 publications retrieved takes 
a minimum of 40 weeks. In clinical systematic reviews, Borah and colleagues (2017) 
showed the average clinical systematic review registered on PROSPERO 
(International Prospective Register of Systematic Reviews) takes an average 67.3 
weeks to complete.  ML algorithms can be employed to learn this categorisation ability, 
based on training instances that have been screened by human reviewers (Cohen et 
al., 2006).  
 
Several applications of ML are possible. The least burdensome is when a review is 
being updated, where categorisations from the original review are used to train a 
classifier, which is then applied to new documents identified in the updated search 
(Cohen et al., 2006; Cohen et al., 2012; Wallace et al., 2012a). When a screening is 
performed de novo, without such previous collection, humans first categorise an initial 
set of search returns, which are used to train an ML model. The performance of the 
model is then tested (either in a validation set or with k fold cross validation); if 
performance does not meet a required threshold then more records are screened, 
chosen either through random sampling or, using active learning (Lewis & Gale, 1994). 
Active learning involves interaction from the human user during the classification 
process to optimize the machine learning performance, for example, users may 
classify either of those with highest uncertainty of predictions (Wallace et al., 2010a; 
Bornmann & Mutz, 2015; Lui et al., 2016) or those most likely to be included (Miwa et 
al., 2014; Wallace et al., 2012b; Kontonatsios et al., 2017]. Here we use a de novo 
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search with subsequent training sets identified by random sampling, and we introduce 
a novel use of machine prediction, in identifying human error in screening decisions. 
 
Machine learning approaches have been evaluated in context of systematic reviews 
of several medical problems including drug class efficacy assessment (Cohen et al., 
2006; Cohen et al., 2012; Lui et al., 2012), genetic associations (Wallace et al., 2012a), 
public health (Shemilt et al., 2014; Miwa et al., 2014), cost-effectiveness analyses 
(Wallace et al., 2012a), toxicology (Howard et al., 2015), treatment effectiveness 
(Wallace et al., 2010b; Rathbone et al., 2015) and nutrition (Wallace et al., 2010b). 
To the best of our knowledge there have been only two attempts to apply such 
techniques to reviews of preclinical animal studies (Howard et al., 2015; Liao et al., 
2018). These can be broad and shallow reviews or focussed and detailed reviews, 
and can have varying prevalence of inclusion.   
 
Here we outline the ML approach taken to assist in screening a corpus for a broad 
and shallow systematic review seeking to summarise studies using non-human 
animal models of depression, based on a corpus of 70,365 records retrieved from two 
online biomedical databases. Here the aim was to identify the amount of training data 
required for an algorithm to achieve the level of performance of two independent 
human screeners, so that we might reduce the human resource required.  
 
Sena and colleagues developed guidelines for the appraisal of systematic reviews of 
animal studies (2014). These guidelines consider dual extraction by two independent 
human reviewers as a feature of a high quality review. From a large corpus of reviews 
conducted by CAMARADES we estimate the inter-screener agreement to be between 
95% and 99%. Errors may occur at random (due to fatigue or distraction) or, more 
consequentially, systematic error, which, if included in a training set, might be 
propagated into a ML algorithm. Sources of systematic errors with certain types of 
records are at greater risk of misclassification. To our knowledge the nature of this 5% 
residual human error in systematic review methodology has not been formally 
investigated. The training data used for ML categorisation is based on training 




The aim was to explore the use of established ML algorithms as part of a preclinical 
systematic review framework at the classification stage, to investigate if the ML 
algorithms could be used to improve the human gold standard by identifying human 
screening errors and thus improve the overall performance of ML.  
 
3.2 Methods 
We applied two independent machine learning approaches to the screening of a large 
(70,365 records) systematic review. Because we did could not predict how many 
training instances would be required, first I selected 2000 records at random to 
provide the first training set. Of these, only 1993 were suitable due to data deposition 
errors. These were then screened by 2 human reviewers with previous experience 
with reviews of animal studies, with a third expert reviewer reconciling any differences. 
The resulting ML algorithms gave a score between 0 and 1. To ensure that the true 
sensitivity was likely to be 95% or higher we chose as our cut-point the value for which 
the lower bound of the 95% confidence interval of the observed sensitivity exceeded 
95% when applied to the unseen validation dataset. This level of performance was 
chosen to match the comparable level of gold-standard human reviewing. I then 
repeated this process adding a further 1000 randomly selected (996 useable) citations 
to the training set; and then again adding a further 3000 randomly selected (2760 
useable) citations to the training set. At each stage, performance of the approaches 
was assessed on a validation set of unseen documents, using a number of different 
metrics. Next, the best performing algorithm was used to identify human errors in the 
training and validation sets by selecting those with the largest discrepancy between 
the human decision (characterised as 0 for exclude or 1 for include) and the machine 
prediction (a continuous variable between 0 and 1). Performance of the approaches 
trained on the full 5749 records is reported here, and of each of the iterations is 
available in Supplementary Materials 1. The error analysis was assessed on the net 
reclassification index, and the performance of the ML approach is compared before 






3.2.1 Step 1: Application of ML tools to screening of a large preclinical systematic 
review 
3.2.1.1 Training Sets 
70,365 potentially relevant records were identified from Pubmed and EMBASE. The 
search strings were composed of the animal filters devised by the Systematic Review 
Center for Laboratory animal Experimentation (SYRCLE) (de Vries et al., 2014b; 
Hooijmans et al., 2010), NOT reviews, comments, or letters AND a depression 
disorder string (for full search strings see Bannach-Brown et al., 2016a and protocol 
in Chapter 3). The training set and the validation set were chosen at random from the 
70,365 by assigning each record a random number using the RAND function in excel 
and ranking them from smallest to largest. The training set consisted of 5749 records. 
The validation set consisted of 1251 records. The training set and validation set were 
screened by two independent human screeners with any discrepancies reconciled by 
a third independent human screener. The human screening process involved an 
online tool (app.syrf.org), which randomly presents a reviewer with a record, with the 
title and abstract displayed. The reviewer makes a decision about the record, included 
(1) or excluded (0). A second reviewer is also randomly presented with records. If a 
record receives two ‘included’ decisions, the screening for this record is considered 
complete. If reviewer 1 and reviewer 2 disagree, the record gets presented to a third 
reviewer who makes a decision. The record then has an average inclusion score of 
0.666 or 0.333. Any record that has an inclusion score above 0.6 is included, those 
scoring less than 0.6 are excluded, and screening is considered complete. Datasets 
are available on Zenodo, as described in “Availability of Data & Materials” below, 
Performance was assessed at each level on a validation set of unseen records. The 
training and validation set were selected consecutively from the initial random 
ordering. For the training set of 5749 records, the validation set was the subsequent 
72 
 
1251 records. This validation set had more than 150 “included” records, which can 
give reasonably precise 95% confidence intervals for sensitivity and specificity.   
 Figure 3.1. Diagram of the Layout of the Study.  
 
3.2.1.2 Feature Generation 
First, documents in the training set were transformed into a representation appropriate 
for the machine learning algorithms. Documents were created by concatenating the 
title and the abstract. Every case (document) is represented by a fixed number of 
features, numerical quantities describing certain properties that might be used by the 
classifier to extract rules and make predictions about inclusion. The classifiers 
described below used generally similar approaches  
 
We used “bag-of-words” (BoW), a model for representing words in documents to, to 
characterise document titles and abstracts in both classifiers. To account for the 
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relative importance of words within a given document, and difference in words used 
between documents we used ‘Term Frequency – Inverse Document Frequency’ (TD-
IDF). This is defined as: 
 
𝑡𝑓𝑖𝑑𝑓(𝑤𝑖 , 𝑑𝑗) = 𝑡𝑓(𝑤𝑖 , 𝑑𝑗) ∗
|𝐷|
|{𝑑: 𝑤𝑖 ∈ 𝑑}|
 
The score for the i-th word in context of the j-th document takes into account not only 
how many times the word occurred there (tf), but also how many other documents (d) 
from the whole corpus (D) contain it as well. This helps to reduce the score for words 
that are common for all documents and therefore have little predictive power. This 
helps the classifier to focus on terms which help to distinguish between documents, 
rather than on terms which occur frequently (Manning et al., 2008). We allowed n-
grams, defined as a string of n words derived a given document or article; we did not 
use stemming; and used the MySQL text indexing functionality “stopword” list to 
remove frequently occurring words which provide little relevant information for 
classification purposes (Oracle, 2018).  
 
Because bag-of-words representation generates as many unigram features as there 
are words in the collection (typically at least several thousand); and many more when 
using higher-order n-grams, we used additional approaches. Latent Semantic 
Indexing (LSI) and Latent Dirichlet Allocation (LDA) represent textual data in a more 
efficient way. In LSI (Deerwester et al., 1990), the training set is represented as a 
matrix, where rows correspond to documents, columns to terms (words or n-grams), 
while cells contain frequency or TF/IDF score of a given term in a given document. 
The matrix is then decomposed using a general matrix factorisation technique known 
as Singular Value Decomposition (SVD) and truncated to the first n dimensions. 
Because of the properties of SVD the new features will be such linear combinations 
of features of the old space that minimise the differences between the original and the 
transformed space. In case of textual data, it means that those words that frequently 
occur in the same documents (probably because of the similar meaning) will be 
treated in the same way. The n is set a-priori to a reasonably low value – usually a 
few hundred. LDA exploits distributional similarities between words but based on 
explaining document contents using a Bayesian network (Blei et al., 2003). This 
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method is based on the premise that every document is a mixture of topics, which in 
turn consist of related words. The correspondence between documents and topics 
and between topics and words can be inferred via Gibbs sampling process. As a result, 
similarly to LSI, every document is represented by a sequence of n numbers, 
indicating how related it is to every topic (Kontonatsios et al., 2017). Unlike in SVD, 
the model fitness to the data cannot be expressed through the amount of variance of 
the original matrix it explains and the optimal number of topics may be different for 
every collection and classification task. Following previous work in the domain (Miwa 
et al., 2014) and the user guide for MALLET (the tool we use for LDA, which 
recommends values between 200 and 400) we elected to generate 300 topics Here 
we use three feature sets, BoW, LDA and SVD (LSI) individually, in pairs and finally 
all together; preliminary evaluation through the cross-validation on the training set 
suggests that LDA+SVD and bag-of-words with a simple linear classifier deliver the 
most robust performance. 
 
3.2.1.4 Classifiers 
Following the transformations made in feature selection, the documents are then used 
to train the machine learning classifier. The classifier most commonly used for 
document classification in context of systematic reviews (Wallace et al., 2010a; Miwa 
et al., 2014; Cohen et al., 2012; Wallace et al., 2012a; Lui et al., 2016; Wallace et al., 
2012b; Kontonatsios et al., 2017; Wallace et al., 2010b) is the Support Vector 
Machine (SVM) as it has frequently been used for tasks involving text. SVM is a 
supervised learning algorithm, learning to classify new documents based on a training 
set of labelled documents (Mertsalov & McCreary, 2009). This algorithm represents 
training documents as points in a multi-dimensional space defined by all available 
features. To be able to classify cases into positive and negative category, it seeks a 
hyperplane dividing the space into one side corresponding to included documents and 
the other to excluded ones. Based on the training data, the optimal hyperplane is 
constructed so that it maximises both the number of training cases located on the 
“correct” side of decision boundary and their distance from the plane (margin). The 
new, unseen, documents are then ranked according to their location with respect to 
the boundary. Those far from it are confidently predicted as included or excluded, 
according to which side of the plane they lie. The cases which the model has less 
confidence about will be located close to the hyperplane. Logistic regression is a 
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similar linear classifier, which instead of hyperplane, seeks such coefficients of a 
linear combination of feature values that will give high values for positive cases 
(included documents) and low for negative (excluded documents). Both of these 
approaches could be enriched with feature selection elements to mitigate the 
problems with multitude of features. 
 
Three feature sets (BoW, LDA and SVD (LSI)) were tested on SVMs, logistic 
regression and random forests (Breiman, 2001). The two algorithms described below 
performed best for this dataset of 70,365 records, on the broad topic of preclinical 
animal models of depression. 
 
3.2.1.5 Approaches 
Here, two approaches were developed independently, using different classification 
models and feature representations, but sharing the linear classification principles. 
 
3.2.1.5.1 Approach 1 
Approach one used a tri-gram ‘bag-of-words’ model for feature selection and 
implemented a linear support vector machine with Stochastic Gradient Descent (SGD) 
as supported by the SciKit-Learn python library (Pedregosa et al., 2011). This 
classifier was chosen as it is efficient, scales well to large numbers of records, and 
provides an easily interpretable list of probability estimates when predicting class 
membership (i.e. scores for each document lying between 0 and 1). Efficiency and 
interpretability are important, as this classifier is already deployed in a large 
systematic review platform (Thomas et al. 2010), and any deployed algorithm 
therefore needs not to be too computationally demanding, and its results understood 
by users who are not machine learning specialists. The tri-gram feature selection 
approach without any additional feature engineering also reflects the generalist need 
of deployment on a platform used in a wide range of reviews: the algorithm needs to 
be generalisable across disciplines and literatures, and not ‘over-fitted’ to a specific 
area. For example, the tri-gram “randomised controlled trial” has quite different 
implications for classification compared with “randomised controlled trials” (i.e. ‘trials’ 
in plural). The former might be a report of a randomised controlled trial; while the latter 
76 
 
is often found in reports of systematic reviews of randomised trials. Stemming would 
remove the ‘s’ on trials and thus lose this important information. Here, the algorithm 
needs to be generalisable across disciplines and literatures, and not be ‘over-fitted’ 
to a specific area. This approach aims to give the best compromise between reliable 
performance across a wide range of domains and that achievable from a workflow 
that has been highly tuned to a specific context. 
 
3.2.1.5.2 Approach 2 
Approach 2 used a regularised logistic regression model built on LDA and SVD 
features. Regularisation refers to the mathematical technique of adding a co-efficient 
to a model to reduce the number of features and reduce over-fitting of the algorithm. 
Namely, the document text (consisting of title and abstract) was first lemmatised with 
the tool GENIA tagger (Tsuruoka et al., 205) and then converted into bag of words 
representation of unigrams, which was then used to create two types of features. First, 
the word frequencies were converted into a matrix TF/IDF scores, which was then 
decomposed via SVD implemented in scikit-learn library and truncated to the first 300 
dimensions. Second, an LDA model was built using MALLET library (McCallum & 
Kachites, 2002), setting 300 as a number of topics. As a result each document was 
represented by 600 features, and an L1-regularised logistic regression model was 
built using glmnet package (Friedman et al., 2010) in R statistical framework.  
 
In this procedure every document is represented with a constant, manageable 
number of features, irrespective of corpus or vocabulary size. As a result, we can use 
a relatively simple classification algorithm and expect good performance with short 
processing time even for very large collections. This feature is particularly useful when 
running the procedure numerous times in cross-validation mode for error analysis 
(see below). 
 
For a given unseen test instance, the logistic regression returns a score 
corresponding to the probability of it being relevant according to the current model. 





3.2.1.6 Assessing Machine Learning Performance 
The facets of a machine learning algorithm performance that would be most beneficial 
to this field of research are high sensitivity (see table 1), at a level comparable to the 
95% we estimate is achieved by two independent human screeners. We therefore 
need to be confident that the sensitivity is 95% or higher, which we do by setting our 
cut point such that the lower bound of the 95% confidence interval of the observed 
sensitivity is 95% or higher. Once the level of sensitivity has been reached, the aim is 
to maximise specificity, to reduce the number of irrelevant records included by an 
algorithm. Although specificity at 95% sensitivity is the goal, I provide values of other 
measures for better illustration of the performance.  
 
3.2.1.6.1 Performance metrics 
Performance was assessed using sensitivity (or recall), specificity, precision, 
accuracy, and Work Saved over Sampling (WSS) (see table 1), carried out in R (R 
version 3.4.2) using the ‘caret’ package (Kuhn, 2017). 95% Confidence Intervals were 
calculated using the efficient-score method (Newcombe, 1998). Cut-offs for were 
determined manually for each approach by taking the score that achieved 95% 
sensitivity (including the lower 95% confidence level), and the specificity at this score 
was calculated.  
 
Table 3.1 Equations used to assess performance of machine learning algorithms 
Sensitivity or Recall TP / (TP+FN) 
Specificity TN / (TN+FP) 
Precision TP / (TP+FP) 
Accuracy (TP+TN) / (TP+FP+FN+TN) 
WSS@95% ((TN+FN) / N) – (1.0 – 0.95) 






3.2.2 Step 2: Application of ML tools to training datasets to identify human error 
3.2.2.1 Error Analysis Methods 
The methodology for the error analysis was outlined in an a priori protocol, published 
on the CAMARADES website on 18th December 2016 (Bannach-Brown et al., 2016b). 
To generate the machine learning scores for the set of records that were originally 
used to train the machine (5749 records), the non-exhaustive cross-validation method, 
5-fold validation, was used. This method involved randomly partitioning the set of 
records into 5 equal sized subsamples. One subsample was set aside, and the 
remaining 4 subsamples were used to train the algorithm (Rodriguez et al., 2010). 
Thanks to this process, every record has a score computed by a machine learning 
model built without including it in the training portion. These scores were used to 
highlight discrepancies or disagreements between machine decision and human 
decision. The documents were ordered by the machine assigned labels in order of 
predictive probability, from most likely to be relevant to least likely to be relevant. The 
original human assigned scores were placed next to the machine-assigned scores, to 
highlight potential errors in the human decision. A single human reviewer 
(experienced in animal systematic reviews) manually reassessed the records where 
discrepancies were highlighted starting with the most discrepant. To avoid 
reassessing the full 5749 record dataset, a stopping rule was established such that if 
the initial human decision was correct for five consecutive records, further records 




Figure 3.2. Error Analysis. The methodology for using cross-validation to assign ML 
predicted probability scores. The ML predicted probability scores for the records were 
checked against the original human inclusion decision.  
 
After the errors in the training set were investigated and corrected as described above 
a new model was built on the updated training data. The outcome of error analysis is 
presented as reclassification tables, the area under the curve (AUC) being used to 
compare the performance of the ML algorithm trained on the ‘old’ training set of 
records, and the net reclassification index (NRI) (Kerr et al., 2014) used to compare 
the performance of the classifier built on the updated training data with the 
performance of the classifier built on the original training data. The following equation 
was used: 
NRI binary outcomes = (Sensitivity + Specificity) second test - (Sensitivity + Specificity) first test 
(Pencina et al., 2008) 
The AUC was calculated using the DeLong method in the ‘pROC’ package in R (Robin, 
2017).  
 
Further, I applied the same technique as above to identify human screening errors in 
the validation dataset. Due to the small number of records in the validation set (1251 
records), it was assumed that every error would be likely to impact measured 
80 
 
performance, and so the manual screening of the validation set involved revisiting 
every record where the human and machine decision were incongruent. The number 
of reclassified records was noted. The inter-rater reliability of all screening decisions 
on training set and validation set between Reviewer 1 and Reviewer 2 were analysed 
using the ‘Kappa.test’ function in the ‘fmsb’ package in R (Nakazawa, 2018).  
 
3.3 Results 
In this section I first describe the performance from the ML algorithms. I then show 
the results from the analysis of human error, and finally describe the performance of 
the ML algorithm after human errors in the training and validation set have been 
corrected.  
 
3.3.1 Performance of Machine Learning Algorithms 
Table 2 shows the performance of the two machine learning approaches from the 
SLIM (Systematic Living Information Machine) collaboration. The desired sensitivity 
of 95% (including lower bound 95% CI) has been reach by both approaches. Both 
approaches reached 98.7% sensitivity based on learning from a training set of 5749 
records, with an inclusion prevalence of 13.2% (see below). Approach 1 reached a 





Figure 3.3 Performance of Machine Learning Approaches.  
For the interactive version of this plot with cut-off values, see code and data at 
https://github.com/abannachbrown/The-use-of-text-mining-and-machine-learning-
algorithms-in-systematic-reviews/blob/master/ML-fig3.html   
 
Table 3.2 Performance of machine learning approaches on depression training 
dataset. 
 Approach 1 Approach 2 
Training Set Size 5749 5749 
Optimal Cut-Off Score 0.1 0.07 
Sensitivity 98.7% 98.7% 
Upper 95% CI 99.7% 99.7% 
Lower 95% CI 9.49% 94.9% 
Specificity 86.0% 84.7% 
Precision 50% 47.66% 
Accuracy 1096/1251 = 87.6% 1081/1251= 86.4% 





3.3.2 Error Analysis & Reclassification 
Cohen’s κ was run to determine the interrater agreement of screening decisions 
between Reviewer 1 and Reviewer 2. Κ = 0.791 (95% CI, 0.769 to 0.811), p < 0.0001, 
with 281 records requiring a third reviewer decision. To assess whether machine 
learning algorithms can identify human error and therefore improve the training data, 
error analysis was conducted. Seventy-five papers out of 5749 papers had predictive 
scores very far from the human assigned labels, so were reassessed to see if these 
were due to human errors. Out of 75 rescreened papers, the machine corrected the 
human decision 47 times. The machine was wrong, (i.e. the initial human decision 
was correct) 28 times. The validation set was also rescreened. Ten papers out of the 
1251 records were identified as potential human errors. Out of 10 errors, the machine 
corrected 8 human decisions. These 8 records were all falsely excluded by the human 
and were now included. The initial human decision was correct twice.   
To calculate human error in the training set, the number of errors identified (47) out 
of the training set (5749 records) was calculated to be at least 0.8%. Of the 47 records 
reclassified, 11 records were falsely included in the original screening process and 
were now correctly excluded, and 36 records were falsely excluded in the original 
screening process and were now correctly included. The machine correctly identified 
human screening errors, which were calculated to be just under 1% of the dual 
screened training set. Forty-seven papers out of 760 were ‘correctly’ reclassified, 6% 
of the included papers.  
 
Similarly, the human error rate in the validation set (1251 records) was 0.6%. Again, 
looking at the prevalence of inclusion in this dataset (155/1251), which is 12.4%, the 
8 records of out the now 163 were correctly reclassified which is 4.9% reclassified. All 
8 records we falsely excluded in the original screening process and are now correctly 
included.  
 
Test 1: 98.7% + 86% = 184.7%   
Test 2: 98.2% + 89.3% = 187.5% 




The updated validation set is considered the new gold standard as 8 records were 
now included. The confusion matrix for the performance of the machine learning 
algorithm after the error analysis update on the training records is displayed below in 
table 3.   
 
Table 3.3 Reclassification of records in validation after error analysis 
Test 1 – Original Machine Learning Algorithms results 
Test 2 – Post-
error analysis ML 
results 
 In  Out Total 
In 153 
 




















                     
975 
 Total 155 
 








Analysing the human errors identified by the machine learning algorithm and 
correcting for these errors and re-teaching the algorithm leads to improved 
performance of the algorithm, particularly its sensitivity. This can save considerable 
human time in the screening stage of a systematic review. Consider the remaining 
approximately 64,000 papers, if the ML algorithm results are 3% more accurate, that 
is approximately 2000 papers that are correctly ‘excluded’ that would not be forwarded 






3.3.3 Error Analysis: Improving Machine Learning 
Using the error analysis technique above, of the 47 errors identified in the full training 
dataset of 5749 records, 0.8% were corrected.  We retrained approach 1 on the 
corrected training set and measured performance on the corrected validation set of 
1251 records as we consider this to be the ‘new’ gold standard. The performance of 
the original approach 1 and updated approach 1 was assessed on the corrected 
validation set of 1251 records. The performance of this retrained algorithm in 
comparison to the performance of the original classifier 5 on the updated validation 
set is shown in table 4.  
 
Table 3.4 Performance of machine learning approach after error analysis. 




Cut-Off 0.09 0.10 
Sensitivity 98.7% 98.7% 
Upper 95% CI of 
Sensitivity 
99.7% 99.7% 
Lower 95% CI of 
Sensitivity 
94.9% 94.9% 
Specificity 88.3% 86.7% 
Precision 55.9% 52.61% 
Accuracy 89.7% 88.2% 
WSS@95% 961/ 1251 – (0.05) = 
0.718 








Figure 3.4. Performance of Approach 1 after error analysis. The updated approach is 
retrained on the corrected training set after error analysis correction. Performance on 
both the original and the updated approach is measured on the corrected validation 
set (with error analysis correction).  For the interactive version of this plot with exact 




I compared the area under the ROC curve for the original approach 1 and the updated 
approach 1. The AUC for the original approach 1 was 0.9272 (95% CI calculated 
using DeLong method; 0.914-0.9404). The AUC for the updated approach 1 was 
0.9355 (95% CI calculated using DeLong method; 0.9227-0.9483). DeLong’s test to 
compare the AUC between the ROC of the two approaches was applied ‘, Z = -2.3685, 







3.4.1 Document Classification 
As shown here, machine learning algorithms to have high levels of performance, with 
98.7% sensitivity and 88.3% specificity; this sensitivity is comparable to two 
independent human screeners. The objectives for selecting ML approaches in this 
project was to achieve a minimum 95% sensitivity (including lower bound confidence 
intervals), to minimise the number of potentially relevant papers which are wrongly 
excluded. Thereafter, algorithms were then chosen on the basis of their specificity, to 
reduce the subsequent human time required to sort through and assess papers.  
 
The two approaches have similar performance. The slight differences may reflect the 
method of feature generation. These algorithms have high performance on this 
specific topic of animal models of depression. As demonstrated previously, the 
performance of various classifiers can alter depending on the topic and specificity of 
the research question (Howard et al., 2015).    
 
In this study, the cut-off points were selected using the decisions on the validation set 
to achieve the desired performance. Although this allows the measurement of the 
maximum possible gain using a given approach in an evaluation setting, in practice 
(e.g. when updating a review), the true scores would not be available. The problem 
of choosing a cut-off threshold, equivalent to deciding when to stop when using a 
model for prioritising relevant documents, remains an open research question in 
information retrieval. Based on their experience with a given tool, a reviewer may 
come up with a heuristic fitting their workflow, e.g. if no new includes are seen in the 
100 highest-ranked documents, then everything else could be discarded as well. More 
sophisticated approaches have also been tested (Cormack & Grossman, 2016), but 
they do not guarantee achieving a desired sensitivity level. It has to be noted that ML-
based prioritisation could be useful even if no cut-off is used and all documents are 
screened manually, since seeing the relevant documents first can help to organise 
the process and thus reduce the workload (O’Mara-Eves et al., 2015). In a similar 
broad preclinical research project in neuropathic pain it took 18 person months to 
screen 33,814 unique records – based on these numbers it would take an estimated 
40 person months to screen 70,365 unique records. Performance of machine learning 
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tools demonstrated here can greatly reduce the amount of human resource needed 
for initial title and abstract screening of a large corpus of records retrieved from a 
broad search.  
 
3.4.2 Error Analysis 
By using the ML algorithm to classify the likelihood of inclusion for each record in the 
training set, we highlighted discrepancies between the human inclusion or exclusion 
decision and the machine decision. Using this technique, we identified human errors, 
which were then corrected to update the training set.  
 
Human screening of the training set was conducted using the “majority vote” system; 
it is interesting to consider the potential reasons for errors or ‘misclassifications’ 
arising in this process. Reviewers’ interpretation of the “breadth” of this wide review 
might be one contributing factor to discrepancies. With a less clear cut-off, reviewers 
are unsure of where some articles should be included. Discrepancies arising where 
Reviewer 1 was more inclusive and where Reviewer 2 was less inclusive, thereby 
Reviewer 3 will be the deciding factor. A different approach whereby Reviewer 1 and 
2 discuss discrepancies might be a pinpoint the exact reasons for misunderstandings 
or different interpretations of the inclusion criteria. However, for larger projects when 
using a crowd-sourcing approach with many individual people contributing to each 
Reviewer, this may not be a practical solution.  
 
We have successfully identified human screening errors which were calculated to be 
just under 1% of the training set which was dual screened by two independent human 
reviewers. The prevalence of inclusion in this training set is 13.2% (760 out of the 
5749), so an error of 0.8% is likely to be important Therefore errors of false inclusion 
or exclusion in the training sets may have a substantial impact on the learning of the 
ML algorithm.  This error analysis results in a 3% increase or change in sensitivity 
and specificity, with increased precision, accuracy, and work saved over sampling of 
the algorithm. We observed an increase in specificity of 1.6% without compromise to 
sensitivity. In a systematic review with this number of records this saves considerable 
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human resources, as the number of records required to screen reduces by at least 
1125.  
 
This error analysis was an initial pilot with stopping criteria where if the initial human 
decision was correct five consecutive times, further records were not reassessed. It 
is possible and likely that there are further errors in the human screened training set. 
A more in-depth analysis of the training dataset, investigating every instance where 
the human and machine decision were incongruent, might identify more errors and 
further increase the precision and accuracy of machine learning approaches, further 
reducing human resources required for this stage of systematic review. We have 
shown here that even with minimal intervention (only assessing incongruent records 
until the original human decision was correct 5 consecutive times), the performance 
of ML approaches can be improved.    
 
3.4.3 Limitations & Future Directions 
Here we show the best performing algorithms for this dataset with a broad research 
question. Other dissimilar research questions or topics may require different levels of 
training data to achieve the same levels of performance or may require different topic 
modelling approaches or classifiers. The best performing algorithm outlined here, is 
being applied in an ongoing research project, therefore the ‘true’ inclusion and 
exclusion results for the remaining 63,365 records is not yet known. The ‘true’ results 
will unfold with the fullness of time. 
 
These machine learning algorithms are deployed in an existing systematic review 
online platform, EPPI-Reviewer (Thomas et al., 2010), and are in the process of being 
integrated into the Systematic Review Facility (SyRF) tool, which is focused on the 
preclinical domain (www.app.syrf.org). This will improve the ease of use of machine 
learning functions for systematic reviewers, increase the usage of machine learning 
algorithms for systematic review and significantly reduce the amount of human 
resources required to conduct systematic review across a range of topics. By allowing 
a degree of user control over which classifiers and the levels of performance are 
required for each specific research project. With a broad collaboration such as SLIM 
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we aim to test many ML algorithms across a range of research topics to identify which 
classifiers perform best under which circumstances, to be able to provide 
recommendations to users of SyRF.  
 
This paper outlines a pilot approach to using machine learning algorithms to identify 
human errors in current systematic review methodology. Future research can 
investigate this concept more thoroughly by setting up a more comprehensive 
experimental design. After further investigation into the extent of human error in dual 
reviewing, the picture will be clearer as to the scale of human error and to what extent 
a machine learning algorithm can identify and aid in rectifying this. These tools can 
could be integrated into systematic review platforms, such as SyRF 
(www.app.syrf.org), and may provide feedback to the systematic reviewer during 
screening, and could ultimately flag incorrectly screened records as the human 
screens them for inclusion in a dataset for machine training.  
 
3.4 Conclusions 
As shown here, machine learning techniques can be successfully applied to an 
ongoing, broad pre-clinical systematic review. Machine learning techniques can be 
used to identify human errors in the training and validation datasets. Updating the 
learning of the algorithm after error analysis improves performance. This error 
analysis technique requires further detailed elucidation and validation. These 
machine learning techniques are in the process of being integrated into existing 
systematic review applications to enable more wide-spread use. In future, machine 
learning and error analysis techniques that are optimised for different types of review 
topics and research questions can be applied seamlessly within the existing 
methodological framework.  
 
3.5 Availability of Data & Materials 
The training and validation datasets, error analysis datasheets, as well as all the 




The protocol for the systematic review of animal models of depression is available 
from: http://onlinelibrary.wiley.com/doi/10.1002/ebm2.24/pdf  
The protocol for the Error Analysis is available via the CAMARADES website and can 
be accessed directly from this link: 
https://drive.google.com/file/d/0BxckMffc78BYTm0tUzJJZkc1alk/view  
The results of the classification algorithms and the R code used to generate the results 
is available on GitHub: https://github.com/abannachbrown/The-use-of-text-mining-





4 METHODS DEVELOPMENT – AUTOMATION TOOLS TO AID DOCUMENT 
CATEGORISATION & GROUPING 
 
4.1 Introduction  
Broad, shallow systematic reviews are a useful tool to synthesise evidence of a field 
and provide an overview of a field. Systematic reviews provide an overview of the 
range of treatments investigated, the different methods used to induce and investigate 
depressive-like phenotypes. Quantitative synthesis of data from primary studies 
included in a review, using meta-analysis, can provide insight into the experimental 
design circumstances under which an intervention is effective in animals. This method 
can highlight gaps in the literature for further investigation. This methodology has 
been used extensively by the CAMARADES research team to provide an overview of 
the literature reporting animal models of stroke, neuropathic pain, schizophrenia, 
Alzheimer’s disease, glioma, breast cancer, spinal cord injury, Parkinson’s disease, 
and multiple sclerosis (Sena et al., 2010; O’Collins et al., 2006, Currie et al., 2013; 
Seretny et al., 2014; Bahor et al., 2016, Egan et al., 2016; Jue et al., 2018; Chen et 
al., 2016; Watzlawick et al., 2016; Rooke et al., 2011; Vesterinen et al., 2010). This 
methodology is being applied to the field of animal models of depression (Bannach-
Brown et al., 2016; Kara et al., 2017).  
 
Systematic reviews, while beneficial to the field, require substantial human resources 
to complete. This gives rise to a number of factors that threaten the usefulness of the 
findings of a systematic review. Firstly, the longer the review takes the more out of 
date the results are when published. Usually, larger reviews take longer to complete 
and therefore the results are published later. Combined with the ever-increasing 
amount of literature being published in biomedical sciences, this provides a challenge 
for researchers to get an overview of a field, both for making decisions about 
experimental design of primary studies, informing clinical trial design, as well as 
researchers on the boards of funding bodies who are required to be informed of the 




Some of these challenges are addressed by applying automation tools to systematic 
review methodology. The intersection between biomedical sciences and text-mining 
and machine learning fields is a fast-evolving field where many new programmes and 
techniques are being tested. The speed of innovation in this new field, and the 
collaboration between the two domains is accelerated by sharing tools and data, and 
the exchange of learning across fields. The application of these automation tools to 
the domain of preclinical systematic review is a particularly novel study.  
 
Automation techniques can be applied to the screening phase and the annotation 
phase and are being explored for use in data and outcome extraction. Applying 
automation tools to annotating documents with key-words can help aid categorisation 
and grouping of documents. This is particularly useful in broad, shallow systematic 
reviews where many documents are included in the review and they span across a 
broad domain. After the screening stage has been completed, the next stage is to 
prioritise topics for data extraction stage, based on the areas of interest in the field. 
One approach is to map out and understand the main areas described in the literature, 
for example, the key PICOs of the studies in the review, the Participants, the 
Intervention, the Comparison group, and the Outcomes investigated. The PICOs of 
an animal study can be broadly categorised as the Disease or biological mechanism 
investigated, any Intervention or drugs investigated, Sample size used in the study, 









Several semi-automated techniques exist to aid the PICO extraction process 
(Jonnalagadda et al., 2015). These include extracting various factors about the 
Participants, the Intervention, the Comparison group, and the Outcomes investigated; 
from more broad aspects such as the disease studied to more detailed information 
such as sample size and units of measurement. Automation techniques have primarily 
been applied to texts about clinical trials. These techniques have been shown to be 
effective in extracting these pieces of information from titles, abstract, title & abstract, 
as well as full-text articles (Jonnalagadda et al., 2015). A number of approaches have 
been used to extract these key pieces of information. Some of these approaches have 
been implemented as tools.  
 
One such technique is the use of single regular expression (regex) terms or regex 
dictionaries to search the title, abstract, and full text of relevant documents. Regex 
dictionaries have been applied primarily to aid systematic reviews of clinical studies, 
to extract PICO information and for assisting in assessing the measures taken to 
reduce the risk of bias.  
 
One application of regular expression dictionaries for extracting PICO aspects 
(Patient population & Comparison group) from abstracts of randomised clinical trials 
has been applied by Hara & Matsumoto (2008). Hara and Matsumoto achieved 90% 
accuracy in analysing 200 abstracts. A similar approach using regular expressions 
and the tool ‘gazetteer’ extracted more detailed information regarding the participants 
such as the age, gender, and the number of patients from abstracts on cancer (Kelly 
& Yang, 2013).  Kelly and Yang achieved performance, as measured by F-scores, of 
87%-100% for the various aspects from the analysis of 386 abstracts from a ‘cancer 
and soy’ PubMed search. These tools are applied to the abstracts of articles of interest. 
Kiritchenko and colleagues used a text-classifier approach to extract information from 
full-text articles (2010). They used the tool ‘ExaCT’ 
(http://rctbank.ucsf.edu/home/exact/exact-user-guide) to extract the information 
about the dose and frequency of treatment, the patient sample size, eligibility criteria 
for inclusion in the study, the funders of the study and the primary and secondary 
outcomes. They achieved a precision of 88% based on 50 full-text papers of 
randomised controlled trials, with the automation tool trained on 1050 documents 
(Kiritchenko et al., 2010). Hsu and colleagues (2012) aimed to identify whether a 
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classifier could classify a sentence as containing key information pertaining to the 
hypothesis, the statistical methods used such as confidence intervals and significance 
level, and information about the outcome of the study and conclusions. Using regular 
expressions to classify sentences, they had a precision of 86% and recall of 78% on 
7 papers, with the automation approach trained on 42 full-text papers on 
chemotherapy for lung cancer. For a full review of all approaches currently being 
implemented in systematic reviews of randomised controlled trials and synthesis of 
clinical evidence, see Jonnalagadda et al., 2015.  
 
Similar approaches are applied to extract risk of bias reporting in full-text documents. 
Millard, Flach & Higgins (2016) tested two different machine learning algorithms to 
identify whether an article reported allocation concealment, blinded assessment of 
outcome, and random sequence generation. They used full-text reports of clinical 
trials in the Cochrane risk-of-bias assessment tool, with manually annotated 
sentences reporting the risk of bias reporting to train the automation tools. Authors 
report that algorithms can successfully rank articles by the risk of bias and reduce the 
human resources required to perform risk of bias assessment in clinical trials.  
 
A slightly different approach to classifying documents has been to understand why 
documents are classified into a certain category and which sentences in the document 
are key to understanding this decision. One approach is the use of a technique called 
convolutional neural network (CNN) which are neural networks with layers that feed 
forward information and learning to each layer starting with the input and with no 
hidden layers. This approach allows for more complex data and allows for pooling or 
weighting of information from each layer (Collobert & Weston, 2008). Zhang, Marshall 
and Wallace (2016) used convolutional neural networks, to extract the potential 
sentence with the rationale for the classification of documents. Zhang and colleagues 
combined the distantly supervised approach of CNN with labelled data, the tagged 
sentences from user-input were used to improve performance. Their Rationale-
Augmented CNN (RA-CNN) has high performance on biomedical risk of bias literature 
including data from the Cochrane risk of bias dataset (Marshall et al., 2016). A further 
approach named supervised distant supervision (Wallace et al., 2016b) used semi-
structured data from the Cochrane Database of Systematic Reviews which stores 
PICO information for each clinical trial included in a Cochrane review. Over 12,000 
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distantly labelled documents and 2,821 sentences directly labelled from 133 papers 
were used for their novel approach of supervised distant supervised learning (Wallace 
et al., 2016b). This approach achieved precision levels of between 88.7% and 92.7% 
on 50 articles, to maximise the information gained from a small amount of human 
effort.  
 
Automated tools to assess the risk of bias in animal studies have been investigated. 
Bahor and colleagues use Regex terms to identify the reporting of measures to reduce 
the risk of bias in experiments of animal models of stroke (Bahor et al., 2017). Bahor 
and colleagues achieved accuracy levels between 67% and 100% in 964 full-text 
documents across two different subject areas.  
 
Many of these approaches rely on a dataset of already annotated documents in a 
specific domain or topic, in order to “learn” the classification. In the approach we 
outline below, documents are “grouped” by the tags that are labelled as matching the 
terms of interest. Further, these approaches are primarily applied to the classification 
of randomised controlled trials of human data, which follow more standardised 
reporting guidelines in comparison to the reporting of animal studies. Different 
challenges are present in extracting DISCO or PICO information from animal studies. 
Studies may investigate several research questions either in the same set of animals, 
or in separate cohorts of animals, all of which are presented in the same paper. 
Different studies may use the same outcome assessment tools to measure different 
behaviours or endpoints.  
 
Further, in the reporting of clinical trials, the publishing culture means that key 
information is often reported, and therefore it is often possible to discern the PICO 
from the title and abstract. However, in the literature describing the animal models, 
not all this information may be discernible from the title and abstract alone. For 
example, not all outcome measures investigated in the article, or the exact strain of 
animals used may be mentioned in the abstract, and therefore it is necessary to obtain 
and assess the full-text version of the article. Retrieving full-text articles is reliant on 
institutional library subscriptions, bibliographic tools such as EndNote, and human 
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resources for inter-library loans. In short, the reporting of animal studies varies greatly, 
and full ascertainment of DISCO information often requires the full-text article.  
 
The aim here was to develop regular expression dictionaries to identify PICO or 
DISCO information for animal studies. We aimed to automatically ascertain these key 
pieces of information for grouping and categorising documents, to reduce the human 
resources for this step. The time reduction of this step allows the next step of the 




In this systematic review of animal models of depression, we firstly used machine 
learning classifiers to aid in the screening of 70,365 documents from PubMed and 
EMBASE. For full methodology of this process, see Chapter 3, Bannach-Brown et al., 
2018. After machine-assisted screening, 18,409 documents that were highly likely to 
be relevant to animal models of depression, a prevalence of 26.16%. The field of 
animal models of depression is broad; many different techniques are used to model 
depressive-like phenotypes; different behavioural read-outs are used and the varied 
investigations of the underlying biological mechanisms behind these phenotypes are 
carried out. Further, a range of potentially anti-depressant pharmacological 
interventions are tested in animal models. Therefore, to be able to more efficiently 
select topics for more in-depth systematic review and potential meta-analysis, 
categorising these documents into the key areas of interest can help with the next 
steps of systematic review and potentially, further meta-analysis.  
 
4.2.1 Finding PDFs 
The first step was to identify as many full-text PDFs of the documents as possible. 
The following techniques were used to find PDFs for the 18,409 records. The primary 
approach was to identify as many PDFs as possible out of the 70,365 documents and 
match the PDFs up with the included studies. This was due to the PDF retrieval being 
conducted at the same time as machine learning techniques for screening (see 




Firstly, the ‘Find Full Text’ function in Endnote (v. 7.2.1 (Edinburgh) and v. XT11 
(Aarhus)) was used with eproxy links to both the University of Edinburgh and Aarhus 
University library subscriptions. Eproxy links were added to the Edit > Preferences > 
Find Full Text. The ‘Find Full Text’ function was run on all 70,365 records. 32,895 full-
text PDFs were found.  
 
The open access literature on European PubMed Central (EuPMC) was interrogated 
using the ContentMine ‘getpapers’ function in node.js 
(https://github.com/ContentMine/getpapers). The depression PubMed search string 
was slightly altered for EuPMC (see Appendix 1) and used to interrogate the EuPMC 
database via their API with the ‘getpapers’ function. 22,003 references were identified.  
Due to time constraints of the project with ContentMine and memory constraints of 
the API, the full 22,003 were not downloaded and used in this project.  
 
With many full-text PDFs left to retrieve, a search for further tools to assist the retrieval 
process was carried out. The search identified a tool called PaperFetch 
(papertoolbox.com, the website has since been taken offline). This software uses 
PubMed IDs to search for full-text articles online. Full-texts downloads from the 
publisher’s websites were enabled with eproxy access. This programme was run on 
the 62,410 documents. PaperFetch retrieved 19,949 PDFs. Following this, we were 
contacted by the University of Edinburgh library that access to PubMed and a number 
of individual journals had been revoked for the IP address the programme was run 
from, due to a violation of PubMed and journals’ terms and conditions. The 
programme made requests to PubMed more than 3 times per second. Access to 
PubMed was revoked for approximately 2 months.  
 
In total, after pairing PDFs with records, these methods retrieved 11,724 full-text PDFs 





4.2.2 PDF Matching 
PDFs and the corresponding records were matched in MS Access using a unique ID 
generated from the four digits of the year the article was published, and the title. e.g. 
‘2012 - Emotional memory impairments in a genetic rat model of depression: 
involvement of 5-HT/MEK/Arc signalling in restoration” 
 
4.2.3 Regex Dictionaries 
We expanded upon an approach first used in the CAMARADES team to describe 
measures to reduce the risk of bias in the animal literature of stroke (Bahor et al., 
2017). We applied the technique of using regex dictionaries to categorise papers was 
applied to literature reporting animal models of depression. This literature has initially 
three key areas of interest that we are interested in mapping: firstly, different 
techniques used to model depressive-like phenotypes in animals, secondly, different 
pharmacological therapies used to reduce depressive-like phenotypes in animals, and 
thirdly, different outcome assessments used to measure depressive-like phenotypes. 
The first two key areas are discussed here. These dictionaries were built with the help 
of a fellowship awarded to ABB with the text-mining organisation ContentMine 
(http://contentmine.org/).   
 
Firstly, commonly used methods to induce depressive-like phenotypes were collated 
from recently published reviews (Cryan & Mombereau, 2004; Caldarone et al., 2015; 
Henn & Vollmayr, 2005; Cyran & Slattery, 2007).  
 
Secondly, synonyms and commonly used abbreviations were added. Then, all the 
known terms were converted to regex format using tutorials in www.regular-
expressions.info. Each regex term was tested in www.Regex101.com with text that is 
known to contain variations of the regex term. The regex terms were adjusted 
accordingly if there were errors or mismatches. The methods to induce depression in 
animals were broadly categorised into; genetic inductions, pharmacological 
inductions such as drug-withdrawal, the use of stress (either in childhood or adulthood) 




The same methodology to create the Regex dictionary for animal models of 
depression was applied to antidepressants tested in the animals or with animal 
models. The list of anti-depressants was collected from an open access resource on 
Wikipedia (https://en.wikipedia.org/wiki/List_of_antidepressants). The links for known 
trade names of drugs in various countries were followed and these were added to the 
regex items. The antidepressant drugs were broadly classified into: tricyclic 
antidepressants (TCAs), serotonin selective reuptake inhibitors (SSRIs), NMDA 
acting drugs, other serotonin acting drugs, noradrenaline reuptake inhibitors (NRIs), 
serotonin and noradrenaline reuptake inhibitors (SNRIs), antipsychotics, combination 
drugs, and drugs acting on other mechanisms and unknown mechanisms.   
 
These regex dictionaries were created in two formats. One that fits with the 
ContentMine “ami” package, and a second format that fits with the R package created 
by Jing Liao “shihikoo/AutoAnnotation” (https://github.com/shihikoo/AutoAnnotation/).  
 
The below Table 4.1 presents the format of example entries for the two regular 
expression dictionaries.  
Term ContentMine Regex AutoAnnotation Regex 







4.2.4 PDF to Text Conversion 
The Github package “AutoAnnotation” developed by Dr Jing Liao was used to convert 
PDFs to text format. This package uses the R package ‘pdftotext’ to convert readable 
PDFs into text. This program categorises documents into 4 groups after conversion 




Table 4.2 The number of pdfs successfully converted to text. 
Conversion Status Number of Documents 
Error: Failed to read file 6685 
Error: Pdf not found 418 
Error: Text file not found 964 
OK: File is read Successfully 10342 
Total: 18409 
 
The regex dictionaries for model and drug were run through all records, identifying 
matched regex’s in the title, abstract, and where available, in the full-text PDF. The 
average number of times a regex term occurs in a document and across the whole 
corpus of documents (18,409 unique records) was calculated using various R 
packages (v. 3.4, see full code in Appendix 2). Documents where none of the model 
or drug regex terms occurred were removed. 13,462 of the 18,409 documents had no 
regex terms from the Model dictionary identified. 15,165 of the 18,409 documents had 
no regex terms from the Drug dictionary identified.  
 
4.2.5 Application of Regex Dictionaries 
The regular expression dictionaries were run on the citations included by machine-
assisted citation screening. The number of times a regular expression dictionary term 
appeared in a document was calculated using the AutoAnnotation R package (Liao, 
2017). This package utilises ‘gregexpr’the text-mining base package to ascertain the 
number of times a regular dictionary expression term occurs in a body of text. Two 
measures were created from this number. 1) The number of documents a term occurs 
in; 2) The average number of times a regex term occurs in these documents (termed 
“frequency of occurance”). These two measures were used to create visualiations of 
the corpus of literature on animal models of depression. Treemap plot visualisations 
were generated using the ‘plotly’ (Sivert , 2018; (v. 4.7.1) and ‘treemapify’ (Wilkins, 
2018) packages in R. The category of regex term, for example fluoxetine categorised 
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as SSRI (see section 4.2.3), we used to group similar drugs or models together in the 
treemap plot.  
 
4.3 Results  
The treemap plots for “Methods of Model Induction” and “Antidepressant Drugs” were 
generated; see figures 4.2 A and B. These plots display the frequency of regular 
expression dictionary terms in the animal model of depression corpus. The area of 
each tile is proportional to the number of documents the term appears in. The colour 
of each tile is proportional to the average frequency of the term in each document. 
These plots allow the viewer to ascertain the commonly used models and drugs in the 
literarute visualliy.  
 
4.3.1 Shiny App Development 
This code was developed into a ‘Shiny’ app in R (see app here, 
https://camarades.shinyapps.io/Preclinical-Models-of-Depression/). The application 
is interactive, free to use and open access, and connects with the systematic review 
platform SyRF. Users can select the specific drug or model of interest, view the 
frequency of the documents, as well as the frequency of terms across the whole 
corpus, export the studies that have been ‘tagged’ as containing the topic of interest, 
and import the studies directly into their systematic review project in SyRF to continue 
their systematic review to completion. Links to the source code are available in 





Fig 4.2 A Treemap plot that show the frequency of model terms in the depression 
corpus. The area of each tile is proportional to the number of documents the term 
appears in. The colour of each tile is proportional to the average frequency of the term 





Fig 4.2 B. Treemap plot that show the frequency of drug terms in the depression 
corpus. The area of each tile is proportional to the number of documents the term 
appears in. The colour of each tile is proportional to the average frequency of the term 
in each document.  
 
4.4 Discussion  
We have used these regex dictionaries of key DISCO terms for three ongoing reviews, 
a systematic review and meta-analysis of ketamine as an antidepressant (see 
preliminary data in Chapter 5), and a systematic review and meta-analysis of the 
Flinders Sensitive Line model of depression, and a systematic review and meta-
analysis of LPS-induced depression. Our approach in these reviews has been to 
export the list of document IDs where the key term of interest occurred at least once 
in either title, abstract or full-text PDF, manually check that documents are in fact 
relevant, before extracting outcome data, experimental design characteristics, and 
risk of bias information for the studies relevant to the research question. In one step, 
this tool has greatly reduced time in comparison to manually extracting the topics of 




This approach is very malleable; any regex dictionary can be used to investigate any 
range of topics. However, updating these broad dictionaries also requires human 
input to remain current. Real world concepts and the terminology to describe these 
concepts change over time, which is what is known as concept drift. Concept drift 
presents a potential issue for automation tools as it may make the dictionaries more 
out of date and makes model learning a more complex task as predictions become 
less accurate with time (Webb et al., 2017). The question is how to capture this drift 
in key concepts of disease modelling in animals and how to account for this in the use 
of automation tools to improve preclinical research. In future, the integration of 
concept drift into our understanding of the reporting of key terms in the literature, 
through increased collaboration with machine learning and text-mining teams, would 
help us ensure that dictionaries stay current.  
 
Staying up-to-date with the current literature and novel techniques and approaches 
within a field is demanding. There is an insurmountable number of papers published 
on PubMed a year, an average of two papers per minute (Landhuis, 2016). Further, 
depression is a complex and heterogeneous disease. Understanding the behaviour 
and underlying biological mechanisms through the use of animal models highlights 
this. The same outcome measure can be used to assess many different types of 
behaviour, for example, the open-field test can be used to measure anxiety, 
locomotion, and exploratory behaviour, and others. The complexity of behaviour, our 
tools to understand behaviour and biology, the association between the two to identify 
biomarkers, combined with the lack of standardised terminology or reporting 
structures captures this issue (Michie & Johnston, 2017). Further, the poor reporting 
of experimental studies intensifies the complexity (Michie & Johnston, 2017).  
 
One approach to deal with this information overload and the complexity of the 
research is to improve the currently curated dictionaries and introduce a crowd-
sourced effort from many researchers across the field to create a field-wide ontology. 
With more collaboration with field-specific research groups, we can expand upon the 
detail of the existing curated dictionaries. A more in-depth understanding of the 
synonyms used in this field and the various methods of describing the techniques 
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would enable this approach to continue to be relevant and useful and reduces the 
waste of research resources simply due to the inadequacy of our quality and structure 
of reporting of experiments, and the terminology used (Michie & Johnston, 2017). With 
the aim of making synthesised research more accessible, perhaps improving the 
search terms for accessing the accumulated evidence or body of evidence that we 
have on a field, would increase this accessibility (Michie & Johnston, 2017). Creating 
an ontology, a systematic structure for organising the knowledge, might facilitate 
investigations into the relationships between these variables, improve our 
understanding of the field and specific sub-domains, the relationship between sub-
domains, and potentially reveal new patterns that emerge through the use of 
computer-aided investigation (Michie & Johnston, 2017). 
 
The use of ontologies to improve preclinical research is an emerging field. Teams 
within spinal cord injury have created an ontology for improving the understanding of 
spinal cord injury which has spurred the generation of new biological hypotheses 
(Callahan et al., 2016; Callahan et al., 2017). The Federal Interagency Traumatic 
Brain Injury Research (FITBIR) organisation also has a similar approach to sharing 
data and creating common dictionaries and ontologies of terminology used. Data 
sharing and the use of ontologies in spinal cord injury has led to multi-centre animal 
trials, improved reporting of experimental studies, and the application of novel 
techniques to answer biological hypotheses (Nielson et al., 2015).  
 
There is a very broad range of both behavioural, physiological and neurochemical 
read-outs and techniques used in animal models of depression. Collecting and 
mapping all of these concepts accurately might prove difficult and may only be 
feasible with a combined effort from researchers in the field. However, experience in 
other fields demonstrates the utility of these collaborations.  
 
4.4.1 Limitations 
A limitation of the current study is the proportion of studies that either did not have a 
PDF available through university subscriptions or PDFs that were unable to be 
converted to text because the file was corrupted, or because of the format of the PDF 
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meant it was unable to be converted to text with the object character recognition 
software involved in the R packages. In total, the regex dictionaries were unable to 
be run through the full texts of 8,067 documents. The majority of these documents 
(6,685 documents) were unable to be found through the university subscriptions. 
Although university library subscriptions are comprehensive, it is not feasible with 
publisher subscriptions fees for libraries to have access to all available knowledge, 
especially when it is behind a paywall. The benefits of open access and data-sharing 
are discussed in Chapter 2. In future, with a culture shift in academia towards 
recognising the benefits of open access, this will become less of an issue and all 
knowledge pertaining to a field will be available to be synthesised.  
 
A second limitation of this study is the extensiveness and breadth of the regular 
expression dictionaries.  There were many documents where none of the terms, from 
either the model dictionary or the drug dictionary, were found. The reason for this 
could be that some of the documents may not be relevant to the research question. 
This is likely as the specificity of the machine learning approach used was 89.7% (see 
Chapter 3). Further it could be due to not having the full-text PDF available. Where 
only the title and abstract are available, not all methods to induce depression or all 
drugs tested may be reported and therefore key information may be missed. In 
addition, it is likely that the dictionaries are not comprehensive enough, as this is an 
initial attempt at mapping this field. They will require updating as more resources are 
invested in mapping the knowledge and extensive dictionaries and ontologies are 
formed. This process will be expedited with the collaboration of experts in the field to 
contribute to these ontologies to improve preclinical modelling of depression.   
 
4.4.2 Future Directions 
The next steps of this project are to validate the dictionary accuracy by checking the 
categorisation against a human decision and to investigate if there is a correlation 
with the number of times a term occurs and how accurate the categorisation is. When 
using the frequency of each term’s occurrence to make predictions regarding the 
DISCO information, there is potentially an optimal cut-off number for each topic. For 
example, if a term occurs below 3 or 5 times per full-text document, it might be likely 
that this drug is not investigated in the study and is merely mentioned in the 
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introduction or discussion. Another potential approach is to identify whether running 
dictionaries on sections of an article is more precise than running the dictionaries on 
the whole article. For example, is the key information regarding model and drug 
intervention adequately described only in the Methods and Results section of an 
article, where running the dictionaries only on these sections removes noise? 
 
Future steps for expanding this work is to build a dictionary for the outcome 
assessments reported in articles describing animal models of depression. Outcome 
measures of behaviour in animals are complex and often, not all outcome measures 
assessed are reported in the title and abstract. Therefore, not having access to the 
full-text PDFs for understanding the breadth of outcome measures used could be a 
potential challenge to creating an ontology.  Here, establishing working groups and 
crowd-sourced data sharing groups with experts and laboratories in animal models of 
depression to develop ontologies of our current understanding of the field may be 
particularly useful.  
 
Although this is an initial attempt at mapping key terms within the field of animal 
models of depression, mapping the overlap of model induction techniques with the 
drugs tested in the literature might provide further insights. Investigating which 
documents contain multiple key-terms, where the terms overlap, may reveal 
information such as where drugs have not been investigated in certain models, such 
as genetic models. Highlighting gaps in the literature could lead to the generation of 
new hypotheses which can be tested.  
 
In future, a link with a repository of preregistered preclinical trials could enable the 
easy extraction of key DISCO terms. This approach has been used with mapping 
PICO terms with published clinical trials on PubMed and the original ClinicalTrials.gov 
trial registration (Kim et al., 2016). They achieved an accuracy of 90% across PICO 
terms. This is another technique to extract key information that might prove useful to 






This chapter outlines the approach used to create custom regular expression 
dictionaries of methods to induce depressive-like phenotypes and drug interventions 
relevant to depression, applying these dictionaries to a corpus of documents, with the 
aim of categorising and grouping documents into key areas of interest. This approach 
has already informed three ongoing reviews. This is the first known approach to 
applying text-mining and dictionary-based approaches to documents of animal 
models of psychiatry. However, much work is still needed to validate and expand this 
approach to ensure that the approach is successful in increasing the accessibility of 
the accumulated evidence, and for use in developing biological hypotheses. I hope 
that researchers from the field of animal models of depression may contribute to 
dictionaries and ontologies in future to harness the full potential automation tools to 





5 INTERVENTIONS TARGETING THE GUT MICROBIOTA IN ANIMAL MODELS 
OF DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
This results from this review have been completed with help from Anthony Shek (AS), 
an honours student at CAMARADES, and Dr. Sarah McCann (SKM), a post-doc at 
CAMARADES. This chapter reports a systematic review and many of the methods 
are done in duplicate for good practice. Where steps of the review have been done in 
duplicate, the contribution will be highlighted by using “we/our”. 
 
5.1 Introduction & Background 
Major depressive disorder (MDD) is the leading source of disability globally (Marcus 
et al., 2012) and treatment-resistance among patients is roughly 50% (Thomas et al., 
2013). Therefore, better understanding of the mechanisms behind MDD and the 
search for potentially effective and novel therapeutic targets are high research and 
healthcare priorities. Communication between the gut microbiome and the brain may 
play a role in neuropsychiatric disorders (Cryan & O’Mahony, 2011). The role of gut 
microbiota in depression is a rapidly growing research field. There has been particular 
interest in the use of 'psychobiotics' to improve symptoms of low mood in depression. 
The term 'psychobiotics' is defined as "a live organism that, when ingested in 
adequate amounts, produces a health benefit in patients suffering from psychiatric 
illness" (Dinan, Stanton & Cryan, 2013, pg 708). Increasing amounts of research are 
being conducted to better elucidate the mechanisms under which psychobiotics 
impact mood and cognition in neuropsychiatric disorders. Current evidence from 
animal models of depression suggests that psychobiotics communicate using the gut-
brain axis and via the central nervous system (CNS), bacterial metabolism and 
mediating immune signalling.  
 
The gut microbiome primarily communicates bi-directionally with the brain via the 
vagus nerve, which is the main afferent pathway from the abdomen to the brain 
(Sherwin et al., 2016). A number of other mechanisms have been explored, as 
evidence highlights that psychobiotics can impact independently of the vagus nerve, 
in experiments with vagotomised rodents (Klarer et al., 2014; Bravo et al., 2011). 
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Mechanisms involved in immune response mediation, tryptophan metabolism, and 
enteroendocrine signalling have been investigated as potential mechanisms behind 
depression or the efficacy of treatments for depression. Bacterial commensals have 
been shown to regulate enteroendocrine signalling, which produce peptides such as 
serotonin cholecystiokinin (CKK), glucagon-like peptide-1 (GLP-1), and peptide YY 
(PYY), which are involved in key processes in depression such as limbic responses 
to fear, neurogenesis, and weight loss/gain (Sherwin et al., 2016). Further, gut 
microbiota can impact tryptophan metabolism which is involved in serotonin synthesis, 
a key neurotransmitter implicated in depression and antidepressant responses 
(Jenkins et al., 2016). 
 
Gut microbiota has been shown to have significant impact on the CNS and 
neurotransmission involved in depression, including the production GABA which is 
able to cross the blood brain barrier (Takanaga et al., 2001; Sherwin et al., 2016), 
dopamine and noradrenaline production in the gut, immunoregulation via histamine, 
regulating brain derived neurotrophic factor (BDNF) expression, controlling the 
microglial activation associated with depression, and modulation of the hypothalamic-
pituitary-adrenal (HPA) axis activation (Sherwin et al., 2016).  
 
Psychobiotics, in the form of probiotics and prebiotics, are gut microbiota-targeting 
compounds to reduce depressive-like outcomes in animal models.  The definition of 
probiotics is “a live micro-organism that, when ingested in adequate amounts, 
produces a health benefit in the host” (Kennedy, Kirk & Gardiner, 2001). Many 
probiotic strains have been shown to impact behaviour and physiology in human 
depression and animal models of depression (Abildgaard et al., 2017; Tillmann et al., 
2018; Wang et al., 2016). Prebiotics, substrates that are selectively utilised by a host 
organism providing a health benefit (Gibson et al., 2017), have also been reported to 
have been investigated in neuropsychiatric outcomes of depressive-like and anxiety-
like phenotypes (Burokas et al., 2017; Mika et al., 2017; Thompson et al., 2017; 
McVey Neufeld et al., 2017). Some of these psychobiotics have been tested in 
randomised controlled trials (RCTs). Two recent reviews of RCTs identified studies 
investigating the effects of probiotics (Huang et al., 2016; Romijn & Rucklidge, 2015). 
Meta-analysis of five studies concluded that probiotics reduced depression symptoms 
(Huang et al., 2016) and a summary of 10 RCTs concluded that probiotics were 
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generally more effective than placebo in standardised depression rating scales 
(Romijn & Rucklidge, 2015). The mechanisms behind the effect of probiotics have in 
depression are yet to be fully elucidated.  
 
Studies have also investigated the effect of antibiotics, and what impact this has on 
depressive-like outcomes in animals. Antibiotics are known to impact the composition 
of the gut microbiome and decrease diversity (Francino, 2015; O’Mahony et al., 2014). 
It is generally hypothesised that antibiotics negatively impact depressive-like 
outcomes, via some of the proposed mechanisms above, but further investigations 
are required to fully understand the implications for mood disorders.  
 
Animal models are beneficial tools to mimic aspects of human depression, to 
understand the underlying mechanisms behind the disorder and characterise 
antidepressant interventions. Rodents are a commonly used species to mimic 
depression, due to the experimental control. Systematic review and meta-analyses of 
non-human animal data are hypothesis-generating tools that provide an overview of 
the field and can be used to inform the experimental design. Systematic reviews in 
other neuroscientific fields, such as Alzheimer’s disease, stroke, and multiple 
sclerosis, have provided evidence as to the components of experimental design that 
may influence efficacy of an intervention (Egan et al., 2016; O’Collins et al., 2006; 
Vesterinen et al., 2010).  
 
In this systematic review and meta-analysis we set out to review the efficacy of 
interventions targeting the gut microbiota in animal models of depression. We 
investigated interventions that either were aimed at inducing depressive-like 
behaviour or interventions to reduce depressive-like behaviour. We aimed to provide 
an overview of the literature. We aimed to describe the quality of the data available, 
and if possible, meta-analysis to determine study design characteristics that influence 
efficacy (particular bacterial strains used in psychobiotics, route of administration of 
psychobiotics), and areas where uncertainty remain and further animal experiments 





5.2 Methods & Materials 
The methodology for this systematic review was laid out in a pre-specified protocol 
published on the CAMARADES repository of Systematic Review Protocols 
(http://www.dcn.ed.ac.uk/camarades/research.html#protocols) on 13th February 2017.  
 
5.2.1 Search Strategy 
Studies of interventions targeting the gut microbiota in animal models of depression 
were identified from an existing database of studies of animal models of depression. 
This database was collated using the search string in the protocol outlined in chapter 
2 (Bannach-Brown et al., 2016). The original search was carried out in May 2016. 
This database was searched using the key terms; “microbiota”, “gut microbiome”, 
“germ-free”, “gut-brain axis”, “probiotic”, “antibiotic”. Abstract screening was carried 
out by AS and ABB. Any screening discrepancies were resolved by a discussion 
between the two reviewers. Full-text screening was carried out simultaneously with 
data extraction by AS and ABB. 
 
5.2.2 Inclusion & Exclusion Criteria 
Publications were included if they tested an intervention that claimed to impact or work 
via the gut microbiome. Interventions could either act as a method of model induction 
in depression or as a potential treatment of depression, in an in vivo rodent experiment. 
Publications were included where any quantitative outcome of depression had been 
assessed. Studies were included if there was an appropriate control group and where 
the sample size, the mean and the variance in each group had been reported for the 
primary outcome of behaviour. There were no exclusion criteria based on age, sex, 
weight or method of model induction. There were no exclusion criteria based on 
dosage, timing or frequency of administration of the intervention. Studies were 
excluded if only anxiety-like behaviour was investigated, or if genomic, proteomic, 
metabolic or metabolomics outcomes were the sole outcome, without a behavioural 






Figure 5.1. PRISMA flowchart of studies included in this review.  
 
5.2.3 Data Extraction from Primary Studies 
For each publication, information on quality (see the following section) and 
experimental design characteristics (animal species, strain and intervention tested) 
were entered into the CAMARADES Data Manager, a centralised Microsoft Access 
Database. For all included studies, details regarding the following information was 
extracted:  
- The method of model induction 
- The strain, sex and age or weight of animals 
- Animal husbandry conditions in particular any germ-free or pathogen free 
housing conditions 
- Information regarding the diet of the animals 
- Intervention characteristics such as the dose, the route of administration, the 
timing and number of administrations where reported 
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The number of animals, mean and measure of variance (either SD or SEM) for control 
group and treatment group were extracted for each outcome of interest. The primary 
outcome measure was efficacy on behavioural scores. Further, data for genetic, 
microbial, neurochemical, hormonal, anatomical, metabolic, and immunological 
outcomes were also extracted. See Table 5.1 for classification of outcomes. Where 
data were presented graphically, universal desktop ruler 
(https://avpsoft.com/products/udruler/) or the in-built measuring tool in Adobe was 
used to extract numerical values. Data extraction was carried out in duplicate by AS 
& ABB, with a third screener (SKM) involved in the reconciliation stage. 
 




Behavioural Any test in live animals looking at 
behaviour 
Forced Swim Test, 
Elevated Plus Maze 
Microbial Any measure of bacterial colonies as 
measured by, for example, mRNA or 
protein expression 
Beta diversity, 
Alpha diversity in 
gut microbial 
colonies 
Neurochemical Neurochemical readouts including 
neurotransmitter levels or metabolites, 
neurogenesis, neuronal excitability, as 














Anatomical Any measure of body structure or 
composition  
Body weight, brain 
structure or size, 
colon permeability 
Metabolic Any readouts of body metabolism Glucose or insulin 
levels or turnover, 
fecal boli, urine 
reactivity 
Immune Any physiological responses to foreign 
bodies (e.g. viruses, fungi, bacteria in 
the body) as detected via antigens 
Cytokines, LPS, T-
cell response, 
Interferon, IL-1, IL-4 
Inflammatory Any physiological response to damage 
such as trauma, heat, stress, toxins, 
bacteria – including mRNA or protein 





Oxidative Stress Any oxidative stress response that 
signals a disturbance between 
antioxidant defences and production of 










5.2.4 Assessment of Quality 
Methodological quality was assessed by recording the reporting on any of the 
following four items; whether a study reported the randomisation of animals to control 
and treatment groups or model and control groups, whether a study reports the 
blinding of investigators under the assessment of outcome measures, allocation 
concealment, and if authors report a sample size calculation (Macleod et al., 2004). 
Further, we assessed whether authors report that experiments comply with animal 
welfare regulations, whether authors have included a statement of potential conflicts 




5.2.5 Data Reconciliation 
Two independent reviewers (AS & ABB) extracted data from publications. Extracted 
data at the level of the publication and the outcome were compared and any 
discrepancies were checked and corrected. Effect sizes for each comparison were 
calculated for each reviewers’ extracted data and compared.  Where effect sizes 
differed by more than 10%, the original article was checked, and graphs were re-
extracted.  Where effect sizes for comparisons differed by less than 10%, the mean 
of the effect sizes and the errors (SEM/SD) were calculated.   
 
5.2.6 Data & Meta-Analysis 
For all outcome measures, the effect size measure standardised mean difference 
(SMD) was calculated for each comparison. A comparison is defined as a pair of 
cohorts of animals, one cohort that receives an intervention, and the other cohort 
receives an appropriate control for that intervention (Vesterinent et al., 2014). SMD 
was used as we cannot infer the ‘normal’ behaviour or ‘normal’ biological readouts of 
an animal, and data are presented on different scales. All equations used are taken 
from Vesterinen and colleagues (2014).  SMD is calculated using Hedge’s G 
standardised effect, as it has a correction factor for small sample size (fewer than 10 
animals per group), with the following equation:   
𝑆𝑀𝐷𝑖 =  





) × 𝑑𝑖𝑟𝑒𝑐𝑡𝑖𝑜𝑛    
 
Where ‘direction’ refers to the correction factor applied to the effect size to account 
for the direction, whether a higher score in the outcome represents a worse or better 
outcome (Vesterinen et al., 2014). Spooled is calculated with the following equation:  






          












Comparisons were combined using random-effects modelling, with Hartung-Knapp 
adjustment, with a restricted maximum likelihood estimate of between study variance. 
Random effects meta-analysis assumes that true effects differ between studies and 
allow us to explore the differences between the studies that contribute to differences 
in effect sizes. Firstly, the weight of each study is calculated by the inverse of the sum 
of within study variance and tau-squared (𝜏2) as a measure of between study variance: 
𝑊+𝜏2








      
𝑄 = sum of the squared differences in effect sizes between studies and the pooled 
effect size  (𝑄 =  ∑ 𝑊∗𝑘𝑖=1 × (𝐸𝑆𝜃𝑖 − 𝐸𝑆𝑓𝑖𝑥𝑒𝑑)2), 𝑑𝑓  = degrees of freedom, and 𝐶  = 
measure used to convert the heterogeneity value into an average and put the value 
back into original units. The weighted effect size for each study is:  
𝐸𝑆𝑟𝑎𝑛𝑑
∗ =  𝐸𝑆𝜃𝑖 × 𝑊+𝜏2
∗    
                
The effect sizes from studies are summarised and divided by the sum of weights alone, 
to get a pooled effect size. The summary effect estimate and the standard error of the 
estimate is calculated with the following equations:  














    
        
The 95% confidence intervals for the summary effect size are calculated with the 
following equation:  
95% 𝐶𝐼 =  𝐸𝑆𝑟𝑎𝑛𝑑𝑜𝑚  ± 1.95996 ×  𝑆𝐸𝑟𝑎𝑛𝑑𝑜𝑚        
 
If several outcomes in the same category, e.g. several measures in the forced-swim 
test, were reported from the same cohort of animals, these were combined or nested 
using fixed effects meta-analysis and this aggregate estimate was used for further 
analysis in the random-effects model. Fixed effects meta-analysis is similar to random 
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effect meta-analysis, but the assumption is that true effects do not differ between 
comparisons and that all studies share one true effect size. The fixed effect model 
assumes that any variation between studies is due to sampling error. The weight of 
each study is the inverse of the variance. The effect size for each comparison is 
calculated by multiplying the effect size by the weight.  
Weight:    𝑊𝑖 =  
1
𝑆𝐸𝑖




     
The weighted effect size for each comparison is summarised and divided by the sum 
of weights alone, to give the pooled effect size:  





     
The standard error and 95% confidence intervals of the summary effect are calculated 
with the below equations:  
𝑆𝐸𝑓𝑖𝑥𝑒𝑑 =  
1
√∑ 𝑊∗𝑘𝑖=1
 and 95% 𝐶𝐼 =  𝐸𝑆𝑓𝑖𝑥𝑒𝑑  ± 1.95996 ×  𝑆𝐸𝑓𝑖𝑥𝑒𝑑   
Where multiple intervention groups were used with a single control/vehicle group, the 
number of animals in the control group was divided by the number of intervention 
groups. The impact of study design characteristics and study quality were assessed 
with stratified meta-analysis. These were assessed separately in studies investigating 
microbiota interventions to induce depression, and studies investigating microbiota 
interventions as treatments. The study design characteristics pre-specified are 
outlined in Table 5.2. The models used were grouped into models that directly 
targeted the gut microbiota (Direct) and models that indirectly targeted the gut 
microbiota or stipulated that stress impacted the gut microbiota (Indirect).  Treatments 
were grouped into interventions that had proposed antibiotic properties and 
interventions that had proposed probiotic properties. The underlined outcomes in 
Table 5.2 were used in the analysis. The reason for not investigating all the pre-
specified study design characteristics was that there were not enough comparisons 
(e.g. only 1 comparison used female animals). The age of animals was not presented 
uniformly across primary studies. Some studies reported the weight of an animal, 
whereas other studies reported the age in weeks. These cannot reliably be combined 
into a single scale. The weight varies greatly between strains and is also different for 
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animal from different breeders. Therefore, we did not combine this variable. Further, 
treatment dose was not able to be combined onto a single meaningful scale as some 
studies administered antibiotics (in mg/kg) and other studies administered probiotics 
(in Colony Forming Units, CFU).  
 
Table 5.2 Stuidy Design Charcteristics for Model and Treatment Interventions 
Study Characteristics for Model 
Induction Interventions: 
Study Characteristics for Treatment 
Interventions: 
Direct or Indirect Gastrointestinal 
Manipulation 
Type of Treatment Intervention 
(Probiotic or Antibiotic) 
Strain of Rodent Treatment Dose 
Age of Animals Route of Administration 
Sex of Animals Number of Times Administered 
Number of times the outcome was 
assessed 
Treatment given pre or post model 
induction 
 
Univariate meta-regression was used to investigate treatment dose as a possible 
source of heterogeneity. Meta-regression and stratified meta-analysis was performed 
using a Meta-analysis Online Platform based on R (code available here: 
https://github.com/qianyingw/meta-analysis-app).  
 
Stratified meta-analysis partitions heterogeneity within groups of similar studies, and 
between groups of studies. Random effects effect size and Q are calculated for each 
group and grouped into similar studies and subtracted from the total heterogeneity; 
residual heterogeneity between groups remains.  The heterogeneity between groups 
is tested using the chi-square test. Meta-regression is a weighted linear regression 
describing the line of best fit between the effect size and the covariates added to the 
model. Meta-regression takes into account the within-study variance and the between 
study variance (𝜏2) . For meta-regression, 𝜏2  is calculated using the restricted 
maximum likelihood estimate (Thompson & Sharp, 1999). Adjusted R2 is the variance 
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in the outcome measure that is accounted for by the independent variable. Changes 
in 𝜏2 reflect the variance that is explained by the covariates and therefore residual 
heterogeneity. An F-ratio is calculated to ascertain how much the addition of 
covariates has improved the prediction of the model.  
 
A simulation study by Wang et al., (2018) at CAMARADES identified that stratified 
meta-analysis using SMD has low statistical power to detect the effect of a variable of 
interest, but a low false positive rate, so we can be confident in any significant results 
found. A Holm-Bonferroni correction was applied to correct for multiple testing. The 
significance level for the analysis of study design characteristics in modelling 
experiments was adjusted to p < 0.025. The significance level for the analysis of study 
design in treatment experiments was adjusted to p < 0.010. The significance level for 
the analysis of measures to reduce the risk of bias in modelling and treatment 
experiments was adjusted to p < 0.017.  
 
All effect size measures are reported as standard difference (SD) with upper and 
lower 95% confidence intervals.  
 
5.2.7 Publication Bias 
The risk of publication bias was assessed using visual inspection of a funnel plot, 
Egger’s regression (Egger et al., 2007) and trim and fill analyses (Duval & Tweedie, 
2000) were used to identify potentially missing studies.  
 
5.3 Results 
5.3.1 Identifying Publications 
A systematic search was conducted in PubMed and EMBASE in May, 2016. 70,365 
unique publications were identified from the search. Machine-learning algorithms 
were employed to screen the studies based on a sub-set of documents with human 
decisions (2 independent reviewers with 3rd for reconciliation). A performance of 98.7% 
sensitivity and 88.7% specificity was achieved. 18,409 documents were included in 
the review by the machine-assisted approach, which formed the depression database. 
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99 studies were identified in the database as containing the microbiota keywords of 
interest. 47 publications were included at title and abstract screening. 15 publications 
were included in this review after full-text screening.  
 
5.3.2 Microbiota Interventions as treatments in animal models of depression 
10 studies reported a microbiota-targeting intervention to rescue depressive-like 
behaviour where a model of depressive-like behaviour had been induced. These 
interventions to treat depressive-like behaviour were grouped into interventions that 
had proposed antibiotic properties and interventions that had proposed probiotic 
properties.  
 
5.3.2.1 Intervention Variables 
Of interventions that had probiotic properties, no two products or strains were the 
same. Products or strains of bacteria used were (8 different probiotic treatments): 
Probio’Stick, L. salivarius HA113, L. rhamnosus (JB-1), Bifidobacterium infantis 
35624, L. helveticus NS8, L. plantarum PS128, B. Longum 1714, B. Breve 1205, and 
fecal samples from healthy control patients given once (fecal colonisation). Of 
interventions that had antibiotic properties (3 different antibiotic treatments), products 
used were; minocycline, Streptomycin Sulphate & Penicillin G, and an antibiotic 
cocktail made up of vancomycin, neomycin, metronidazole, and amphotericin B. 
These interventions were administered to animals between 14 days and 45 days, 
once daily, either via oral gavage or orally.  
 
We pre-specified that at least 25 independent comparisons per outcome measure 
were required for quantitative analysis with meta-analysis. As above, a comparison is 
defined as a pair of cohorts of animals, one cohort that receives an intervention, and 
the other cohort receives an appropriate control for that intervention (Vesterinent et 
al., 2014). There were only a small number of primary studies included in this review, 
but as this is an emerging field, and we were looking to inform a primary animal 
experiment, we decided to explore heterogeneity with meta-analysis of the primary 




In the 17 comparisons from 9 studies that investigated microbiota-targeting 
interventions as treatments in behavioural outcomes (621 animals), overall 
interventions led to a significant improvement in depressive-like behaviour (0.702 SD; 
95% CIs [0.3928; 1.0120]), figure 5.2. There was moderate heterogeneity between 
the studies 𝜏2= 0.226, I2 = 68.9%, Q = 51.50, df = 16, p < 0.0001. Sample sizes of 
model induction groups ranged from 7 animals per group, to 69 animals per group, 
with a median of 10 animals per group. The impact of study design characteristics on 
heterogeneity was investigated.  
 
Figure 5.2. Forest plot of the effects of microbiota interventions to reduce depressive-
like behaviour in the meta-analysis. Positive effect sizes indicate an improvement in 
behaviour and negative effect sizes indicate a worsening in behaviour associated with 
depression. Solid orange squares represent the effect size of each comparison with 
95% confidence intervals. The blue diamond represent the pooled effect size, with the 
edges of the diamond representing the 95% confidence intervals. The solid line 
represents the line of no effect, if 95% confidence intervals cross this line, the study 
is not effective. The dashed line represents the global effect. 
 
 
Improvement in behaviour Worsening in behaviour 
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5.3.2.2 Impact of Study Design 
None of the four study design characteristics (drug category, route of administration, 
timing of administration, or number of administrations) investigated significantly 
explained heterogeneity between the studies. The study design characteristics for 
each study are summarised in Appendix 3, Table 1 
 
5.3.2.3 Impact of Measures to Reduce the Risk of Bias 
We investigated 4 measures to reduce the risk of bias; random allocation to group, 
blinded assessment of outcome, allocation concealment, and reporting of a sample 
size calculation. Random allocation to treatment or control group accounted for a 
significant proportion of the heterogeneity between studies (Fig 5.3), difference in Q 
= 7.01, χ2 = 3.84, df = 1, p = 0.008. Reporting of random allocation of animals to group 
was associated with greater estimates of effect. Blinded outcome assessment did not 
significantly account for heterogeneity between the studies. There were not enough 
studies that reported a sample size calculation (1 study reported sample size 
calculation) or allocation concealment (no studies reported allocation concealment) to 
explore these variables as potential sources of heterogeneity. All studies reported 
compliance with animal welfare regulations and all but one paper reported a conflict 
of interest statement so these variables were not investigated as potential sources of 
heterogeneity. Source of funding did not significantly explain differences in effect 
sizes between the studies. Two studies reported private funding, six studies reported 
public funding, and two studies reported both public and private funding. An overview 
of the reporting for measures to reduce the risk of bias for each study is presented in 




Fig 5.3. Effect sizes associated with random allocation to treatment or control group 
in experiments. The grey section signifies the overall effect size including 95% 
confidence intervals. The bars signify the effect size in each sub-group. Errors bars 
are 95% confidence intervals. 11 comparisons did not report random allocation. 6 
comparisons reported random allocation.  
 
5.3.2.4 Other Outcomes 
We extracted eight other outcomes from the primary articles; microbial (6 
comparisons), neurochemical (67 comparisons), hormonal (16 comparisons), 
anatomical (8 comparisons), metabolic (3 comparisons), immune (13 comparisons), 
inflammatory (8 comparisons), and oxidative stress (1 comparisons). Due to the small 
number of studies, these were not able to be investigated with quantitative analysis. 
An overview of the outcomes investigated in primary articles reporting gut microbiota-





Figure 5.4. The category of outcome measures in experiments investigating gut-
microbiota interventions as treatments. Behavioural (17 comparisons), microbial (6 
comparisons), neurochemical (67 comparisons), hormonal (16 comparisons), 
anatomical (8 comparisons), metabolic (3 comparisons), immune (13 comparisons), 
inflammatory (8 comparisons), and oxidative stress (1 comparisons).  
 
5.3.2.5 Publication Bias 
For studies that used gut-microbiota interventions as treatments, there were 
seventeen comparisons (0.702 SD; 95% CIs [0.3928; 1.0120]). The funnel plot 
revealed slight asymmetry which was not significant with Egger’s Regression.             
 
5.3.3 Interventions targeting the gut microbiota to induce depression 
Thirteen studies reported an intervention to induce depression that was stipulated to 




Of the 13 studies, 8 studies used mice and 5 studies used rats. All but two studies 
used male animals, one study used female animals and one study did not report the 
sex of animals used. The models used were grouped into models that directly targeted 
the gut microbiota (8 experiments) and models that indirectly targeted the gut 
microbiota or stipulated that stress impacted the gut microbiota (7 experiments). 13 
different models were used across the papers. The direct manipulations of the gut 
microbiota to induce depressive-like behaviour were; Germ-free housing, magnesium 
deficient diet, high sucrose diet, high fat diet, ciprofloxacin, gastric gavage, and 
prolonged weaning. Indirect manipulations of the gut microbiota to induce depressive-
like behaviour investigated were; water avoidance stress, forced swim test, maternal 
separation, chronic mild stress, and chronic restraint stress.  
 
We pre-specified that at least 25 independent comparisons per outcome measure 
were required for quantitative analysis with meta-analysis. There were only a small 
number of primary studies included in this review, but as this is an emerging field, and 
were looking to inform a primary animal experiment, we decided to explore 
heterogeneity with meta-analysis of the primary outcome, behaviour.  
In the 16 comparisons from 9 studies that report microbiota-targeting 
interventions to induce depression and investigated behavioural outcomes (407 
animals), overall interventions led to a significant worsening of depressive-like 
behaviour (-0.549 SD; 95% CIs [-1.079; -0.019]), figure 5.5. There was high 
heterogeneity between the studies 𝜏2= 0.78, I2 = 82.4%, Q = 85.11, df = 15, p < 0.0001. 
Sample sizes of model induction groups ranged from 6 animals per group, to 44 
animals per group, with a median of 14 animals per group. The impact of study design 




Figure 5.5. Forest plot of the effects of microbiota interventions to induce depressive-
like behaviour that was stipulated to act through gut microbiome alterations in the 
meta-analysis. Negative effect sizes indicate a worsening in behaviour, positive effect 
sizes indicate improvement in behaviour associated with depression. Solid blue 
squares represent the effect size of each comparison with 95% confidence intervals. 
The pink diamond represent the pooled effect size, with the edges of the diamond 
representing the 95% confidence intervals. The solid line represents the line of no 
effect, if 95% confidence intervals cross this line, the study is not effective. The 
dashed line represents the global effect.  
 
5.3.3.1 Impact of Study Design 
Three study design characteristics were investigated as potential sources of 
heterogeneity; model category (direct or indirect), type of animal (rat or mouse), and 
sex of the animals used. The category of model significantly explained heterogeneity 
between the studies (difference in Q = 10.23, χ2 = 3.84, df = 1, p = 0.0013), Figure 
5.6A. Studies using indirect models (4 comparisons), the more commonly used 
models in the field e.g. chronic mild stress, were associated with greater effect sizes 
(-0.96 SD, [-1.40; -0.52]), whereas direct models (12 comparisons) were not effective 
at inducing depressive-like effects (-0.38 SD, [-1.07; 0.32]). The type of animal used 
Improvement in behaviour Worsening in behaviour 
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in the experiment significantly explained differences in effect size between the studies 
(difference in Q = 20.11, χ2 = 3.84, df = 1, p = 7.31 x 10-6), Figure 5.6B. Studies that 
used rats (6 comparisons) were associated with greater effect sizes (-1.21 SD, [-2.08; 
-0.33]), whereas no effects were seen in studies using mice (10 studies, -0.129 SD, 
[-0.739; 0.48]). All but one study used male animals, therefore this variable was not 
able to be investigated as a source of heterogeneity. A summary of study design 
characteristics in studies exploring microbiota interventions to induce depression is 
presented in Appendix 3, Table 2.  
 
Figure 5.6A & B. (A) Effect sizes associated with model category (4 comparisons 
reported direct gut-microbiota manipulation, 12 comparisons reporting indirect gut-
microbiota manipulation), and (B) type of animal used in the experiment (6 
comparisons used rat, 10 comparisons used mice). The grey sections signify the 
overall effect size including 95% confidence intervals. The bars signify the effect size 
in each sub-group. Errors bars are 95% confidence intervals. 
 
5.3.3.2 Impact of Measures to Reduce the Risk of Bias 
We investigated 4 measures to reduce the risk of bias; random allocation to group, 
blinded assessment of outcome, allocation concealment, and reporting of a sample 
size calculation. Random allocation to model or control group did not explain 
significant heterogeneity between studies. 4 studies reported random allocation to 
group, 9 studies did not report random allocation to group. No studies reported 
allocation concealment, and only one study reported a sample size calculation, 
therefore we were unable to explore these variables as potential sources of 
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heterogeneity. Only one study did not report a conflict of Interest statement, and 
compliance with animal welfare regulations. Source of funding did not significantly 
explain heterogeneity between the studies. 2 studies reported private funding, 5 
studies reported public funding, 3 studies reported both public and private funding, 1 
study did not report any funding, and 1 study reported no funding. The reporting of 
measures to reduce the risk of bias are summarised in Appendix 3, Table 4.  
 
5.3.3.3 Other Outcomes 
We extracted eight other outcomes from the primary articles; microbial (10 
comparisons), neurochemical (58 comparisons), hormonal (9 comparisons), 
anatomical (8 comparisons), metabolic (3 comparisons), immune (18 comparisons), 
inflammatory (8 comparisons), and oxidative stress (5 comparisons) outcomes. Due 
to the small number of studies, these were not able to be investigated with quantitative 
analysis. An overview of the outcomes investigated in primary articles reporting an 







Figure 5.7. The category of outcome measures in experiments investigating gut-
microbiota interventions to induce depression. Behavioural (16 comparisons), 
microbial (10 comparisons), neurochemical (58 comparisons), hormonal (9 
comparisons), anatomical (8 comparisons), metabolic (3 comparisons), immune (18 
comparisons), inflammatory (8 comparisons), and oxidative stress (5 comparisons) 
outcomes. 
 
5.3.3.4 Publication Bias 
For studies that used gut-microbiota interventions to induce depression, there were 
sixteen comparisons contributed to the pooled effect size (-0.549 SD; 95% CIs [-1.079; 
-0.019]). We observed slight funnel plot asymmetry which was not significant with 
Egger’s Regression.             
 
5.3.4 Overview of Neurochemical Outcomes & Brain Regions 
There was a broad range of neurochemical outcomes investigated in the primary 
studies, 67 comparisons in model induction studies and 58 comparisons in treatment 
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studies. These neurochemical outcomes reported were investigated in many different 
brain regions. Knowledge regarding, for example, neurotransmitter levels and 
neurogenesis in depression reports that different neurochemical outcomes are likely 
to display different levels of expression in separate brain regions. As there were too 
few studies to investigate the effects of microbiota interventions on individual 
neurochemical readouts in separate brain regions, this information from all 
neurochemical outcomes (both model induction and treatment studies) is presented 
in a diagram to provide an overview (figure 5.8).  
 
Figure 5.8. Neurochemical outcomes investigated in all studies, both model induction 
and treatment intervention, separated by brain area they were investigated in.  
 
5.4 Discussion 
The results from this systematic review and meta-analysis indicate that up until May 
2016, there are few investigations into gut microbiota interventions in animal models 
of depression. There was a broad range of outcomes investigated in the studies 
included in this review, from behaviour to inflammatory and oxidative stress response 
outcomes. Many studies investigated several biological outcomes including behaviour, 
which can potentially elucidate the underlying biology of depression. The 3Rs 
advocate for maximising the information gathered from each animal, to reduce the 




A range of interventions was used in primary articles. Both antibiotic and probiotic 
interventions were investigated in models of depression, perhaps reflecting the 
exploration of mechanisms behind the impact gut microbiota alterations have on 
mood. No two studies investigated the same probiotic strain; therefore, we cannot 
compare the relative effectiveness of different strain using meta-analysis. This may 
reflect the early investigation into these products on depressive-like behaviour in 
animal models of depression.  
 
Both interventions directly and indirectly targeting the gut microbiota to induce 
depression were investigated. Indirect models had higher effect sizes than direct 
models, suggesting that manipulations of the gut microbiota may not induce 
depressive-like behaviour in animals. Indirect models included traditional model 
induction techniques such as chronic mild stress. This may reflect the investigation of 
the impact of stress on the gut microbiota, as a possible additional mechanism 
through which depressive-like behaviour is induced. 
 
With few studies and many variables investigated, the findings from the meta-analysis 
of pooled effects of microbiota-targeting treatments and microbiota-targeting model 
induction methods should be interpreted with caution. This is a rapidly evolving field, 
where most of the studies included in this review being preliminary studies. An update 
to this systematic review would ideally allow for data to compare the effects of different 
strains of probiotics.  
 
5.4.1 Internal Validity 
There were 4 studies that reported random allocation to group. This was a significant 
source of heterogeneity between studies in experiments using microbiota 
interventions to treat depression, where studies that reported random allocation to 
control or treatment were associated with higher effect size. This finding should be 
interpreted with caution as there were only 4 studies contributing to this sub-group in 
the analysis. Systematic reviews and meta-analyses of animal models in other 
neurological fields report the opposite to the finding here. Studies that do not report 
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measures to reduce the risk of bias often have overstated effect sizes (Macleod et al., 
2015).  
 
A sample size calculation was only reported in one study.  A recent systematic review 
of the reporting of sample size calculations found that most studies submitted to a 
leading neuroscience journal, Nature Neuroscience, had lower reporting of sample 
size calculations and studies were not adequately powered; they did not have 
adequate sample size to detect even large effects (Carter, Tilling & Munafò, 2017). If 
studies are not adequately powered, there is an increased probability that significant 
effects are identified as a false positive.  
 
Blinded assessment of outcome was reported in 40% of treatment studies and in 53% 
in model studies. This is relatively high in comparison to reviews of animal models in 
other neurological fields (McCann et al., 2014; Vesterinen et al., 2013; Egan et al., 
2016). This may reflect that this is a relatively new field, with papers published since 
2010, which was the same year that the ARRIVE guidelines to improve the reporting 
of animal studies was published (Kilrenny et al., 2010). However, no studies reported 
all three; randomaisation, blinding, and sample size calculation.  
 
5.4.2 External Validity 
Only one study across both meta-analyses used female animals. The sex of animals 
used in these experiments is consistent with the sex bias in laboratory animals used 
in biomedical research (Zucker & Beery, 2010). Mental health disorders affect both 
males and female. In particular for depression, the female to male ratio in disability 
from depression is 1.7:1 (Murray et al., 2013) and the annual prevalence is 5.5% for 
females and 3.2% for males (Whiteford et al., 2013). The higher rates of prevalence 
and disability from the disorder, should be further rationale for investigating the 
underlying biological effects of stress and the effects of antidepressant treatments in 




The timing of administration is an important factor in the external validity of these 
experiments and has implications in the use of gut microbiota-targeting treatments. 
Three studies gave the intervention before the model induction, four studies 
administered the treatment simultaneously to the model induction, and three studies 
gave the intervention after the model induction. Typically in the clinic, patients are 
prescribed an antidepressant after they show symptoms and meet diagnostic criteria 
for depression. Gut microbiota targeting interventions such as probiotics and 
prebiotics are available without a prescription, therefore it is possible to take probiotics 
as prophylactics to reduce the response to a stressful event or taking probiotics during 
a stressful life-period may improve outcome.  Further studies are required to 
understand if probiotics are able to act as prophylactics and the potential mechanisms 
behind this.  
 
The most commonly reported behavioural outcome measure was the forced swim test 
and the tail suspension test. Although, this is widely used as an anti-depressant 
screening test and used as a measure of depressive-like behaviour, it has been 
critiqued for being a test of stress coping behaviour or behavioural adaption, and not 
measuring an internal state of the animal (Molendijk & de Kloet, 2015; Commons et 
al., 2017). The FST is often used to argue that an experimental design variable has 
“induced depressive-like behaviour”, when it is not a model of depression as the 
dependant variable is the response to the test rather than an intrinsic state in the 
animal (Porsolt et al., 1978; Nestler & Hyman, 2010). The predictive validity of current 
animal models and read-outs may be improved with the use of more naturalistic 
outcome measures such as assessment of home cage and spontaneous behaviour, 
and preference testing. These may assist in measuring the intrinsic states of animals, 
their natural behaviour and their positive or negative emotional states (King, 2003; 
McArthur & Borsini, 2006), and potentially close the translational gap between studies 
of animal models of depression and clinical findings.  
 
5.4.3 Publication Bias 
There was no evidence of publication bias in this data set. Publication bias is the 
observation that studies with small or no effects remain unpublished and studies with 
positive findings are published. Publication bias has been shown to be present in other 
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fields of preclinical modelling and are seen to have an impact on the statement of 
efficacy (Macleod et al., 2015; Sena et al., 2010). It is likely that no publication bias 




The main limitation of this systematic review is that the most recent information 
included was identified in May 2016. The investigation of gut microbiota in animal 
models of neuropsychiatric disorders is a rapidly evolving field and many studies have 
been published since. An update to this systematic review is planned, these are only 
preliminary results. The pre-specified protocol outlined that sex and strain were only 
to be investigated as potential sources of heterogeneity in model induction meta-
analysis and not in treatment analysis. This oversight was not analysed post-hoc as 
there were few studies.  
 
The protocol pre-specified that all the outcome categories, such as neurochemical 
and microbial outcomes would have been investigated quantitatively. With the amount 
of studies included in the systematic review and with the wide range of biological 
outcomes assessed across different brain and anatomical regions, the decision not to 
summarise them quantitatively was made. We hope that with an update to this 




This systematic review and meta-analysis provides an overview of the literature until 
2016 on animal models of depression where gut microbiota-targeting interventions 
were used. This review found that a broad range of outcomes investigated. Meta-
analysis of the primary outcome revealed that gut microbiota-targeting interventions 
significantly improved behavioural outcomes. Meta-analysis revealed that gut 
microbiota-targeting interventions to induce depression significantly worsened 
behavioural outcomes. With few studies and many variables investigated, the findings 
from the meta-analysis should be interpreted with caution. Microbiota-targeting 
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interventions are reasonably novel in the field of neuropsychiatry and appear 
promising. However, it is clear from this study that most of the studies are preliminary 
studies and further research is needed. A gap in the literature is that interventions 
were mainly in the form of probiotics or antibiotics, no studies in this systematic review 
investigated prebiotics. A further gap in the literature is the need for experiments that 
control threats to interval validity, such as implementing randomisation, blinding, and 
the conduct of an a prior sample size calculation. No studies in this systematic review 
reported all three of these measures. Therefore, to address these gaps in the literature, 
I conducted a primary animal experiment investigating the effect of prebiotics in an 
animal model of depression, the Flinders Sensitive Line, employing measures to 
reduce the risk of bias. This experiment is reported in Chapter 7. In future, an update 
to this systematic review would ideally allow for data to compare the effects of different 




6 THE ANTIDEPRESSANT EFFECT OF KETAMINE IN ANIMAL MODELS OF 
DEPRESSION AS MEASURED BY THE FORCED SWIM TEST: A SYSTEMATIC 
REVIEW AND META-ANALYSIS 
 
The findings from this review have been collected and collated with help from Grace 
Wallace (GW), an honours student at CAMARADES, Oskar Jefsen (OJ), a research 
year medical student at TNU, Aarhus University, Fraser Sneden (FS), a research 
assistant at CAMARADES, and Kaitlyn Hair (KH), a PhD student at CAMARADES. 
Their respective contributions are highlighted throughout.  This chapter reports a 
systematic review and many of the methods are done in duplicate for good practice. 
Where steps of the review have been done in duplicate, the contribution will be 
highlighted by using “we/our”. 
 
6.1 Introduction 
Major Depressive Disorder (MDD) is the leading source of disability globally (Marcus 
et al., 2012) and treatment resistance among patients is roughly 50% (Thomas et al., 
2013). Therefore, better understanding mechanisms behind MDD and the search for 
potential effective and novel therapeutic targets are high research and healthcare 
priorities. Current antidepressant therapies are not rapid acting, the number of 
patients who experience full remission with citalopram over 8-12 weeks is 
approximately 33% (Insel, 2006).  Treatment resistance, defined as failure to respond 
to two or more anti-depressant trials (Souery et al., 2006), is common. Even patients 
that do receive standard care with treatment of SSRIs, only respond adequately 
approximately 30-50% of the time (Rush et al., 2006; Thomas et al., 2013). Conway 
and colleagues note that current definitions are vague (ranging from 1 to 8 failed 
antidepressant treatment trials), which has likely contributed to the varying estimate 
of prevalence of treatment resistant depression (Conway et al., 2017). They propose 
an update to the operational definition of treatment resistant depression (Conway et 
al., 2017), to include a fixed number of anti-depressant trials the patient has tried and 
call for a definition where antidepressants with different mechanisms of action have 
been tested. Despite work being carried out to correctly identify treatment resistant 
depression, it is clear that the current treatments are not adequate for all patients with 
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depression, and where current treatments are effective they are not rapid-acting to 
reduce symptoms.   
 
Animal models are commonly used to mimic aspects of the phenotype of the human 
disorder and to characterise candidate antidepressant agents. Animal models have 
been established to mimic treatment-resistant depression. Treatment resistant 
depression is defined in animal models as not responding to clinically used 
antidepressants and are validated by comparing treatment resistance rates in patients 
(Caldarone et al., 2015). Caldarone and colleagues review the commonly used animal 
models for mimicking treatment resistant depression, which include administration of 
hormonal or inflammatory agents such as ACTH and IL-6, stress models such as 
CMUS with non-responder groups, genetic models such as BALB/cOLaHsd as well 
as single gene transgenic animals, and combinations of these models (Caldarone et 
al., 2015). ACTH administration appears to be the most commonly used model. A 
dose of approximately 100ug ACTH, when administered for 14 days has been shown 
to be most effective (Kitamura et al., 2002), and this finding has been replicated in 
rats and mice (Walker et al., 2013 (rats); Caldarone & Brunner, 2009; Iwai et al., 2013 
(mice)).  
 
One potential target for treatment resistant depression is ketamine. Ketamine, the N-
methyl-D-aspartate (NMDA)-receptor antagonist, initially marketed in 1970, has been 
used across healthcare and veterinary medicine for anaesthesia.  More recently, it 
was discovered that ketamine could reverse depressive-symptoms in patients with 
treatment resistant depression (Berman et al., 2000). Since this initial randomised 
controlled trial, several subsequent trials have been conducted.  Seventy-three 
studies were retrieved in Clinicaltrials.gov when searching ketamine and major 
depressive disorder (August 2018), twenty-seven of which are completed. In the 
published reports from these clinical trials, the anti-depressant response is rapidly 
acting, within 2-4 hours, which is maintained for 4-7 days (Williams & Schatzberg, 
2016). Approximately 40-60% of patients showed reduced symptoms after 24 hours 




The mechanisms of action that ketamine have been found to act through include 
synaptic plasticity and neurotrophic signalling (Murrough, 2012). Ketamine has been 
shown to increase the number of synapses and the synaptic function in the PFC 
through mammalian target of rapamycin (mTOR) and extracellular signal-regulated 
kinase (ERK) signalling pathways (Liu et al., 2017). The antidepressant activity of 
ketamine has been shown to be dependent on rapid synthesis of BDNF through 
tyrosine kinase receptor (TrkB) (Autry et al 2011). Ketamine has been shown to 
decrease activity in the PFC and the orbital frontal cortex and increase activity in the 
posterior cingulate in a human fMRI study (Deakin et al., 2008). The behavioural and 
biological effects of ketamine have been investigated in standard animal models of 
depression as well as animal models of treatment resistant depression.  
 
The forced swim test (FST) is a commonly used assessment tool to test anti-
depressant efficacy and assess depressive-like behaviour. The FST was developed 
by Porsolt and colleagues in 1977. The FST involves subjecting animals to an acute 
stressor of being in a water tank from which they are unable to escape, where animals 
after some time give up and display immobility or behavioural despair. The FST is 
used in mice and rats with slight modifications between the species. When the FST is 
used with rats, they are often subjected to a pre-swim session, with no pre-swim 
session used typically in studies involving mice.  
 
Systematic review and meta-analyses of non-human animal data are hypothesis-
generating tools which provide an overview of the field and can be used to inform the 
experimental design. Systematic reviews in other neuroscientific fields, such as 
Alzheimer’s disease, stroke, and multiple sclerosis, have provided evidence as to the 
components of experimental design that may influence efficacy of an intervention 
(Egan et al., 2016; O’Collins et al., 2006; Vesterinen et al., 2010). We aim to apply 
these methodologies to the use of ketamine in animal models of depression and 







In this systematic review and meta-analysis we set out to review the efficacy of 
ketamine in animal models of depression that assess depressive-like behaviour on 
the forced swim test (FST). We aimed to provide an overview of the literature. We 
aimed to describe the quality of the data available, and if possible, meta-analysis to 
investigate study design characteristics that influence efficacy (dose, timing, and route 
of administration of ketamine).  
 
6.2 Methods 
The methodology for this systematic review was laid out in a pre-specified protocol 
published on the CAMARADES repository of Systematic Review Protocols 
(http://www.dcn.ed.ac.uk/camarades/research.html#protocols) on 8th February 2018.  
 
6.2.1 Search Strategy 
Studies reporting the use of ketamine in animal models of depression were identified 
from an existing database of studies of animal models of depression. This database 
was collated using the search string in Bannach-Brown et al., 2016 (Chapter 2). The 
original search was carried out in May 2016. This database was searched using the 
regular expression dictionary terms; [kK]etamine|[kK]etalar|[eE]sketamine|JNJ-
54135419|[kK]etanest S|\([sS]\)[-| ]?[kK]etamine|[sS]\(\+\)[-| ]?[kK]etamine 
 
Abstract screening was carried out by GW and ABB, any screening discrepancies 
were resolved by KH. Full-text screening was carried out by GW & OJ to identify 
papers that reported forced swim test outcomes. GW, OJ, FS and ABB carried out 
full-text screening and data extraction. KH performed reconciliation of outcome data.  
 
6.2.2 Inclusion & Exclusion Criteria 
Publications were included if they tested ketamine in the Forced Swim Test (FST) to 
measure depressive-like behaviour, in an in vivo experiment, where any quantitative 
outcome of depression had been assessed. Studies were included if there was an 
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appropriate control group (received a vehicle of saline in the same volume) and where 
the sample size, the mean and the variance in each group had been reported for the 
primary outcome, behaviour. There were no exclusion criteria based on species or 
strain of animal, age, sex, weight or method of model induction. There were no 
exclusion criteria based on dosage, timing or frequency of administration of the 
ketamine. Studies were excluded if only anxiety-like behaviour was the only 
behavioural outcomes investigated. There were no exclusion criteria pertaining to 
date of publication but studies were excluded at full-text if not in English due to the 
time constraints of the project.  
   
 
 Figure 6.1. PRISMA flowchart of studies included in this review.  
 
6.2.3 Data Extraction from Primary Studies 
For each publication, information on quality (see the following section) and 
experimental design characteristics (animal species, strain and intervention tested) 
were entered into the SyRF, an online Systematic Review Facility developed by 
CAMARADES & NC3Rs. For all included studies, details regarding the following 
information was extracted:  
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- The method of model induction, such as stress, pharmacological or lesion 
models 
- The species, strain, sex and age or weight of animals 
- Ketamine characteristics: 
o Type of ketamine (Ketamine, R-ketamine, S-ketamine)  
o Dose 
o Route of administration 
o Number of administrations 
- Age of animal at administration (if reported) 
- Time between ketamine administration and outcome assessment 
- Animal husbandry conditions  
The number of animals, mean and measure of variance (either SD or SEM) for control 
group and treatment group were extracted for each outcome of interest. The primary 
outcome measure was efficacy in the forced swim test. Any measure from the forced 
swim test was extracted (e.g. immobility, swimming, struggling, or head-shakes) 
 
Where data were presented graphically, universal desktop ruler 
(https://avpsoft.com/products/udruler/) or the in-built measuring tool in Adobe was 
used to extract numerical values. Data extraction was carried out in duplicate by GW, 
FS, OJ and ABB. KH carried out reconciliation of extracted outcome data. 
 
6.2.4 Assessment of Quality 
Methodological quality was assessed by recording the reporting on any of the 
following four items; whether a study reported the randomisation of animals to control 
and treatment groups, whether a study reports the blinding of investigators under the 
assessment of outcome measures, allocation concealment, and if authors report a 
sample size calculation (Macleod et al., 2004). Further, we assessed whether authors 
report that experiments comply with animal welfare regulations, whether authors have 
included a statement of potential conflicts of interest, and what the source of funding 





6.2.5 Data Reconciliation 
Two independent reviewers (GW, OJ, FS & ABB) extracted data from publications. 
Extracted data at the level of the publication and the outcome were compared and 
any discrepancies were checked and corrected. Effect sizes for each comparison 
were calculated for both reviewers and compared, where effect sizes differed by more 
than 10%, the original article was checked and data was re-extracted from graphs or 
tables in the primary articles.  Where effect sizes for comparisons differed by less than 
10%, the mean of the effect sizes and the errors (SEM/SD) were calculated.   
 
6.2.6 Data & Meta-Analysis 
For the primary outcome, the forced swim test, the effect size measure standardised 
mean difference (SMD) was calculated for each comparison. As above, a comparison 
is defined as a pair of cohorts of animals, one cohort that receives an intervention, 
and the other cohort receives an appropriate control for that intervention (Vesterinent 
et al., 2014). SMD was used as we were not able to infer the ‘normal’ behaviour or 
‘normal’ biological readouts of an animal, and data are presented on different scales. 
All equations used are taken from Vesterinen and colleagues (2014) and are 
described fully in Chapter 5. The effect sizes from each comparison were combined 
using random-effects modelling, with Hartung-Knapp adjustment, with a restricted 
maximum likelihood estimate of between study variance. Random effects meta-
analysis assumes that true effects differ between studies and allows us to explore the 
differences between the studies that contribute to differences in effect sizes. If several 
measures were taken from the FST, e.g. immobility, swimming, and struggling, were 
reported from the same cohort of animals, these were combined or nested using fixed 
effects meta-analysis and this aggregate estimate was used for further analysis in the 
random-effects model. Fixed effects meta-analysis is similar to random effect meta-
analysis. However, the assumption is that true effects do not differ between 
comparisons. The weight of each study is the inverse of the variance. Where multiple 
intervention groups were used with a single control/vehicle group, the number of 
animals in the control group was divided by the number of intervention groups. 
Random-effects meta-analysis and meta-regression was carried out in Stata using 
the metareg function. Nesting was carried out in R. The impact of study design 
characteristics and study quality was assessed with meta-regression. The study 
design and intervention characteristics pre-specified are outlined in Table 6.1 below. 
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Table 6.1 Pre-specified study design characteristics.  
Study Design Characteristics investigated:  
Method of Model Induction  
(Chronic Stress, FST, genetic, learned helplessness, CORT/LPS insult, Other)  
Sex of animals 
Age or weight of animals 
Species of animal 
Form of ketamine  
(Ketamine, R-ketamine, S-ketamine, DehydroNorKetamine, Ketalar,  
NorKetamine) 
Dose  
Route of administration 
Frequency of administrations (Single admin or multiple admins) 
Timing of treatment administration (before, during, after model induction) 
Timing of treatment in relation to outcome assessment 
 
In table 6.1, the characteristics not underlined were unable to be investigated. The 
age of the animals was not able to be investigated as a variable of interest, because 
primary articles reported either age in weeks or weight in grams, which were unable 
to be combined validly. No studies reported a sample size calculation, so this was 
unable to be investigated. Only one study investigated an alternative route of 
administration, other than intraperitoneal, therefore this was not investigated. Meta-
regression was used to investigate treatment dose as a possible source of 
heterogeneity. Meta-regression was performed using a Meta-analysis Online Platform 
based on R (code available here: https://github.com/qianyingw/meta-analysis-app). 
Methodology behind this approach is outlined in (Chapter 5: Methods > Data & Meta-
Analysis).  
 
A simulation study by Wang et al., (2018) at CAMARADES identified that stratified 
meta-analysis using SMD has low statistical power to detect the effect of a variable of 
interest, but a low false positive rate, so we can have confidence in any significant 
results found. A Holm-Bonferroni correction was applied to correct for multiple testing. 
The significance level for the analysis of study design in ketamine experiments was 
adjusted to p < 0.006. The significance level for the analysis of measures to reduce 





6.2.7 Publication bias 
The risk of publication bias was assessed using visual inspection of a funnel plot, 
Egger’s regression (Egger et al., 2007) and trim and fill analyses (Duval & Tweedie, 
2000) were used to identify potentially missing studies.  
 
6.3 Results 
6.3.1 Identifying publications 
A systematic search conducted in PubMed and EMBASE in May, 2016 retrieved 
70,365 unique publications. Machine-learning algorithms were employed to screen 
the studies based on a sub-set of documents with human decisions (2 independent 
reviewers with 3rd for reconciliation). A performance of 98.7% sensitivity and 88.7% 
specificity was achieved (for more detail of the methodology used, see Chapter 3). 
18,409 documents were included in the review by the machine-assisted approach, 
which formed the depression database. 259 studies were identified in the database 
using the Regex Dictionaries. These 259 studies were screened by two independent 
human reviewers with a third reviewer resolving any disagreements. 97 articles were 
included at the title and abstract screening stage. 67 publications that reported FST 
outcomes were included in this review after full-text screening. The most frequent 
reason for exclusion at the full-text screening stage were publications not in English, 
or publications not reporting the FST as an outcome. The study selection process is 
highlighted in the PRISMA flowchart in figure 6.1.  
 
6.3.2 Effect of ketamine on depressive-like behaviour in the FST 
The effect of ketamine on behaviours in the forced swim test was reported in 67 
publications. After nesting the instances where several outcomes from the FST were 
reported in the same cohort of animals at the same time of assessment, we had 182 
comparisons, using 3,203 animals. Data are summarised in Appendix 3 Tables 1 and 
2.  
 
The use of ketamine was reported in 159 experiments, 6 reported Ketalar, 5 reported 
S-Ketamine, 5 reported NorKetamine, 4 reported R-Ketamine, and 3 comparisons 
146 
 
reported DehydroNorKetamine.  85 experiments reported administering ketamine 
before the model induction, 18 reported administration during model induction, and 
79 comparisons reported administration after model induction. 98 experiments 
reported using mice, 84 reported using rats. 151 comparisons reported using male 
animals, 18 using female animals, 7 using both sexes, and sex was not reporting in 7 
comparisons. Sample size of treatment groups ranged from 5 animals to 18 animals, 
with a median of 8 animals per group. The dose administered ranged from 0.25 mg/kg 
to 160 mg/kg. The timing between the treatment administration and outcome 
assessment ranged from 19 days before outcome assessment to 20mins prior to 
outcome assessment. Ketamine was reportedly administered once in 150 
experiments, and ketamine was administered more than once in 32 studies. The 
method of model induction was an immune or inflammatory insult (corticosterone, 
dexamethasone, lipopolysaccharide, or adrenocorticotropic hormone) in 13 
experiments, chronic stress was administered in 49 experiments, a genetic model of 
depression was used in 12 experiments, the forced swim was the only induction of 
stress in 101 experiments, learned helplessness was used in 5 experiments, and 2 
utilised other methods of model induction (drug-withdrawal and neuropathic pain 
induced depression). This data is summarised in Appendix Table 1. Only one study 
investigated an alternative route of administration, other than intraperitoneal, 
therefore this was not investigated using meta-analysis. 
 
Taking all forms and doses of ketamine together, there was a significant improvement 
in depressive-like behaviour in the FST (0.869 SD, 95% CIs [0.738; 1.001], figure 6.2. 
There was no significant statistical evidence of heterogeneity observed between the 




Figure 6.2. Timber plot of the effect sizes from 182 experiments investigating the 
effect of ketamine in forced swim test outcomes. Black dots represent effect size 
(SMD), error bars represent 95% confidence intervals. The grey bar behind the plot 













6.3.3 Publication Bias 
I observed funnel plot asymmetry, which was confirmed with Egger’s regression. Trim 
and fill analysis suggested 43 theoretical missing studies correcting the SMD effect 
size to 0.685 SD [0.497; 0.873] when these missing studies were included in pooled 
effect size (see figure 6.3). This suggests a 27% relative overestimation in treatment 
effect, an absolute difference of 0.184 SD.  
 
Figure 6.3. In experiments reporting the effects ketamine on depressive-like 
behaviour, plotting studies by effect size and the inverse square root of the sample 
size on a funnel plot suggests asymmetry. Filled black circles represent published 
experiment. Unfilled white circles represent theoretically missing studies imputed with 
trim and fill analysis. The solid line represents the global effect size (0.869 SD) and 
the dashed line represents the adjusted global effect size which includes the 
theoretically missing studies (0.685 SD). 
 
6.3.4 Impact of Study Design Variables  
Planned analysis of the effects of study design variables on heterogeneity was not 
carried out as no heterogeneity was observed in this dataset, however, I did assess 
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whether these variables were associated with effect size. The study design and 
intervention characteristics (method of model induction, sex of animals, species, the 
form of ketamine, dose, frequency of administration, timing of treatment 
administration, and timing of treatment in relation to outcome assessment) were 
investigated using a multivariate meta-regression model with Knapp-Hartung 
modification. The timing of administration was significantly associated with a reduction 
in effect size (beta coefficient: -0.004 [-0.006; -0.002], p = 0.001, figure 6.4), when 
other variables were kept constant. For every 1 minute prior to the outcome 
assessment, there was a -0.004 decrease in depressive-like behaviour. None of the 
other study characteristic variables had a significant association with the effect size. 
A summary of these study design characteristics is available in Appendix Table 1. 
 
 
Figure 6.4. A visualisation of the effect of timing of administration of ketamine (mins 
prior to outcome assessment) on effect size (SMD). Circles represent the effect size 
of individual comparisons. The size of the circle represents the precision of the study 
(the inverse of its within-study variance). The red solid line represents a linear 




6.3.5 Impact of Measures to Reduce the Risk of Bias 
Planned analysis of the effects of measures to reduce the risk of bias on heterogeneity 
was not carried out as no heterogeneity was observed in this dataset. However, I 
assessed whether these measures were associated with effect size. The impact of 
reporting study quality characteristics (random allocation to group, blinded 
assessment of outcome, allocation concealment, conflicts of interest, compliance with 
animal welfare regulations, and source of funding) were investigated using a 
multivariate meta-regression model with Knapp-Hartung modification. None of the 
study characteristic variables had a significant association with the effect size at the 
corrected alpha level. 18% of studies reported randomisation of animals to group. 38% 
of studies reported blinding assessment of outcome. 3% of studies reported allocation 
concealment and 0% of studies reported conducting a sample size calculation. An 
overview of the reporting of measures to reduce the risk of bias for each study is 
presented in Appendix Table 2. 
 
6.3.6 Other Behavioural Outcomes 
We extracted the reporting of other behavioural outcomes from the primary articles. 
Other than the forced swim test, 37 studies reported depressive-like outcome 
assessments (tail suspension test, sucrose preferences test, and learned 
helplessness), 32 reported the open field test, 21 studies reported assessment of 
anxiety-like behaviour (novelty suppressed feeding or hypophagia, elevated plus 
maze, marble burying, light-dark box, and the hole board test), 10 studies reported 
assessment of locomotor activity on the rotarod or other equipment, 5 studies reported 
the assessment of cognitive outcomes (attentional set-shifting or conditioned place 
preference), and 8 studies reported the assessment of other behaviour outcomes (the 
splash test, cold or mechanical allodynia, prepulse inhibition, and stereotype rating). 





Figure 6.5. A doughnut plot of the additional behavioural outcomes assessed in 
studies investigating ketamine in the forced swim test. Sections of the doughnut plot 
represent the number of studies reporting the category of behavioural outcome.  
 
6.4 Discussion 
This study assesses the preclinical literature reporting administration of ketamine for 
the treatment of depressive-like behaviour in animals. We investigated the effects of 
ketamine on behaviour in the forced swim test. Pooling data from 67 studies, ketamine 
significantly improved depressive-like behaviour in the forced swim test. We did not 
observe any statistically significant heterogeneity between the studies. The time 
ketamine was administered before the outcome assessment had a significant 
negative association with effect size, with longer time between administration and 




Interestingly, the 95% confidence intervals for individual effect sizes crossed zero. 
With pooling the data together into a summary effect, this increases the precision of 
the estimate.  The lack of statistically significant heterogeneity between studies may 
be due to the imprecision of the individual studies. In this meta-analysis, effect sizes 
ranged from -2.22 SD to 8.97 SD. However, with overlapping confidence intervals, 
the relative differences in effect size are not statistically identified as heterogeneous. 
Further, if the true heterogeneity between the studies is low, many studies are 
required to show significant heterogeneity between the studies. Further, tests to 
detect heterogeneity are generally low powered (Higgins et al., 2003). The forced 
swim test is a uniform test with many researcher s following the original protocol by 
Porsolt and colleagues (1978). There may be slight differences between experiments, 
for example, the temperature of the water, the length of the test session, the use of a 
pre-swim session, testing in the light or dark phase of the animals, which have not 
been investigated in this review.  
 
Several forms of ketamine were investigated in this review. Ketamine was 
investigated in 87.3% of experiments, 6% of experiments reported investigating the 
enantiomers S-ketamine and R-ketamine. Although the form of ketamine used was 
not significantly associated with effect size, the investigation of different enantiomers 
in animal models may provide useful understanding of the potential side-effects and 
inform clinical trial design (Muller et al., 2016). The smallest dose administered was 
0.25 mg.kg and the highest doses administered by primary studies in this review were 
160 mg/kg, which may have neurodegenerative effects (Green & Cote, 2009).  
 
6.4.1 Internal validity 
18% of studies reported randomisation of animals to group. 38% of studies reported 
blinding assessment of outcome. 3% of studies reported allocation concealment. This 
is generally poor reporting of measures to reduce the risk of bias. A sample size 
calculation was not reported in any study. When studies are not adequately powered 
there is an increased probability that significant effects are false positive (Carter, 
Tilling & Munafò, 2017). No single measure to reduce the risk of bias was significantly 
associated with effect size when all other risk of bias variable were accounted for. We 
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were not able to investigate the impact of measures to reduce the risk of bias on 
heterogeneity between studies.  
 
6.4.2 External validity 
The timing of administration is an important factor for the external validity of the 
findings. 46% of experiments reported administering ketamine prior to model 
induction (85/182 comparisons), which may not reflect the treatment regime in clinical 
settings. Typically in the clinic, patients are prescribed an antidepressant treatment 
after they show symptoms and meet diagnostic criteria for depression. Ketamine is 
being investigated as a rapid-acting antidepressant in treatment-resistant depression 
and in acute instances of suicidal ideation (Kashani et al., 2014). Therefore, the 
external validity of findings from studies that administer ketamine prior to model 
induction may be brought into question. The external validity is called into question 
even if, as in this case, no significant differences in effect sizes were observed 
between studies that report administration before or after model induction. This non-
significant finding may have been affected by the observed imprecision of primary 
studies.  
 
As with my systematic review of microbiota-targeting interventions (Chapter 5), sex 
bias is obvesrved in the animals used in primary studies of ketamine efficacy. 18 out 
of the 182 experiments reported using female animals, and 7 out of 182 experiments 
reported using both sexes, which is unfortunately consistent with experiments in other 
areas of biomedical research (Zucker & Beery, 2010). This highlights a gap in the 
research. Further research can be conducted to understand the mechanisms 
responsible differences between sexes in animal models of depression to inform 
human treatment.  
 
6.4.3 Publication Bias 
There was evidence of publication bias in the literature reporting the effects of 
ketamine in animal models of depression. Trim and fill analyses imputed 43 
hypothetical studies. Egger’s regression estimated that there was a 27% relative 
overstatement of efficacy of ketamine in this literature. This suggests that studies with 
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smaller or negative effects are less likely to be published in this field. This result is 
similar to findings of publication bias has been identified in other neurological fields 
(Sena et al., 2010).   
 
6.4.4 Limitations 
The main limitation of this systematic review is that the search was carried out in May 
2016. Several studies may have been published since which may alter the pooled 
effect size estimate. Further, this systematic review only reports data from one 
outcome, the forced swim test. The analysis of other depressive-outcomes, such as 
the tail suspension test and sucrose preference test, as well as other behavioural 
outcomes, such as cognitive and anxiety-like behaviour, may add to our 
understanding of the variables that contribute to any differences in effect sizes 
between studies, if these tests are more precise than the forced swim test. The 
investigation of other behavioural outcomes may help shed light on potential side-
effects such as hyperlocomotion and systematic review of this data may allow for 
analysing the effects of dose on side-effects.  
 
6.5 Conclusion 
This systematic review and meta-analysis provides an overview of the literature on 
animal models of depression that investigate the effects of ketamine in the forced 
swim test. Overall, ketamine significantly reduced depressive-like behaviour. The 
timing between ketamine administration and outcome assessment was associated 
with significant decreases in effect size. There was no statistically significant 
heterogeneity in this dataset. This may be due to the low power of heterogeneity tests 
or the imprecision of the primary studies included in the review. There was low 
reporting of measures to reduce the risk of bias in the literature reviewed. Study 
design characteristics, such as 46% of studies administering ketamine prior to model 
induction, only 18 studies using female animals, and all but one study administering 
ketamine intraperitoneally, call into question the external validity of the studies. 
Further animal studies are needed that explore aspects of experimental design that 
can improve the translation of findings from animal studies into clinical trials.  Further 
investigation into behavioural outcomes such as anxiety-like behaviour and locomotor 
activity may provide insight into the potential side-effects of ketamine that have been 
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investigated with animal models of depression and allow for the investigation of 







7 ADMINISTRATION OF GALACTO-OLIGOSACCHARIDE PREBIOTICS IN THE 
FLINDERS SENSITIVE LINE ANIMAL MODEL OF DEPRESSION 
The experiment in this chapter was designed with help from Sandra Tillmann, a PhD 
student at the Translational Neuropsychiatry Unit, Aarhus University and Professor 
Gregers Wegener.  
 
7.1 Introduction 
Major Depressive Disorder (MDD) is the leading source of disability globally (Marcus 
et al., 2012) and treatment resistance among patients is roughly 50% (Thomas et al., 
2013). Therefore, better understanding mechanisms behind MDD and the search for 
potential effective and novel therapeutic targets are high research and healthcare 
priorities. Animal models are commonly used to mimic aspects of the phenotype of 
the human disorder and to characterise candidate antidepressant agents. The 
Flinders Sensitive Line (FSL) is a well-established and validated genetic model of 
depression (Overstreet & Wegener, 2013). The FSL rats are bred to display 
cholinergic sensitivity and later found to display depressive-like behaviour in the 
forced swim test (FST), compared to their control strain, the Flinders Resistant Line 
rats (FRL) (Overstreet & Wegener, 2013). FSL rats respond to acute and chronic 
antidepressant administration and display reduced hippocampal plasticity (Chen et al., 
2010) and elevated rapid eye movement (REM) sleep (Benca et al., 1996) in 
comparison to FRL rats.   
 
Communication between the gut microbiome and the brain may play a role in 
psychiatric disorders, with research focussing on the bidirectional signalling at the 
neural, hormonal and immunological levels (Cryan & O’Mahony, 2011). Interventions 
targeting the gut microbiota may serve as potential treatments for depression, and 
this drives increasing research into the effect of probiotics and prebiotics in 
neuropsychiatric disorders. Probiotics have been defined as “live organisms, that 
when ingested in adequate amounts, exert health benefits.” (Dinan et al., 2013). 
Several probiotic strains have been investigated in psychiatric disorders and have 
reported effects on behaviour and physiology, in laboratory animals and humans (for 
a review see Wang and colleagues (2016)). Commercially available probiotic products, 
“Ecological Barrier” and “Probio’Stick”, have been tested in FSL rats (Abildgaard et 
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al., 2017; Tillmann, et al., 2018). Prebiotics, defined as galacto-oligosaccharides and 
fructo-oligosaccharides that stimulate the activity of Bifidobacteria and Lactobacilli in 
the gut, have also been reported to have a positive impact, reducing anxiety and 
depressive-like phenotypes and stress-related physiology in mice and rats (Burokas 
et al., 2017; Mika et al., 2017; McVey Neufeld et al., 2017; Thompson et al., 2017; 
Savignac et al., 2013) and in humans (Perez-Cornago et al., 2016; Schmidt et al., 
2015; Tillisch et al., 2013). Further, prebiotics have been shown to increase the 
diversity of gut microbial composition, with evidence from mice (Burokas et al., 2017) 
and rats (Mika et al., 2017). Thompson and colleagues (2017), however, showed no 
difference in gut microbiota composition in F344 rats receiving prebiotics. One 
prebiotic that is commercially available is Bimuno®. Bimuno® contains beta- 
galactooligasaccharide (B-GOS) produced from lactose in cow’s milk (Bimuno, 2018).  
 
In Chapter 5 I conducted a systematic review and meta-analysis of literature reporting 
gut microbiota-targeting interventions in animal models of depression and identified 
gaps in the current literature. The systematic reivew identified that interventions used 
were mainly in the form of probiotics or antibiotics, no studies in this systematic review 
investigated prebiotics. A further gap in the literature was the need for experiments 
that control threats to interval validity, such as implementing randomisation, blinding, 
and the conduct of an a prior sample size calculation. No studies in the systematic 
review reported all three of these measures. 
 
Based on previous studies showing promising effects of other prebiotics to reduce 
depressive- and anxiety-like behaviour and based on a systematic review of literature 
reporting gut microbiota-targeting interventions (Chapter 5), we will investigate the 
effect of Bimuno® on rat behaviour and gut microbiota composition in the FSL model, 








We hypothesise that FSL animals receiving Bimuno® prebiotics will display reduced 
depressive-like behaviour in the FST and reduced anxiety-like behaviour in the 
Elevated Plus Maze (EPM) in comparison to control (same composition but without 
active ingredient). As our secondary outcome, we hypothesise that FSL animals 
receiving prebiotics will display increased diversity in the gut microbiome, in 
comparison to FSL animals receiving control, as measured on true beta diversity. We 
want to analyse gut microbiome diversity because we hypothesise that this is the 
mechanism through which prebiotics influence behaviour. Little is known about these 
mechanisms and we therefore aim to shed light on the commensal influence of 
prebiotics (Sherwin et al., 2016). We hypothesise that animals receiving Bimuno® 
prebiotics will have altered weight and food intake in comparison to animals receiving 
control.  
 
7.2 Methods  
7.2.1 Animals 
Ethics has been approved by Aarhus University animal ethics committee (permission 
ID 2012-15-2934-00254). 8-14 week-old male FSL and FRL rats bred in-house at 
TNU, Aarhus University were used. Animals were housed in pairs, in standard cages 
with a plastic bottom and metal rack top half, purchased from Techniplast (Cage 
1291H Eurostandard Type III H, 425 × 266 × 185 mm, Tecniplast, Italy). The bedding 
material in each cage was made out of wooden chips (aspen wood from Tapvei®, 
Finland) along with access to a tunnel shelter, nesting material, and a wooden stick. 
Animals were maintained in a 12hr light/dark cycle with lights off at 1300hrs (time 
point 0). Seven days prior to the experiment start, the animals were moved to the 
experimental facility and the new lightning regime was started. Animals were under 
the care of FELASA-accredited in-house animal technicians. Animals had free access 
to tap water and standard chow (purchased from Brogaarden®, Altomen 1324).  
 
7.2.2 Power calculation to determine the number of animals 
Our sample size calculations are based on published behavioural findings from 




Data were extracted from Burokas et al., (2017) who investigated effects of prebiotics 
in the FST using male C57L/6J mice (Fig. 6D in the publication). These data (mean, 
SEM, and group numbers) were used to run a one-way ANOVA and determine an eta 
squared (= SSbetween/SStotal) of 0.579. This eta squared value was used to 
compute effect size f = (√(𝑒𝑡𝑎
2
1 − 𝑒𝑡𝑎2
⁄ )) which is 1.1747. This effect size was used 
in the power calculation carried out in R (v. 3.4.3) using the function “pwr.anova.test”. 
A significance level of 0.01 and a power of 0.9 were chosen. This gave the result of 6 
experimental units per group. For full R code see Appendix 5. An experimental unit is 
the entity subjected to an intervention independently of all other units where it is 
possible to assign two experimental units to different treatments groups (NC3Rs, 
2018). In this experiment, the cage is the experimental unit.  
 
Data were extracted from McVey Neufeld et al., (2017) who used prebiotics and 
probiotics in a maternal separation model of depression in the open field using male 
Sprague-Dawley rats. Data is from the amount of time spent in the centre of the open 
field (Fig 1.B in the publication) for the model group. These data (mean, SD or SEM, 
and group numbers) were used to run a one-way ANOVA and determine an eta 
squared (= SSbetween/SStotal) of 0.522. This eta squared value was used to 
compute effect size f = (√(𝑒𝑡𝑎
2
1 − 𝑒𝑡𝑎2
⁄ )) which is 1.046. This effect size was used 
in the power calculation carried out in R (v. 3.4.3) using the function “pwr.anova.test”. 
A significance level of 0.01 and a power of 0.9 were chosen. This gave the result of 6 
experimental units per group.  For full R code see Appendix 5. 
 
Based on the a priori sample size calculations above and experience from previous 
in-house experiments, a conservative estimate of sample size for this study of 8 
experimental units per group was selected. This number is two per group larger than 
the power calculation and was selected to account for possible attrition or possible 
exclusions throughout the experiment (see criteria below). With 8 experimental units 
per group, power of 90%, and a significance level of 0.01, we are powered to detect 
an effect of f = 0.86. This effect size we consider biologically relevant to see a relevant 
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reduction in immobility behaviour in the FST. The full R code for these calculations is 
provided in the appendix.  
 
7.2.3 Prebiotics Administration 
The prebiotic and control treatment was administered for 28 consecutive days (4 
weeks). The treatments were administered within the first hour after lights off, the first 
hour of the animals’ active phase.  We tested the commercially available prebiotic 
product “Bimuno®” Powder (Bimuno, United Kingdom), which contains 
Galactooligosaccharides (B-GOS). A dose of 4 g/kg dissolved in tap water was 
administered to each animal per day, via syringe feeding. The dose was adjusted 
each week according to the weight of the animals. This prebiotic was chosen due to 
its superior effect on behaviour over FOS (Savignac et al., 2013). This dose was given 
to recreate the findings in previous literature (Savignac et al., 2013; Williams et al., 
2016).  
 
7.2.4 Control Administration 
The control for the prebiotics was a mixture consisting of similar components to the 
Bimuno powder but without the active ingredient B-GOS. The control consisted of 50% 
lactose, 27% glucose, and 23% galactose (purchased from Sigma Aldrich). The 
control was administered at a dose of 4 g/kg/day, following the dosing regimen of 
previous literature (Williams et al., 2016; Savignac et al., 2016). The control was 
administered at the same time as the prebiotics, via syringe feeding, with the dose 
adjusted each week according to the weight of the animals. Animals were weighed 
each week, the weight was average per cage, and cages were divided into two groups, 
higher and lower weighing cage. The dose of prebiotic was calculated based on higher 
and lower cage weight averages. The table (7.1) below reports the doses given to 







Table 7.1 Doses given to each animal each week. 
Week Lower Dose Higher Dose 
Week 1 1.25g 1.46g 
Week 2 1.29g 1.55g 
Week 3 1.37g 1.61g 
Week 4 1.36g 1.67g 
 
7.2.5 Syringe-feeding Details 
Treatment was administered via syringe-feeding. The prebiotic, within a sweetened 
vehicle of glucose, was mixed with tap water, and added to a syringe. This is a newly 
established method for the accurate individual dosing of probiotics in rats (Tillmann & 
Wegener, 2017). With a training phase of roughly 3–4 days, to allow the rats to 
become accustomed to the administration and the taste, the rats willingly consume 
the mixture and approach the edge of the cage when the syringe is presented. This 
new method has been used for volumes of probiotic + vehicle solution up to 3 ml. This 
method of administration has been chosen to reduce the stress associated with oral 
gavage, and to increase the accuracy of dosing with administration of prebiotics in 
drinking water. In this experiment, the prebiotic Bimuno was added to tap water to 
give a total volume of 1.5 ml, as the smaller the volume, the sweeter the solution, 
which is thought to be more desirable for the rats to consume. Animals were fed at 
the start of the active cycle, time point +0 hours.  
 
7.2.6 Measures to Reduce the Risk of Bias 
7.2.6.1 Randomisation & Allocation Concealment  
On the first day of the experiment, animals were moved from the breeding facility into 
the experimental facility. Animals were pair-housed; the two animals in each cage 
were the same strain and received the same treatment. Cages were randomly 
assigned to a group, Treatment or Control, to ensure allocation concealment during 
the handling and administration of treatment throughout the experiment. 
Randomisation was carried out using block randomisation with the online tool, The 
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Sealed Envelope (https://www.sealedenvelope.com/simple-randomiser/v1/lists), by a 
colleague not involved in the day-to-day running of the experiment. Cages were 
labelled with a unique randomisation code (e.g. GU9, LI3, etc) and a colour which 
signified the treatment given. This was done to minimise potential unconscious bias 
by ‘remembering’ which cages get which colour of treatment.  Treatments were 
identified as red or blue. The cages (the experimental unit) were assigned randomly 
to treatment and the observational unit was the individual animal where the outcome 
of interest is measured. The observational unit (the animal) is nested within the 
experimental unit. The order of the cages was randomised in the racks at the 
beginning of the experiment to reduce possible effects from air-conditioning vents 
and/or being closer to the door. The placement of the cage was not be taken into 
consideration as a variable during analysis of the outcome data. Animals had 7 days 
to acclimatise to new housing facilities. The experimenter was blinded to which 
solution (prebiotic or vehicle control) each rat receives, as powders for the whole 
experiment were transferred to identical tub containers and labelled as ‘blue’ or ‘red’ 
by a colleague not involved in the experiment.  
 
7.2.6.2 Blinded Assessment of Primary Outcome 
The primary outcome was the FST. This outcome is recorded on video and scored 
manually. The videos were assessed blinded, before the group identity of the animals 
is revealed. The open field test and the elevated plus maze were analysed using the 
automated Ethovision scoring. All videos were analysed after all behavioural 
outcomes had been carried out. The primary experimenter was formally unblinded to 
the true group identity after the output of the data analysis files had been uploaded to 




Figure 7.1. Experimental Design Setup 
 
7.2.7 Outcome Assessment:  
Behavioural assessment occurred during the rats’ active phase, starting 
approximately 1 hour after administration of prebiotics, time point +1 hour, and lasting 
approximately 3 hours, until time point +4 hours.  
 
7.2.7.1 Forced Swim Test  
The primary outcome was performance on the forced swim test. On day 26 of the 
experiment, at time point +1 hr, at the start of the animals’ active phase, the FST was 
be performed. The set-up consisted of 4 clear glass cylinders (60 cm in height × 24cm 
in diameter), separated with black opaque dividing walls, filled with water up to 40 cm. 
The temperature of the water was maintained at 25 °C ± 1°C. On the first day, the 
pre-swim session, the animals were placed in the tanks for 15 minutes. On the second 
day of testing, animals were placed into the tanks for 5 minutes. Both sessions were 
recorded by video camera. Both testing sessions were conducted in red light 
conditions, the rooms were only illuminated with red light at a wavelength of 625–740 
nm as rats are less sensitive to red light (Peirson et al., 2018). The water was changed 
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in-between each test. Three behavioural parameters were assessed from the video 
footage, passive behaviour, immobility, and 2 active behaviours, swimming and 
climbing behaviour. Passive behaviour is defined as “the rat making no further 
movements beyond those needed to keep its head above the water” (Abildgaard et 
al., 2017). For each 5 second period, the predominant behaviour was recorded 
(immobility, swimming, or climbing). All FST sessions were scored by an experimenter 
blinded to the group assignment of the animals.  
 
7.2.7.2 Open Field Test  
Locomotor activity in the open field test (OFT) was assessed on day 27, immediately 
prior to the second FST session. Locomotor activity was assessed in a 100 cm × 100 
cm (x 20 cm in height) black open field arena. Each animal was placed in the arena 
in the same starting location. Animals were assessed for 5 minutes in red light. All 
sessions were video-recorded and analysed using Noldus Ethovision XT9. Locomotor 
activity was assessed as the distance each animal moved in centimetres. The arena 
was cleaned with ethanol between each animal.  All video recordings were scored by 
an experimenter blinded to the group assignment of the animals using the Noldus 
Ethovision automated scoring. 
 
7.2.7.3 Elevated Plus Maze 
Anxiety behaviour was assessed on day 24 in the elevated plus maze. The plus-
shaped maze has two open arms and two closed arms (length: 50 cm x width: 10cm) 
and the centre zone measures 10 cm x 10 cm. Each animal was placed in the arena 
in the centre, facing the same open arm. Animals were assessed for 5 minutes and 
were tested during their active phase at time point +1hr. The light intensity in the open 
arms was 80–100 lx and 20 lx in the closed arms. Animals were kept in an adjacent 
dark experimental room and moved individually into the bright experimental room for 
testing. All sessions were video-recorded and analysed using Noldus Ethovision XT9. 
Anxiety behaviour was measured by calculating the time spent in the open arms in 
proportion to the time spent in the open arms and closed arms;  
(𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =
𝑡𝑖𝑚𝑒 𝑠𝑝𝑒𝑛𝑡 𝑖𝑛 𝑜𝑝𝑒𝑛 𝑎𝑟𝑚𝑠
𝑡𝑖𝑚𝑒 𝑠𝑝𝑒𝑛𝑡 𝑖𝑛 𝑜𝑝𝑒𝑛 𝑎𝑟𝑚𝑠  +  𝑡𝑖𝑚𝑒 𝑠𝑝𝑒𝑛𝑡 𝑖𝑛 𝑐𝑙𝑜𝑠𝑒𝑑 𝑎𝑟𝑚𝑠
); and number of entries 
into the open arms (defined as entire body of rat in the open arm). The arena was 
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cleaned with ethanol between each animal.  All video recordings were scored by an 
experimenter blinded to the group assignment of the animals using the Noldus 
Ethovision automated scoring. 
 
7.2.7.4 Body Weight & Food Consumption 
Animals were weighed every week throughout the experiment, to assess if prebiotics 
administration influences weight gain, and also to adjust the dose of the prebiotics or 
control administered (4g/kg). Weekly food and water intake in the home cage was 
recorded.  
 
7.2.7.5 Microbiota Analysis 
Fecal boli were collected at the start of the experiment (day 1) and on the day of 
euthanisation (day 28). Fecal boli were collected directly from the anus of each animal 
into sterile tubes on dry ice, and frozen and stored at −80˚C. Fecal boli were intended 
to be analysed using 16S RNA sequencing to assess the composition of gut 
microbiota. These analyses were not carried out as there was an error during the 
shipping process and samples were identified without dry-ice in the package. As there 
may have been differential thawing of the sample and differential growth of bacterial 
communities within the fecal matter, we determined that the findings from the 
analyses would not be reliable and were therefore not carried out.  
 
7.2.8 Exclusion Criteria 
Exclusion criteria were pre-specified. Animals would be excluded if they displayed 
illness behaviour as assessed by trained, in house veterinarians. Animals would be 
excluded from statistical analysis if there were technical difficulties with video 
recording equipment or video files had been corrupted. No animals would be excluded 
from the statistical analysis if they successfully complete all aspects of the study. One 





7.2.9 Experimental Procedure 
Step 1: Animals were bred in house. Rats were moved into experimental housing and 
had a 7-day acclimatisation/habitation period to the animal housing facility prior to the 
start of the experiment. Cages were randomised into 2 groups; Treatment & Control.  
Step 2: On day 1 of the experiment, each rat was weighed and fecal boli were 
collected. Then the first administration of prebiotics or control was given.   
Step 3: Animals remained continuously on this treatment regimen for 4 weeks (28 
days). Rats were weighed every week. The animals’ daily food and water 
consumption was recorded.  
Step 4: On day 24 animals were subjected to the elevated plus maze.  
Step 5: On day 26 animals were subjected to the pre-swim of the FST. 
Step 6: On day 27 the open field test and the FST were carried out.  
Step 7: On day 28 animals were euthanized.  
 
Tabl 7.2 The timing of outcome measure administration to each group. 








FSL Prebiotics 4 weeks Day 24 Day 27 Day 28 
FSL Control 4 weeks Day 24 Day 27 Day 28 
FRL Prebiotics 4 weeks Day 24 Day 27 Day 28 
FRL  Control 4 weeks Day 24 Day 27 Day 28 
 
7.2.10 Data Analysis Pipeline 
Data from the open field and FST were analysed in Ethovison. Videos were stored on 
an internal network drive. Video from each animal were scored blinded to the animal’s 
group assignment. Data cleaning and statistical analysis was carried out in R studio 




7.2.11 Statistical Analysis 
To test the hypothesis that probiotics improve depressive-like behaviour on the FST 
and anxiety-like behaviour in the EPM, the primary outcome being immobility time, a 
two-way ANOVA was conducted with 2 independent variables, treatment (control or 
prebiotic) and strain (FSL or FRL). Data were analysed at the level of experimental 
unit, the cage. Values from individual animals in the cage were averaged to give a 
cage value. Data were tested to see if they met the assumptions of two-way ANOVA. 
Levene’s test was used to test homogeneity of variances. Shaprio-Wilk test was used 
to test normality of residuals. Data met the assumptions so a two-way ANOVA without 
any corrections was performed. All raw data and data analysis code were uploaded 
to OSF.   
 
7.2.12 Amendments to Methods from Pre-specified Protocol 
The protocol specified that 5-7 weeks old animals would be used. In this experiment 
animals between 8-14 weeks were used instead, as the breeding rate of the animals 
was not high enough to have 64 animals within a 2-week age bracket. There was a 
mistake in the protocol, which specified that the control would be the Bimuno Free 
Powder with the wrong composition, which is not a product. The control given was 
made up of similar components to the Bimuno powder but without the active ingredient 
B-GOS, consisting of 50% lactose, 27% glucose, and 23% galactose. The volume of 
the solution fed via syringe was reduced from 2ml to 1.5ml. The smaller the volume, 
the easier for the animals to consume, especially during the training of syringe feeding. 
I tested the weight of the powders each week to ensure that they properly dissolved 
in the amount of tap water, so that dosing was as accurate as possible. I administered 
the OFT for 5 minutes instead of 15mins specified in the protocol. The primary 
outcome of the OFT was to measure locomotor activity, which can be accurately 
assessed with a 5 minute testing period, so the length of the test was reduced to 
reduce the unnecessary stress to the animals. As there was no funding for 
neurochemical brain analyses, I did not dissect brains from the animals at 
euthanisation. I collected fecal boli on the first day behavioural testing (day 24) instead 
of on the day of euthanisation (day 28) with the aim of isolating the effects of prebiotics 
on gut microbiota, without the stress of the behavioural testing.  
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Further, it was not specified in the protocol that correction for multiple testing would 
be applied. With 7 outcomes investigated, the conventional level of significance being 
alpha = 0.05, when a Holm-Bonferroni correction to account for multiple testing is 
applied, the level of significance is 0.007.  
 
7.3 Results  
I was interested in the effects of prebiotics on seven outcomes; immobile, swimming, 
and struggling behaviour in the forced swim test, total distance moved in the open 
field test, proportion of entries to the open arms and frequency of whole body entries 
to the open arms in the elevated plus maze, and weight gain across the experiment.  
 
7.3.1 Forced Swim Test 
The primary outcome was immobility in the forced swim test as a measure of 
depressive-like behaviour in response to an inescapable stressful situation. There 
was no significant difference in time spent immobile between the FSL animals and 
the FRL animals (F(1,28) = 8.09, p = 0.008) at the corrected alpha level. There was 
no effect of the prebiotics on immobility (F(1,28) = 3.34, p = 0.07).  Struggling 
behaviour differed significantly between the FSL animals and the FRL animals (F(1,28) 
= 18.05, p = 0.0002), with FRL animals showing more struggling behaviour than FSL 
animals. There was no effect of the prebiotics (F(1,28) = 0.32, p = 0.57).  No significant 




Figure 7.2A&B. Mean time spent A) Immobile (top) and B) Struggling (bottom) in the 
Forced Swim Test. Red (prebiotics) and blue (control) dots indicate performance of 
individual cages, black dots denote the mean for each group, error bars = SD, n = 8 




7.3.2 Open Field Test 
Locomotor activity was measured by total distance travelled in the open field test. 
There was a significant difference in the total distance travelled between the FSL 
animals and the FRL animals (F(1,28) = 29.89, p < 0.0001), FSL animals travelled 
further than the FRL animals. There was no effect of the prebiotics (F(1,28) = 0.003, 
p = 0.95). 
 
Figure 7.3. Mean distance travelled in the Open Field test (5mins). Red (prebiotics) 
and blue (control) dots indicate performance of individual cages, black dots denote 
the mean for each group, error bars = SD, n = 8 experimental units per group. 
 
7.3.3 Elevated Plus Maze 
There were no significant differences between model or drug groups in the proportion 
of time spent in the open arms. There was a significant difference in FSL and FRL 
animals in the number of entries into open arms, defined as entire body of rat in the 
open arm, (F(1,28) = 8.52, p = 0.006), with no effects of treatment (F(1,28) = 0.03, p 




Figure 7.4. Mean frequency of full body entries to the open arms in the Elevated Plus 
Maze. Red (prebiotics) and blue (control) dots indicate performance of individual 
cages, black dots denote the mean for each group, error bars = SD, n = 8 experimental 
units per group. 
 
7.3.4 Weight 
At the beginning of the experiment, all the groups had different weights. The mean 
weight of the FRL Prebiotics group was highest, mean weight in FSL Prebiotics and 
FRL Control were roughly similar, and the mean weight of the FSL Control group was 
lowest (Table 7.3). I calculated the weight gain across the experiment (weight at 
euthanisation minus the starting weight). There was a significant difference in FRL 
and FSL animals in weight gain (F(1,28) =37.57, p < 0.0001). There were no 
significant differences between treatment groups or significant interactions between 





Fig 7.5. Mean weight (g) gain for each group across the study. Red (prebiotics) and 
blue (control) dots indicate performance of individual cages, black dots denote the 




Table 3. Mean and SD values for all outcomes.   




FRL Control FRL Prebiotics 
FST Immobility 
(secs) 
75.0 (31.11) 105.31 
(53.99) 



























time spent in 
open arms (%) 
23.89 
(10.58) 





full body entries 


















































All values displayed are mean (SD).  
 
7.3.5 Post-hoc Analysis  
I decided, post-hoc, to analyse the data for the primary outcomes, behaviour on the 
forced swim test, omitting correction for multiple testing and using the typical unit of 




When no correction for multiple testing was applied, there was a significant difference 
in time spent immobile between the FSL animals and the FRL animals (F(1,28) = 8.09, 
p = 0.008), FSL animals spent more time immobile than FRL animals. There was no 
effect of the prebiotics on immobility (F(1,28) = 3.34, p = 0.07).  Struggling behaviour 
differed significantly between the FSL animals and the FRL animals (F(1,28) = 18.05, 
p = 0.0002), with FRL animals showing more struggling behaviour than FSL animals. 
There was no effect of the prebiotics (F(1,28) = 0.32, p = 0.57).  No significant 
differences between model or drug groups were observed in swimming behaviour.  
 
When data for the primary outcome, behaviour on the forced swim test, were analysed 
with the individual animal as the experimental unit and without correction for multiple 
testing, the effect of treatment on immobility in the forced swim test was significant, 
(F(1,59) = 5.37, p = 0.02), with animals receiving prebiotics spending more time 
immobile in both FSL and FRL animals. There was a significant difference between 
treatment groups in swimming behaviour (F(1,59) = 4.22, p = 0.045), with animals 
receiving prebiotics spending less time swimming than animals receiving control.  
There was a significant difference between model groups in struggling behaviour 
(F(1,59) = 23.97, p < 0.0001), with FSL animals spending less time struggling than 
FRL animals. There was no significant effect of treatment on struggling behaviour.  All 
of the significant effects of treatment, apart from model differences in struggling 
behaviour, are not significant with correction for multiple testing.  
 
7.4 Discussion 
I administered B-GOS prebiotics or a glucose vehicle substance to FSL and FRL 
animals for 4 weeks. I observed behavioural differences between the FSL and FRL 
groups; as expected, the control Flinders Resistant Line animals displayed more 
struggling behaviour in the FST, as a measure of active escape behaviour. I found 
that FSL animals travelled further in the open field test, displaying hyperlocomotion. 
FSL animals displayed more full-body entries to the open arms, as a proxy for anxiety-
like behaviour. As there was a difference between the model groups in locomotor 
behaviour in the open field test, the difference in groups in the frequency of entries to 
the open arms is likely an artefact of the increased locomotion in the FSL group. When 
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the proportion of time spent in the open arms was calculated, there were no significant 
differences between the model or treatment groups.  
 
This study employed measures to reduce the risk of bias, including random allocation 
of animals to treatment or control groups, allocation concealment throughout the 
experiment and the treatment administration and behavioural testing, the outcomes 
were assessed blinded, and an a priori sample size calculation was performed to 
calculate the required power and number of animals required to detect an effect in 
this experiment. The experimental unit, the smallest unit the treatment could 
independently be given, in this study was the cage. Interestingly, the post-hoc analysis 
carried out where analysis was performed on the individual animal level data, 
treatment had a significant effect. The statistical methods used to analyse the data 
assume independence of samples (Altman & Bland, 1997).  Incorrect analysis of data 
that are not independent leads to increased false positive rates (type 1 error; Parsons 
et al., 2017).  
 
Information from a systematic review and meta-analysis (Chapter 5) informed this 
study. As of 2016 there was a range of probiotics investigated, but no prebiotics were 
tested, and the most commonly used behavioural outcome measure used was the 
forced swim test.  
 
I did not observe any significant effects of the B-GOS prebiotics in any depressive-
like or anxiety-like outcomes. I did see an effect of the prebiotics in differentially 
affecting weight at the model groups at the time of euthanisation, with animals 
receiving prebiotics weighing more than the control groups in the FRL animals but not 
in the FSL model of depression.  
 
All four groups started off the experiment at significantly different weights. In general, 
it is observed in the breeding colonies that FRL animals weigh more than FSL animals 
(Overstreet et al., 2005). There were already differences between drug groups, with 
prebiotic groups weighing more than vehicle groups. Investigating differences in 
weight at euthanisation, there appears to be a differential effect of the treatment 
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administration, with prebiotics increasing the weight in the FRL group but with no 
differences between groups observed in the FSL group. The differential weight 
differences are after 28 days of administration of prebiotics. A follow-up study could 
investigate the effects of the prebiotics after 8 weeks of administration.   
 
There are various possible reasons why I did not see effects of the prebiotics in this 
study. Gut microbiota differ between species, the relative abundances of most of the 
dominant genera are for example quite different in mice and humans (Nyugen et al., 
2015). Rat gut microbiota (Sprague Dawley, the ancestral strain of the FSL and FRL) 
has been shown to have 46 bacterial species, with relative abundance of the bacterial 
communities progressively decreasing with age (Flemer et al., 2017). It may be that 
the prebiotic has little effect in rodents due to differences between humans and rats 
in gut microbiota composition. Prebiotics and probiotics are being investigated in 
randomised controlled trials in depressed patients and a recent systematic review and 
meta-analysis concluded that they are overall effective (Huang et al., 2016). Further, 
the age range of the animals used in this study (8-14 weeks old) may contribute to 
the large variability seen in behaviour, and therefore the lack of significant effects of 
the prebiotics, as age can change the composition of the bacterial communities in the 
gut (Flemer et al., 2017). A similar study using probiotics in FSL and FRL animals 
found no effects of probiotics administered alone but when animals were on a high fat 
diet, FSL animals displayed reduced immobility behaviour in the forced swim test 
(Abildgaard et al., 2017b). B-GOS stimulate the growth of Bifidobacterium. It is 
possible that at the start of the experiment, animals did not have high numbers of this 
colony of bacteria, and therefore the relative benefit of B-GOS is small.  
 
The forced swim test was the outcome measure chosen to assess depressive-like 
behaviour in this experiment as it is the most widely used in the field. It may however, 
not be the most effective measure. The FST measures the response to a test, an 
inescapable situation, which may reflect learning or coping and may not be reflective 
of a long-term depressive state in the animals (Molendijk & de Kloet, 2015; Commons 
et al., 2017). Future studies utilising more naturalistic outcomes such as social 
behaviour in the home cage may improve our understanding of depressive-like 




A key limitation of this study is the lack of biological outcome assessments. The 
secondary outcome measure of this study was to identify the impact of B-GOS 
administration on gut microbiota beta diversity and to observe any changes in 
microbial communities before and after administration of the prebiotics. Without 
biological readouts, I am unable to investigate whether the lack of behavioural effects 
of the prebiotics were accompanied by similar effects in gut microbiota diversity. 
Without analysis of microbiota composition, I am unable to ascertain whether there 
were initial differences in the FSL and FRL animals that may have contributed to 
differential effects of the prebiotic, which no study has done to date. Future studies 
can investigate the effects of prebiotics not only on gut microbiota changes, but also 
on inflammatory pathways and neurotransmitter levels. Inflammatory and immune 
system responses have been observed in animal models of depression that are 
altered through gut-microbiota targeting interventions (Abildgaard et al., 2017a, 
Abildgaard et al., 2017b).  The investigation into the effects of prebiotics on 
inflammatory and immune responses would add to this literature.  
 
It was not pre-specified in the protocol that correction for multiple testing should be 
taken into account at the analysis stage. In addition, the sample size calculation was 
carried out not taking into account the nested structure of the experimental design, 
where an individual animal was nested or clustered in a cage and treatments were 
assigned at cage level. The sample size calculation should have been corrected with 
a variance inflation factor to account for the correlation between observations within 
clusters (Parsons et al., 2017). The variance inflation factor relies on knowing the 
intra-cluster correlation coefficient from previous data or an estimate (Parsons et al., 
2017).  This study could have been underpowered to detect effects due to inaccurate 
a priori sample size calculation.  I did not control for litter effects in the random 
allocation of animals to treatment groups. Individual animals or cages may not have 
been fully independent, which is another factor that could have confounded the results 
from statistical analysis.  
 
A further limitation is that the control and the prebiotics were largely composed of 
sugars, which are likely involved in neural mechanisms in reward, therefore, the 
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behavioural measures are not independent of the effects of sugar. Daily sugar 
bingeing has been shown to increase dopamine in nucleus acccumbens (Rada et al., 
2005). The nucleus accumbens is a key area involved in the reward system and anti-
depressant mechanisms of drugs (Nestler, 2015). Future studies could employ an 
additional control group of saline treated or naïve animals, to understand the impact 
of the sugars in the prebiotics and their effect on depressive-like behaviours. 
 
7.5 Conclusion 
In conclusion, I investigated the effects of 4-week administration of B-GOS prebiotics 
or a glucose vehicle substance in FSL and FRL animals on depressive-like and 
anxiety-like behaviour. No effects of the prebiotics were observed. Follow-up studies 
can be conducted to investigate the prolonged effects of prebiotics on depressive-like 
behaviour in FSL animals. Prebiotics are being investigated in randomised controlled 
trials with depressed patients and may prove effective if no effects are seen in rodent 
studies as there are significant differences in the composition of gut microbiota 








8 General Discussion & Conclusions   
 
The aim of this thesis was to use systematic review and meta-analysis techniques to 
synthesise the evidence available on animal models of depression and 
antidepressants investigated, to achieve an overview of what species are selected, 
and what techniques are used to induce depressive-like phenotypes.  
 
I conducted this research because despite the decades of research into depression, 
current treatments are adequate at best and the underlying pathological mechanisms 
are not yet understood. Depression remains a leading source of disability with an 
estimated 322 million people worldwide are suffering with depression (WHO, 2017).  
 
A systematic search of PubMed and EMBASE in May 2016 identified 70,365 unique 
publications that were potentially relevant to animal models of depression (Chapter 
2). The field of animal models of depression was larger than initially anticipated, and 
it was not feasible to manually conduct a systematic review of this literature within the 
time-frame of a PhD, let alone the first step of title and abstract screening. Therefore, 
I developed, tested, and implemented automation tools, with the help of collaborators, 
to the screening stage (Chapter 3) and the annotation stage (Chapter 4) of this 
systematic review of animal models of depression. The machine learning tools 
performed well and were implemented successfully at the screening stage. The 
machine learning approaches were trained on 5,749 records with human screening 
decisions. The best performing algorithm achieved a performance of 98.7% sensitivity 
and 88.3% specificity. The machine learning approach screened 63,365 records that 
did not have human inclusion decisions, reducing the human time required for this 
task by an estimated 40 person months. Using this machine learning approach, I was 
interested to test if machine learning could help identify human screening errors. The 
machine learning algorithm was applied to the records with human decisions using k-
fold validation. Errors were identified and corrected, which when retraining the 
algorithm using the corrected human decisions, improving performance of the 
algorithms. This is a novel approach in the context of systematic review methodology. 
With further testing, this approach may be implemented routinely in the existing 




Machine learning greatly assisted in reducing the human resources required to screen 
publications for inclusion, identifying 18,409 publications that were highly likely to be 
relevant to animal models of depression. This is still a large amount of unique citations 
to manually extract information from. Therefore, I developed automatic annotation 
tools to assist in annotating and grouping these documents by the key terms, method 
of disease model induction, and antidepressant treatments. Dictionaries of key terms 
were converted into regular expression dictionaries and the dictionaries were applied 
to the title, abstracts, and where available, full-text PDFs of the 18,409 included 
studies. This approach was used in three systematic reviews to identify relevant 
studies for further systematic review and meta-analysis e.g. ketamine (Chapter 6). 
This approach may be limited in that without full-text PDFs key outcomes or 
interventions may not be identified. The accuracy of these dictionaries is being further 
investigated in ongoing reviews. Despite these limitations, this approach has proved 
beneficial and highlights the need for domain-agreed ontologies to help categorise 
the increasing amount of literature in animal models of neuropsychiatric disease. 
 
Utilising the automation tools developed, this thesis presents findings from two 
systematic reviews, the first on the available literature on microbiota-targeting 
interventions in animal models of depression (Chapter 5), and the second on the 
effects of ketamine as an antidepressant in literature on animal models of depression 
(Chapter 6). The review of microbiota-targeting interventions identified few 
investigations with a broad range of outcomes and interventions, with no two studies 
investigating the same probiotic strain. This broad range of data likely reflects the 
recent interest in investigating the role of gut microbiota in depression, and the 
exploration of potential mechanisms involved in the effects of interventions, such as 
probiotics, on depressive-like outcomes. The reporting of measures to reduce the risk 
of bias in these studies was relatively high in comparison with previous reviews of 
animal models of other neurological diseases. The studies mainly reported using male 
animals, limiting the generalisability of the findings in primary studies. There was not 
enough data to fully analyse the impact of timing of administration. The investigation 
into whether probiotics may promote resilience to stressful conditions or can reduce 
depressive-like outcomes after exposure to stressful events, may prove useful for 




The findings from the systematic review of microbiota-targeting interventions 
highlighted gaps in the literature where additional animal studies can contribute, the 
investigation of prebiotics had not been identified in the review and existing studies 
were at risk of bias. The findings from the systematic review were used to inform the 
design of a primary animal experiment investigating the effects of prebiotics in 
Flinders Sensitive Line animals (Chapter 7). The effect of the galacto-oligosaccharide 
prebiotics, administered for 28 days, on depressive-like and anxiety-like behaviour 
was investigated in a genetic model of depression. An a priori sample size calculation, 
blinding, and randomisation were employed to reduce the risk of bias. No effect of 
prebiotics was seen on behaviour in depressive-like rats, although differences in 
weight were seen between groups. A follow-up study with longer administration of 
prebiotics, and with gut microbiota and neurochemical outcome assessment may 
further elucidate the impact of prebiotics in depressive-like outcomes.  
 
The systematic review of ketamine as an antidepressant in literature on animal 
models of depression reported data from 182 experiments investigating the effects of 
ketamine on behaviour in the forced swim test. Data showed an overall antidepressant 
effect of ketamine and an increase in timing between ketamine administration and 
outcome assessment was associated with significant decreases in effect size. Future 
animal studies in ketamine can improve the value of animal experiments by exploring 
aspects of study design that may impact effect in clinical trial such as, the timing of 
administration, the route of administration, sex. There was statistically significant 
heterogeneity, which may have been due to the imprecision of the primary studies 
included in the review. With this wide variation seen, a way forward might be to 
establish multi-centre trials of animal models of neuropsychiatric disorders, ensuring 
that any significant effects observed are robust to controlled across-laboratory 
variation.  
 
These reviews analysed and discussed the internal and external validity of animal 
models of depression and antidepressant treatments tested. These findings can be 
used to better understand factors that impact the efficacy of treatments in animal 
models and improve the quality of research conducted, to better understand 
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depression and improve the treatments available to patients. Findings from both the 
systematic review of microbiota targeting interventions and the systematic review of 
ketamine clearly highlight the poor quality of reporting of measures to reduce the risk 
of bias in studies describing animal models of depression. These findings call for the 
conduct of higher quality animal studies. Although the field of depression shows 
slightly higher levels of reporting of measures to reduce the risk of bias than the 
existing body of literature describing animal studies of neurological disorders, this is 
by no means adequate. I hope that the continuing efforts from several stakeholders 
including researchers, journals, and funders will ensure that animal research 
conducted and published adheres to reporting guidelines such as the ARRIVE 
guidelines. This will help to improve the quality of studies on animal models of 
depression. However, evidence from studies investigating the implemention of 
reporting guidelines for animal studies in top journals (Hair et al., 2018; Macleod, 2017) 
shows that mandating the completion of checklists does little to improve actual 
reporting. Therefore varied approaches are needed to for a sustainable improvement 
in reporting. As academic culture shifts and open science practices such as pre-
registration of animal experiments become more prevalent, meta-analysis will be able 
to summarise more accurately the true effect size of an intervention and not rely on 
statistical techniques such as Egger’s regression to adjust for negative and neutral 
unpublished studies.  
 
The systematic reviews in this PhD have highlighted concerns of external validity in 
animal models of depression. It is common in animal experiments describing anti-
depressant interventions intended for clinical use that interventions are administered 
prior to the model induction. For treatments such as probiotics that have fewer 
recorded adverse side effects this may be feasible in a clinical setting. However, for 
interventions such as ketamine where severe adverse side-effects have been 
recorded and patients must be monitored intensively when this treatment is 
administered through an IV, this is less feasible. The clinical trials that have 
commenced to test the administration of intra-nasal ketamine have also noted 
patients experiencing adverse side-effects. Research in animal models can help 
inform clinical trial design by systematically exploring variables to ensure that external 
validity of the experiment is increased. Systematically investigating variables such as 
dose of administration, route of administration, and the sex of the animals can improve 
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external validity. In addition to measuring the primary outcome of effect of an 
antidepressant, also measuring outcomes that assess potential side-effects in 
humans may ensure that significant findings may be more easily translated to a 
clinical setting.  
 
The application of automation tools to this systematic review of animal models of 
depression has allowed for two systematic reviews of the field to be conducted since 
2016. Although these tools are under development, their utility has been highlighted. 
This dataset created using these tools is freely accessible online (Chapter 4). This 
allows other researchers to make use of the dataset to carry out further reviews of 
animal models of depression. The datasets made freely available as part of the 
application of machine learning algorithms for citation screening (Chapter 3) can be 
used as a validation set by developers building new tools. With further refinement and 
with the implementation of living systematic reviews, this dataset can be continuously 
updated with the latest research in the field of animal models of depression. The 
implementation of living systematic reviews is a goal of the International Collaboration 
for the Automation of Systematic Reviews (ICASR) and several research groups are 
working towards this aim. Specifically, the next stage in automating systematic review 
methods is being carried out by the SLIM collaboration to reduce the human effort 
required to extract data from graphs in primary articles (Crammod et al., 2018). Data 
extraction from primary articles is carried out in duplicate as human error in this stage 
can lead to false conclusions being drawn about the data (Mathes et al., 2017). 
Machine-assisted data extraction from graphs may reduce this error and reduce the 
amount of resources required to carry out this step in the systematic review process.  
 
In future, I hope that with the development of novel automation tools and refinement 
of existing tools, systematic review and meta-analysis methodology can be applied to 
the entire knowledge base of animal models of depression. This can only be achieved 
when the human resources required to perform this methodology are sufficiently 
reduced. Pooling data from the model induction techniques and from antidepressant 
treatments investigated will allow us to gain a full summary of the depression in 
animals and further understand the mechanisms behind neuropsychiatric disease. 
The application of novel automation tools can be applied to improve animal modelling 
in other fields. An example of this is the multi-centre work being carried out from 
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collaborative approaches to generate shared ontologies and dictionaries (Nielson et 
al., 2015; Callahan et al., 2016). With key terms mapped across an entire knowledge 
base, this allows for the investigation of network connections and mapping within a 
large dataset, including the correlations between behavioural and biological outcomes. 
This can be used to generate new biological hypotheses. Pooling data from the 
studies investigating antidepressants in animal models of depression could allow for 
the application of advanced meta-analysis techniques such as network meta-analysis. 
This tool applied to clinical systematic review data can allow comparisons to be made 
between the effects in drugs when direction comparisons have not been carried out 
in primary studies (Cipriani et al., 2018). This technique may be useful in the context 
of animal models of depression.  
 
In future, the cultural changes associated with open science, data sharing, and 
automation tools can enable high quality, high speed evidence synthesis in the age 
of information explosion. Olkin’s remark in 1995, that meta-analysis is the key to 
dealing with the increasing amounts of literature, has never been so pertinent. As a 
field, we must work harder to overcome the barriers to understanding complex 
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APPENDIX 1: Europe PubMed Central Search in ContentMine tool ‘getpapers’ 
 
getpapers -q '((("depressive disorder" OR "depression" OR "depressive behavior" OR 
"depressive behaviour" OR "dysthymia" OR "dysthymic") AND animal) NOT ("PTSD" OR 
"posttraumatic stress disorde"r OR "postpartum" OR "schizophrenia" OR 




APPENDIX 2: Shiny Application Code in R 
 
Live Application available at:  
https://camarades.shinyapps.io/Preclinical-Models-of-Depression/  






APPENDIX 3: Summary Tables from Chapter 5: INTERVENTIONS TARGETING THE GUT MICROBIOTA IN ANIMAL MODELS OF 
DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS  
 
 
Table 1. Study Design Characteristics of Gut Microbiota-targeting Interventions to Reduce Depression 
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Table 2. Study Design Characteristics of Gut Microbiota-targeting Interventions to Induce Depression 









Noradrenaline, Occulin & JAMA-
A Protein Expression, 
Doublecortin- expressing 
cells, % 51-Cre-EDTA recovery 
Bravo et al., 2011 Mouse Balb/c Male Forced Swim Test Indirect Corticosterone  
Desbonnet et al., 2010 Rat Sprague Dawley Male Maternal Separation Indirect Forced Swim Test, 
Corticosterone, Noradrenaline, 
Dopamine, Serotonin, DOPAC, 
5HIAA, HVA, Tryptophan, L-
Kynurenine, Kynurenic acid, IL6 
(LPS), IFN-Y (LPS), TNF-alpha 
(LPS), IL-10 (LPS),  
Body Weight 
Farshim et al., 2016 Rat Wistar Male Prolonged Weaning Direct Oxytocin Receptor Binding, 





Gacias et al.,  2016 Mouse C57BL/6 Male Gastric Gavage Direct Forced Swim Test, Social 
Interaction 
Mouse NOD Male Gastric Gavage Direct 
Gárate et al.,  2011 Rat Sprague Dawley Male Chronic Mild Stress Indirect Forced Swim Test, 
Corticosterone, MDA, Body 
Weight, Fecal Boli,  
Blood LPS & LBP,   
mRNA Relative Expression of 




I-kappa-B-alpha, COX-2, & IL-1 
beta, Protein Expression TLR-4, 
MD-2, & NF-kappa B p65, 
Levels of prostaglandin PGE2 & 
15d-PGJ2, NF- B p65 activity 
Ilgin et al.,  2015 Rat Wistar Female Ciprofloxacin (CPX) Direct Noradrenaline, Adrenaline, 
Dopamine, Serotonin,  
GABA, Glutamate,  
Forced Swim Test, MDA, 
Glutathione, Superoxide 
dismutase, Catalase 
Jørgensen et al.,  2014 Mouse BALB/cAnNTac Male High Fat Diet Direct Forced Swim Test, Morris Water 
Maze,  
Body Weight Mouse BALB/cAnNTac Male High Sucrose Diet Direct 
Liang et al.,  2015 Rat Sprague Dawley Male Chronic Restraint 
Stress 
Indirect Object Recognition, Sucrose 




Body Weight, IL-10, IFN-Y, TNF-
alpha 
O’Mahony et al.,  2009 Mouse Sprague Dawley Not 
Reported 
Maternal Separation Indirect Corticosterone, Fecal Boli, TNF-
alpha (LPS), IL-6 (LPS), IFN-Y 
(LPS), IL-4 (LPS), IL-10 (LPS) 
Winther et al.,  2015 Mouse C57BL/6 Male Magnesium Deficient 
Diet 
Direct Forced Swim Test,  
Body Weight 
Wong et al.,  2016 Mouse C57BL/6J Male Chronic Restraint 
Stress 
Indirect Respirometry, Relative 
abundance of:  
Turicibacter,  
Bifidobacterium,  
Akkermansia, Blautia,  
Lachnospiraceae, & 
Lactobacillus 




Table 3. Reporting of Measures to Reduce the Risk of Bias in Gut Microbiota-targeting interventions to Reduce Depression 





















2014 FALSE FALSE FALSE FALSE TRUE TRUE Private 
Bravo et al., 2011 TRUE FALSE TRUE FALSE FALSE TRUE Public 
Desbonnet et al., 2010 FALSE FALSE FALSE FALSE TRUE TRUE Public 
Gacias et al.,  2016 FALSE FALSE TRUE FALSE TRUE TRUE Both 
Gárate et al.,  2011 FALSE FALSE FALSE FALSE TRUE TRUE Both 
Liang et al.,  2015 TRUE FALSE FALSE FALSE TRUE TRUE Private 
Lui et al.,  2016 FALSE FALSE FALSE FALSE TRUE TRUE Public 
Savignac et al.,  2014 FALSE FALSE TRUE FALSE TRUE TRUE Public 
Wong et al.,  2016 TRUE FALSE FALSE TRUE TRUE TRUE Public 
Zheng et al.,  2016 TRUE FALSE TRUE FALSE TRUE TRUE Public 






Table 4. Reporting of Measures to Reduce the Risk of Bias in Gut Microbiota-targeting Interventions to Induce Depression 


















Ait-Belgnaoi et al.,  2014 FALSE FALSE FALSE FALSE TRUE TRUE Private 
Bravo et al., 2011 FALSE FALSE TRUE FALSE TRUE TRUE Both 
Desbonnet et al., 2010 TRUE FALSE TRUE FALSE FALSE TRUE Public 
Farshim et al., 2016 FALSE FALSE FALSE FALSE TRUE TRUE Public 
Gacias et al.,  2016 FALSE FALSE TRUE FALSE TRUE TRUE Both 
Gárate et al.,  2011 FALSE FALSE FALSE FALSE TRUE TRUE Both 
Ilgin et al.,  2015 FALSE FALSE TRUE FALSE TRUE FALSE Not Reported 
Jørgensen et al.,  2014 FALSE FALSE FALSE FALSE TRUE TRUE None 
Liang et al.,  2015 TRUE FALSE FALSE FALSE TRUE TRUE Private 
O’Mahony et al.,  2009 FALSE FALSE TRUE FALSE TRUE TRUE Both 
Winther et al.,  2015 FALSE FALSE TRUE FALSE TRUE TRUE Public 
Wong et al.,  2016 TRUE FALSE FALSE TRUE TRUE TRUE Public 
Zheng et al.,  2016 TRUE FALSE TRUE FALSE TRUE TRUE Public 









APPENDIX 4: Summary Tables from Chapter 6: THE ANTIDEPRESSANT EFFECT OF KETAMINE IN ANIMAL MODELS OF 
DEPRESSION AS MEASURED BY THE FORCED SWIM TEST: A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Table 1. Study Design Characteristics of experiments included in the ketamine systematic review.  
Surname Year Disease Model 
Timing of 
Admin Freq Ketamine Type Dose Sex Species Time 
Akinfiresoye et al. 2013 Genetic During >1 Ketamine 0.25 Male Rat 22 
Akinfiresoye et al. 2013 Genetic During >1 Ketamine 0.5 Male Rat 22 
Antony et al. 2014 Forced Swim Test Before 1 Ketamine 5 Male Mouse 0.33 
Antony et al. 2014 Forced Swim Test Before 1 Ketamine 7.5 Male Mouse 0.33 
Antony et al. 2014 Forced Swim Test Before 1 Ketamine 10 Male Mouse 0.33 
Assis et al. 2009 Forced Swim Test After 1 Ketamine 5 Male Rat 1 
Assis et al. 2009 Forced Swim Test After 1 Ketamine 10 Male Rat 1 
Assis et al. 2009 Forced Swim Test After 1 Ketamine 15 Male Rat 1 
Autry et al. 2011 Forced Swim Test Before 1 Ketamine 3 Male Mouse 0.5 
Autry et al. 2011 Forced Swim Test Before 1 Ketamine 3 Male Mouse 3 
Autry et al. 2011 Forced Swim Test Before 1 Ketamine 3 Male Mouse 24 
Autry et al. 2011 Forced Swim Test Before 1 Ketamine 3 Male Mouse 168 
Baptista et al. 2015 Chronic Stress After 1 Ketamine 10 Male Rat 16 
Burgdorf et al. 2013 Forced Swim Test After 1 Ketamine 10 Male Rat 24 
Carrier et al. 2013 Forced Swim Test Before 1 Ketamine 2.5 Male Rat 0.5 
Carrier et al. 2013 Forced Swim Test Before 1 Ketamine 2.5 Female Rat 0.5 
Carrier et al. 2013 Forced Swim Test Before 1 Ketamine 5 Female Rat 0.5 
Carrier et al. 2013 Forced Swim Test Before 1 Ketamine 5 Male Rat 0.5 
Carrier et al. 2013 Forced Swim Test Before 1 Ketamine 10 Male Rat 0.5 
Carrier et al. 2013 Forced Swim Test Before 1 Ketamine 10 Female Rat 0.5 




Chaturvedi et al. 2001 Chronic Stress Before 1 Ketamine 2.5 Both Mouse 26 
Chaturvedi et al. 1999 Learned helplessness Before 1 Ketamine 5 Both Mouse 0.5 
Chaturvedi et al. 2001 Chronic Stress Before 1 Ketamine 5 Both Mouse 26 
Chaturvedi et al. 1999 Learned helplessness Before 1 Ketamine 10 Both Mouse 0.5 
Chaturvedi et al. 2001 Chronic Stress Before 1 Ketamine 10 Both Mouse 26 
Chiu et al. 2015 Chronic Stress Before 1 Ketamine 2.5 Male Mouse 1.5 
Chiu et al. 2015 Chronic Stress Before 1 Ketamine 25 Male Mouse 1.5 
Chiu et al. 2015 Chronic Stress Before 1 Ketamine 50 Male Mouse 1.5 
Chiu et al. 2015 Chronic Stress Before 1 Ketamine 50 Male Mouse 168 
Chiu et al. 2015 Chronic Stress Before 1 Ketamine 50 Male Mouse 336 
Cruz et al. 2009 Forced Swim Test Before 1 Ketamine 6.25 Male Mouse 0.5 
Cruz et al. 2009 Forced Swim Test Before 1 Ketamine 12.5 Male Mouse 0.5 
Cruz et al. 2009 Forced Swim Test Before 1 Ketamine 25 Male Mouse 0.5 
Cruz et al. 2009 Forced Swim Test Before 1 Ketamine 50 Male Mouse 0.5 
da Silva et al. 2010 Forced Swim Test Before 1 Ketamine 5 Male Mouse 0.17 
da Silva et al. 2010 Forced Swim Test Before 1 Ketamine 10 Male Mouse 0.17 
da Silva et al. 2010 Forced Swim Test Before 1 Ketamine 20 Male Mouse 0.17 
Engin et al. 2009 Forced Swim Test After 1 Ketamine 10 Male Rat 0.5 
Engin et al. 2009 Forced Swim Test After 1 Ketamine 50 Male Rat 0.5 
Franceschelli et al. 2015 Chronic Stress After 1 Ketamine 10 Female Mouse 0.5 
Franceschelli et al. 2015 Chronic Stress After 1 Ketamine 10 Male Mouse 0.5 
Franceschelli et al. 2015 Chronic Stress After 1 Ketamine 10 Male Mouse 168 
Franceschelli et al. 2015 Chronic Stress After 1 Ketamine 10 Female Mouse 168 
Fuchikami et al. 2015 Forced Swim Test After 1 Ketamine 3 Male Rat 24 
Fuchikami et al. 2015 Forced Swim Test After 1 Ketamine 10 Male Rat 24 
Fuchikami et al. 2015 Forced Swim Test After 1 Ketamine 30 Male Rat 24 




Garcia et al. 2008 Forced Swim Test Before >1 Ketamine 5 Male Rat 1 
Garcia et al. 2008 Forced Swim Test After 1 Ketamine 10 Male Rat 1 
Garcia et al. 2008 Forced Swim Test Before >1 Ketamine 10 Male Rat 1 
Garcia et al. 2008 Forced Swim Test Before >1 Ketamine 15 Male Rat 1 
Garcia et al. 2008 Forced Swim Test After 1 Ketamine 15 Male Rat 1 
Ghasemi et al. 2010 Forced Swim Test Before 1 Ketamine 0.5 Male Mouse 0.75 
Ghasemi et al. 2010 Forced Swim Test Before 1 Ketamine 1 Male Mouse 0.75 
Ghasemi et al. 2010 Forced Swim Test Before 1 Ketamine 2 Male Mouse 0.75 
Ghasemi et al. 2010 Forced Swim Test Before 1 Ketamine 5 Male Mouse 0.75 
Gideons et al. 2014 Forced Swim Test Before 1 Ketamine 3 Male Mouse 0.5 
Gideons et al. 2014 Forced Swim Test Before 1 Ketamine 3 Male Mouse 8 
Gideons et al. 2014 Forced Swim Test Before 1 Ketamine 3 Male Mouse 24 
Gigliucci et al. 2013 Chronic Stress After 1 Ketamine 25 Male Rat 24 
Haj-Mirzaian et al. 2015 Chronic Stress After 1 Ketamine 1 Male Mouse 1 
Jett et al. 2015 Forced Swim Test Before 1 Ketamine 10 Male Rat 168 
Kilic et al. 2014 Forced Swim Test Before 1 Ketamine 10 Female Rat 
Koike et al. 2013 CORT/DEX/LPS/ACTH Insult After >1 Ketalar 1 Male Rat 0.5 
Koike et al. 2014 Forced Swim Test After 1 Ketalar 1 Male Rat 24 
Koike et al. 2013 CORT/DEX/LPS/ACTH Insult After >1 Ketalar 3 Male Rat 0.5 
Koike et al. 2014 Forced Swim Test After 1 Ketalar 3 Male Rat 24 
Koike et al. 2013 CORT/DEX/LPS/ACTH Insult After >1 Ketalar 10 Male Rat 0.5 
Koike et al. 2014 Forced Swim Test After 1 Ketalar 10 Male Rat 24 
Li et al. 2015 Forced Swim Test Before 1 Ketamine 3 Male Mouse 0.5 
Li et al. 2015 Forced Swim Test Before 1 Ketamine 10 Male Mouse 0.5 
Li et al. 2014 CORT/DEX/LPS/ACTH Insult After 1 Ketamine 10 Both Mouse 46 
Li et al. 2015 Forced Swim Test Before 1 Ketamine 20 Male Mouse 0.5 




Ma et al. 2013 Chronic Stress During 1 Ketamine 10 Male Mouse 3 
Ma et al. 2013 Chronic Stress During 1 Ketamine 10 Male Mouse 24 
Ma et al. 2013 Chronic Stress Before 1 Ketamine 10 Male Mouse 48 
Mlyniec et al. 2015 Forced Swim Test After >1 Ketamine 0.25 Male Mouse 24 
Moreira et al. 2016 Chronic Stress After 1 Ketamine 10 Female Rat 0.5 
Nosyreva et al. 2014 Forced Swim Test Before 1 Ketamine 3 Male Mouse 24 
Parise et al. 2013 Forced Swim Test After >1 Ketamine 5 Male Rat 24 
Parise et al. 2013 Forced Swim Test After >1 Ketamine 10 Male Rat 24 
Parise et al. 2013 Chronic Stress After 1 Ketamine 20 Male Rat 1 
Parise et al. 2013 Forced Swim Test After >1 Ketamine 20 Male Rat 24 
Perrine et al. 2014 Chronic Stress After 1 Ketamine 40 Male Rat 21 
Petryshen et al. 2016 Forced Swim Test After 1 Ketamine 3 Male Mouse 0.5 
Petryshen et al. 2016 Forced Swim Test After 1 Ketamine 10 Male Mouse 0.5 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 1.25 Male Mouse 0.5 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 1.25 Male Mouse 336 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 2.5 Male Mouse 0.5 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 2.5 Male Mouse 336 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 5 Male Mouse 0.5 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 5 Male Mouse 336 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 10 Male Mouse 0.5 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 10 Male Mouse 336 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 50 Male Mouse 0.5 
Popik et al. 2008 Forced Swim Test During >1 Ketamine 50 Male Rat 0.67 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 50 Male Mouse 336 
Popik et al. 2008 Forced Swim Test During 1 Ketamine 160 Male Rat 168 
Pozzi et al. 2014 Forced Swim Test Before 1 Ketamine 3 NR Mouse 0.5 




Pozzi et al. 2014 Forced Swim Test Before 1 Ketamine 3 NR Mouse 168 
Prabhakar et al. 2011 Forced Swim Test Before 1 Ketamine 2 Male Mouse 0.5 
Ren et al. 2016 Genetic Before 1 Ketamine 3 Female Mouse 8 
Ren et al. 2015 Other After 1 Ketamine 10 Male Mouse 1 
Reus et al. 2011 Forced Swim Test After 1 Ketamine 5 Male Rat 1 
Reus et al. 2015 Chronic Stress After 1 (S)-ketamine 15 Male Rat 0 
Reus et al. 2014 Forced Swim Test During >1 Ketamine 15 NR Rat 1 
Reus et al. 2015 Chronic Stress After >1 Ketamine 15 Male Rat 1 
Reus et al. 2013 Chronic Stress Before >1 Ketamine 15 Male Rat 24 
Salat et al. 2015 Forced Swim Test Before 1 NorKetamine 5 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 Ketamine 5 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 
DehydroNorKeta
mine 5 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 NorKetamine 10 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 
DehydroNorKeta
mine 10 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 Ketamine 10 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 
DehydroNorKeta
mine 50 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 NorKetamine 50 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 Ketamine 50 Male Mouse 0.5 
Salat et al. 2015 Forced Swim Test Before 1 Ketamine 50 Male Mouse 72 
Salat et al. 2015 Forced Swim Test Before 1 NorKetamine 50 Male Mouse 72 
Salat et al. 2015 Forced Swim Test Before 1 Ketamine 50 Male Mouse 168 
Salat et al. 2015 Forced Swim Test Before 1 NorKetamine 50 Male Mouse 168 
Sarkar et al. 2016 Chronic Stress After 1 Ketamine 2.5 Male Rat 27 
Sarkar et al. 2016 Chronic Stress After 1 Ketamine 2.5 Female Rat 27 




Sarkar et al. 2016 Chronic Stress After 1 Ketamine 5 Male Rat 27 
Sun et al. 2016 Chronic Stress After 1 Ketamine 10 Male Rat 0.5 
Sun et al. 2016 Chronic Stress After 1 Ketamine 10 Male Rat 72 
Tang et al. 2015 Chronic Stress After 1 Ketamine 30 Male Mouse 24 
Tang et al. 2015 Chronic Stress After 1 Ketamine 30 Male Mouse 120 
Tizabi et al. 2012 Genetic Before 1 Ketamine 0.5 Female Rat 0.5 
Tizabi et al. 2012 Genetic Before >1 Ketamine 0.5 Female Rat 22 
Tizabi et al. 2012 Genetic Before >1 Ketamine 0.5 Female Rat 168 
Tizabi et al. 2012 Genetic Before 1 Ketamine 2.5 Female Rat 0.5 
Tizabi et al. 2012 Genetic Before >1 Ketamine 2.5 Female Rat 22 
Tizabi et al. 2012 Genetic Before 1 Ketamine 2.5 Female Rat 168 
Tizabi et al. 2012 Genetic Before >1 Ketamine 2.5 Female Rat 168 
Tizabi et al. 2012 Genetic Before >1 Ketamine 2.5 Female Rat 336 
Tizabi et al. 2012 Genetic Before 1 Ketamine 5 Female Rat 168 
Vogt et al. 2015 Forced Swim Test Before >1 Ketamine 30 Male Mouse 1 
Vogt et al. 2015 Forced Swim Test Before >1 Ketamine 30 Male Mouse 24 
Walker et al. 2013 CORT/DEX/LPS/ACTH Insult After 1 Ketamine 6 Male Mouse 28 
Walker et al. 2015 CORT/DEX/LPS/ACTH Insult After 1 Ketamine 10 Male Rat 24 
Wang et al. 2015 Chronic Stress After 1 Ketamine 10 Male Rat 0.5 
Wang et al. 2015 Chronic Stress After 1 Ketamine 10 Male Rat 1 
Wang et al. 2015 Chronic Stress After 1 Ketamine 10 Male Rat 2 
Wang et al. 2015 Chronic Stress After 1 Ketamine 10 Male Rat 4 
Wang et al. 2011 Other After 1 Ketamine 10 Male Rat 24 
Wrobel et al. 2015 CORT/DEX/LPS/ACTH Insult After >1 Ketamine 15 Male Mouse 0.5 
Wrobel et al. 2015 CORT/DEX/LPS/ACTH Insult After 1 Ketamine 30 Male Mouse 0.5 
Xia et al. 2016 Learned helplessness After 1 Ketamine 30 NR Mouse 0.5 




Xu et al. 2013 Forced Swim Test After 1 Ketamine 10 Male Rat 0.5 
Yang et al. 2013 Forced Swim Test After 1 Ketamine 5 Male Rat 0.5 
Yang et al. 2013 Forced Swim Test After 1 Ketamine 10 Male Rat 0.5 
Yang et al. 2013 CORT/DEX/LPS/ACTH Insult After 1 Ketamine 10 Male Rat 1 
Yang et al. 2015 Chronic Stress After 1 (S)-ketamine 10 Male Mouse 48 
Yang et al. 2015 Chronic Stress After 1 (R)-ketamine 10 Male Mouse 48 
Yang et al. 2015 Chronic Stress After 1 (S)-ketamine 10 Male Mouse 168 
Yang et al. 2015 Chronic Stress After 1 (R)-ketamine 10 Male Mouse 168 
Yang et al. 2013 Forced Swim Test After 1 Ketamine 15 Male Rat 0.5 
Yilmaz et al. 2002 Forced Swim Test After 1 Ketamine 160 Male Rat 96 
Yilmaz et al. 2002 Forced Swim Test After 1 Ketamine 160 Male Rat 192 
Yilmaz et al. 2002 Forced Swim Test After 1 Ketamine 160 Male Rat 264 
Zanos et al. 2015 Forced Swim Test After 1 Ketamine 10 Male Mouse 1 
Zanos et al. 2015 Forced Swim Test After 1 Ketamine 10 Male Mouse 24 
Zhang et al. 2013 Forced Swim Test After 1 Ketamine 10 Male Rat 1 
Zhang et al. 2015 Chronic Stress After 1 Ketamine 10 Male Mouse 5 
Zhang et al. 2015 Chronic Stress Before >1 Ketamine 10 Male Rat 24 
Zhang et al. 2014 CORT/DEX/LPS/ACTH Insult After 1 (S)-ketamine 10 Male Mouse 24 
Zhang et al. 2014 CORT/DEX/LPS/ACTH Insult After 1 (R)-ketamine 10 Male Mouse 24 
Zhang et al. 2015 Chronic Stress Before >1 Ketamine 10 Male Rat 72 
Zhang et al. 2015 Chronic Stress Before >1 Ketamine 10 Male Rat 120 
Zhang et al. 2015 Chronic Stress Before >1 Ketamine 10 Male Rat 168 
Zhang et al. 2014 CORT/DEX/LPS/ACTH Insult After 1 (S)-ketamine 10 Male Mouse 168 
Zhang et al. 2014 CORT/DEX/LPS/ACTH Insult After 1 (R)-ketamine 10 Male Mouse 168 
Zhang et al. 2015 Chronic Stress Before >1 Ketamine 10 Male Rat 192 
Zhang et al. 2015 Chronic Stress Before >1 Ketamine 10 Male Rat 288 




Zhang et al. 2015 Chronic Stress Before >1 Ketamine 10 Male Rat 456 
Surname = the first author’s surname, Year = year the study was published, Disease Model = the method of disease model induction, 
Timing of Admin = whether ketamine was administered before, during, or after model induction, Freq = the frequency of ketamine 
administered (once or more than once), Ketamine Type = the form of ketamine administered, Dose = the dose of ketamine administered 
(mg/kg), Sex = sex of the animals used, Species, Time = the time (in mins) ketamine was administered prior to outcome assessment, NR = 





Table 2. Reporting of Measures to Reduce the Risk of Bias in studies investigating ketamine 





Akinfiresoye et al. 2013 Not Reported Yes Not Reported 0 Yes  Yes  Public 
Antony et al. 2014 Yes Yes Yes 0 Yes  Yes  Unknown  
Assis et al. 2009 Not Reported Not Reported Not Reported 0 Not Reported Yes  Public 
Autry et al. 2011 Not Reported Not Reported Not Reported 0 No Yes Unknown 
Baptista et al. 2015 Not Reported Not Reported Not Reported 0 Yes  Yes  Public 
Burgdorf et al. 2013 Not Reported Not Reported Not Reported 0 Yes Yes Unknown 
Carrier et al. 2013 Not Reported Yes Not Reported 0 Not Reported Yes Unknown 
Chaturvedi et al. 2001 Not Reported Not Reported Not Reported 0 No Not Reported Public 
Chaturvedi et al. 1999 Yes Not Reported Not Reported 0 Not Reported Yes  Public 
Chiu et al. 2015 No Not Reported No 0 Yes Yes Public 
Cruz et al. 2009 Not Reported Yes Not Reported 0 Not Reported Yes Public 
da Silva et al. 2010 Not Reported Not Reported Not Reported 0 Not Reported Yes  Unknown  
Engin et al. 2009 Yes Not Reported Not Reported 0 No Yes Public 
Franceschelli et al. 2015 Not Reported Not Reported Not Reported 0 Yes Yes Both 
Fuchikami et al. 2015 Yes Yes Not Reported 0 Not Reported Yes Both 
Garcia et al. 2008 Not Reported Not Reported Not Reported 0 Not Reported Yes  Public 
Garcia et al. 2008 Not Reported Not Reported Not Reported 0 Not Reported Yes  Public 




Gideons et al. 2014 Not Reported Yes Not Reported 0 Yes Yes Public 
Gigliucci et al. 2013 Not Reported Yes Not Reported 0 Not Reported Yes  Public 
Haj-Mirzaian et al. 2015 Not Reported Not Reported Not Reported 0 Not Reported Yes  Unknown  
Jett et al. 2015 Not Reported Yes Not Reported 0 Yes  Yes  Public 
Kilic et al. 2014 Not Reported Yes Not Reported 0 Yes  Yes  Unknown  
Koike et al. 2014 Not Reported Not Reported Not Reported 0 Not Reported Yes Unknown 
Koike et al. 2013 Not Reported Not Reported Not Reported 0 Not Reported Yes  Unknown  
Li et al. 2015 Not Reported Yes Not Reported 0 Not Reported Yes  Public 
Li et al. 2014 Not Reported Yes Not Reported 0 Not Reported Yes  Public 
Liebenberg et al. 2015 Not Reported Yes Not Reported 0 Yes Yes Public 
Ma et al. 2013 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Mlyniec et al. 2015 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Moreira et al. 2016 Not Reported Not Reported Not Reported 0 Yes  Yes  Public 
Nosyreva et al. 2014 Not Reported Yes Not Reported 0 Yes  Yes  Public 
Parise et al. 2013 Not Reported Yes Not Reported 0 Yes Yes Public 
Perrine et al. 2014 Not Reported Yes Not Reported 0 Not Reported Yes  Public 
Petryshen et al. 2016 Not Reported Not Reported Not Reported 0 Not Reported Yes  Private 
Popik et al. 2008 Not Reported Yes Not Reported 0 Yes Yes Public 
Pozzi et al. 2014 Yes Not Reported Not Reported 0 Yes Yes Public 
Prabhakar et al. 2011 Yes Yes Not Reported 0 Not Reported Yes  Unknown  




Ren et al. 2015 No Not Reported Not Reported 0 Yes Yes Both 
Reus et al. 2014 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Reus et al. 2011 Not Reported Yes Not Reported 0 Yes  Yes  Public 
Reus et al. 2015 Not Reported Not Reported Not Reported 0 Not Reported Yes  Public 
Reus et al. 2013 Not Reported Not Reported Not Reported 0 Not Reported Yes Public 
Reus et al. 2015 Not Reported Not Reported Not Reported 0 Not Reported Yes Public 
Salat et al. 2015 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Sarkar et al. 2016 Not Reported Not Reported Not Reported 0 No Yes Public 
Sun et al. 2016 Not Reported Yes Not Reported 0 Yes Yes Public 
Tang et al. 2015 Not Reported Yes Not Reported 0 Not Reported Yes  Unknown  
Tizabi et al. 2012 Not Reported Not Reported Not Reported 0 Not Reported Yes Public 
Vogt et al. 2015 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Walker et al. 2013 Not Reported Yes Not Reported 0 Yes Yes Public 
Walker et al. 2015 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Wang et al. 2015 Yes Yes Not Reported 0 Yes Yes Public 
Wang et al. 2011 Yes Yes Not Reported 0 No Yes  Unknown  
Wrobel et al. 2015 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Xia et al. 2016 Not Reported Yes Not Reported 0 Yes  Yes  Public 
Xu et al. 2013 Yes Not Reported Not Reported 0 Yes Yes Public 
Yang et al. 2013 Yes Not Reported Not Reported 0 Yes  Yes  Public 




Yang et al. 2013 Yes Not Reported Not Reported 0 Not Reported Yes  Public 
Yilmaz et al. 2002 Not Reported Not Reported Not Reported 0 No Yes Public 
Zanos et al. 2015 Not Reported Yes Not Reported 0 Not Reported Yes Public 
Zhang et al. 2013 Yes Not Reported Not Reported 0 No Yes  Public 
Zhang et al. 2015 Not Reported Not Reported Not Reported 0 Yes Yes Public 
Zhang et al. 2014 Not Reported Not Reported Not Reported 0 No Yes Public 
Zhang et al. 2015 Not Reported Not Reported Not Reported 0 Not Reported Yes  Public 
Percentage 
Reporting 
Compliance  12/67 = 17.9% 25/67 = 37.4% 2/67 = 2.9% 0% 
32/67 = 
47.8% 66/67 = 98.5% 55/67 = 82.1% 
Randomisation = Random allocation to group, Blinding = Blinded assessment of outcome, Allocation = Allocation concealment, CoI = Conflict 
of interest, SSC = Sample size calculation, Welfare Regs. = Compliance with animal welfare regulations, Source of Funding = Source of 







APPENDIX 5:  R CODE TO CALCULATE A PRIOR SAMPLE SIZE CALCULATION 
 
## means and standard deviations extracted from graphs  
## in McVey Neufeld et al., 2017 (Mc), and Burokas et al., 2017 (Burokas) 
 
 
## sum of squares from ANOVA tables from the above means and standard 
deviations 
 
SSeffectMc <- 529.7 
SStotalMc <- 1014 
 
ssEffectBurokas <- 32486.91 
ssTotalBurokas <- 56028.04 
 
 
## calculating eta squared 
etasqrdMc <- SSeffectMc/SStotalMc 
etasqrdMc 
 




## calculating effect size f 
fEffectMc <- sqrt(etasqrdMc/(1-etasqrdMc)) 
fEffectMc 
 
fEffectBurokas <- sqrt(etasqrdBurokas/(1-etasqrdBurokas)) 
fEffectBurokas 
 







# effect size f is calculated by  
# between group standard deviation (SD of k means) / within group standard 
deviation (SD of k groups) 
 
pwr.anova.test(k = 4, n = NULL, f = fEffectMc, sig.level = 0.01, power = 0.9) 
 




# to see what our study will be powered at with 8 animals per group 
pwr.anova.test(k = 4, n = 8, f = fEffectMc, sig.level = 0.01, power = NULL) 
 
# to see what effect we can estimate with the n and power 
pwr.anova.test(k = 4, n = 8, f = NULL, sig.level = 0.01, power = 0.9) 
 
